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Abstract 
Tendon injuries continue to be a financial burden on the health care system of many 
western countries, whilst also remaining common and a significant challenge within the 
orthopaedic discipline with no consensus of opinion on the best therapeutic regime to be 
employed. 
Many polymers have been investigated for use in tendon repair. A range of polymers 
have shown good integration with limited immune response. However, to date no 
implant has been capable of delivering the physical properties observed in native 
undamaged tendon. Many of the polymers implanted have resulted in re-rupture or 
reduced mechanical function. Therefore, improvements are required in the choice of 
polymer and mechanical properties of the polymer are required. One means of achieving 
such improvements is to utilise co-polymers such as PHBHHx, which have shown 
favourable elastic properties when the ratio of HHx to PHB has been increased. 
Therefore, a PHBHHx polymer based scaffold was investigated as a potential scaffold for 
tendon repair. Whilst, also investigating the potential of FGF-4, FGF-6 and FGF-8 to 
differentiate both human embryonic and mesenchymal stem cells towards a tenocyte-like 
lineage. Finally, an investigation into whether a controlled production of PHBHHx based 
nanoparticles could produce different nanoparticles sizes that can be predicted and result 
in differing release profiles. This may allow for the synthesis of size controlled 
nanoparticles capable of delivering differing drug concentrations and sustained release 
properties. 
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Results have shown that PHBHHx in conjunction with collagen and tenocytes can be used 
as a scaffold material for the treatment of damaged tendon tissue in vivo. The implanted 
scaffold was capable of returning function and did not elucidate an immune response 
when in situ. 
In Vitro studies demonstrated that the combination of FGF-4, 6 & 8 supplementation of 
differentiation media containing Vitamin C, as being capable of maintaining tendon 
specific genes TNMD and THBS-4 in both embryonic stem cells and mesenchymal stem 
cell when cultured at 2% O2. 
Design of experiment methodology studies have shown that we can accurately predict 
PHBHHx nanoparticle size ranging from 95 – 200nm in size. This function will enable 
accurate size production of nanoparticles for a controlled and sustained release of growth 
factors for tendon regeneration. 
In conclusion, the combination of studies have shown the effectiveness of PHBHHx as 
both a tendon scaffold and potential use in nanoparticle delivery for drug and growth 
factors, such as FGF-4, FGF-6 and FGF-8 which are potentially capable of cellular priming 
of stem cells to differentiate towards a tenocyte “like” lineage. The findings of these 
studies provide a pathway for future innovations in regenerative medicine and wider 
scientific community. 
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1.1 Introduction 
Tissue engineering is an emerging interdisciplinary field that utilises the areas of material 
sciences, stem cell biology and clinical sciences to deliver a fresh approach to the 
development of therapies and treatments to patients. To date, tissue engineering has 
produced fresh approaches to orthopaedics in the development of articular cartilage 
implant [1] and in general medicine with the recent highly publicised development of the 
synthetic larynx implantation [2]. 
The musculoskeletal system consists of three major components: skeletal tissue, which 
provides structural support and defines the mechanical units; muscular tissue, which 
generates force; tendon and ligament, which transmit force generated during muscle 
contraction of the skeleton and contribute to joint stability [3]. Therefore, tendon and 
ligament play a significant role in the modulation of force transmission between bone-
bone, bone and skeletal muscle and consequently protect muscle fibres from contraction 
or high strain induced injuries [3-6]. Tendon injury is a financial burden on the health care 
system of many western countries, with in excess of 4.83 incidents per 100,000 hand 
tendon injuries, 12 incidents per 100,000 Achilles tendon injuries and 3.73 per 100,000 
rota cuff tendon injuries per year [7]. Tendon injuries remain common and a significant 
challenge within the orthopaedic discipline with no consensus of opinion on the best 
therapeutic regime to be employed. 
One of the major problems with surgical tendon repair is the incidence of re-injury and 
possibility of complete tendon rupture leading to further incapacitation which negatively 
impacts on both healthcare economics (in the cost of treatment) and patient economics 
(in relation to loss of income). Failure rates for tendon repair range from 2-13% (4-13% 
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due to suture overloading, 2-4% for Achilles tendon re-rupture, 4.3% percutaneous repair 
and non-surgical bracing 12.2%) [7]. 
Due to the failure rates new strategies have been developed for tendon repair, the three 
most promising approaches include: 
1) Biopolymer based scaffold repair 
2) Stem cell based therapy 
3) Stem cell/biopolymer therapy 
To date many polymers have been investigated as a possible scaffold for tendon repair 
with varying degrees of success. However, the translation of the animal, studies have yet 
to be explored within the human subject. The use of stem cell based therapies remains 
under researched in the area of tendon repair. One possible approach that could lead to a 
more positive outcome could be the combination therapy. The combination of both stem 
cell and biopolymer-based approaches utilising a polymer based nanoparticle delivery 
method for growth factors to induce stem cell differentiation towards a tenocyte lineage. 
The utilisation of such an approach would:- 
1. Enable the body to be utilised as a bioreactor 
2. Localised growth factor induced differentiation 
3. Force transmission to the implant via the body to induce mechanotransduction 
and subsequent differentiation. 
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1.2 Embryonic Development 
During early embryonic development the precise mechanisms of embryonic polarisation 
and spatial patterning have yet to be understood. Embryonic polarisation is the initiator 
of the primary plan for the formation of the body axis. The symmetry of the embryo is 
established after oogenesis. Mammalian development has been best observed within the 
mouse. The mouse oocyte has no clear polarity with no specific molecules responsible for 
lineage specification yet identified [8]. Most embryos develop with bilateral symmetry 
and become polarized along anterior-posterior, dorsal-ventral and left-right axes [9]. One 
of the major milestones in embryonic development is the initiation and generation of the 
asymmetrical architecture which underpins the orientation and polarity of the three-axes, 
Rostral (Head) – caudal (Tail), Dorso (Back) – Ventral (Front), and Left – Right (Figure 1.1), 
which will become the basic body plan along which embryonic development will follow 
[9].  
One, well documented feature of mammalian development is the maintenance of a 
population of pluripotent stem cells which will give rise to the mature organism [10]. The 
inner cell mass (ICM) is made up of 10 – 20 cells, which appear to be developmentally 
identical, which is located at one end of the 3.5 days post coitum (d.p.c) blastocyst [10]. 
Mammalian development requires the regulated proliferation of these cells and 
allocation of descendants to specific cell lineages post differentiation [11-13]. 
At d.p.c 4.0 the ICM cells that line blastocoelic cavity start to differentiate and become 
extraembryonic primitive endoderm. The cells that remain within the ICM retain 
pluripotency and this is now referred to as the “epiblast” which is surrounded by 
extraembryonic endoderm and trophectoderm, it is at this point the embryo implants 
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into the uterine wall [10]. After implantation into the uterine wall the pluripotent cells 
begin to rapidly proliferate and primitive endoderm cells migrate along the pluripotent 
cell surface and differentiate into one of two cell types (visceral endoderm and parietal 
endoderm), the mechanism and control of this migration/differentiation has yet to be 
elucidated [10]. 
 
Figure 0.1 Orientation and Polarity of the three axises. 
The Red arrow indicates the Rostral – Caudal axis, the green arrow indicates Dorso – Ventral axis and blue 
arrow indicates the Left – Right axis [10]. 
 Limb Development 1.2.1
The primitive endoderm cells that remain in contact with the pluripotent cells then 
differentiate into visceral endoderm (possibly by means of juxtacrine or cell-cell signalling 
in conjunction with yet to be identified growth hormones and growth factors, while the 
primitive endoderm cells that migrate onto the blastocoelic surface of the trophectoderm 
now differentiate into parietal endoderm [10]. The formation of the primitive endoderm 
provides the substrate for gastrulation and initiates at 6.5 d.p.c. and it is this process that 
transforms the pluripotent monolayer into a multi-layered embryo consisting of the 3 
W. R. Webb PhD Thesis Chapter 1 
6 
 
primary germ layers namely the mesoderm, ectoderm and endoderm from which all the 
tissues required for adult life give rise [10]. 
Research conducted using Quail-chick chimeras has shown that tendon and cartilage cells 
differentiate from the same mesodermic compartment and this is distinct from the area 
that gives rise to muscle cells [14]. Axial tendon, develop from the sclerotomal 
compartment form along the axis of the body.  The limb-tendon(s) develop from the 
lateral plate and the limb and axial muscles originate from the dermomyotomes [14]. 
Although, these have different origins, tendon and muscle development/morphogenesis 
happens with close spatial and temporal association [14]. 
Ros et al. established that tenocyte differentiation starts at Embryonic day (E) 7 in Quail-
chick chimeras, this was observed by the increase in deposition of ECM [15]. The increase 
in synthesis of ECM leads to the formation of early collagen fibrils and the overall 
architecture of the tendon is apparent by E14 [14]. At E17 proliferation of tendon cells 
appears to have stopped, however there is an increase in the rate of synthesis of collagen 
and associated matrix glycoproteins (as E17 is just prior to birth), this results in an 
increase in length and diameter of the collagen fibrils which results in the provision of the 
required mechanical properties of mature tendon [14]. 
However, Quail-chick based research studies are still unable to address major questions 
such as; 1) Is tendon development initiated by growth factors such as FGF-8?, 2) Micro-
movement induced mechanical stimuli?, 3) A combination of growth factor/micro 
mechano-stimuli?, or 4) Is there a transitional relationship between growth factor 
induced differentiation, which then leads to mechano-stimuli driven differentiation? 
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 Limb Abnormalities 1.2.2
Polydactyly is the most frequent congenital hand malformation observed in humans and 
has a prevalence of 5-19 in 10,000 live births [16, 17]. Research conducted by Bouldin et 
al, which employed the use of Dorking’s chickens suggests the ectopic post-axial digit is 
due to the deregulated-expression of FGF’s in the AER, especially anterior expression of 
FGF-4 within the AER [18].  
However, deregulated- FGF expression is not limited to polydactyly. Bose et al proposed 
that changes in FGF expression by the AER has a role to play in syndactyly and that limb 
patterning is independent to each limb [19] (Figure 1.2).  
 
Figure 0.2 Independent Limb Development 
The above image depicts independent limb development. Each limb develops independently in relation 
to proximo-distal patterning, with each limb bud developing its own polarity axises. The red arrows 
indicates the rostral- caudal axises, the light blue arrows indicate the dorsal-ventral axises and the blue 
arrows indicate the left-right axises. 
Yu et al showed a vital role of FGF-4, FGF-8 and FGF-10 in limb formation. The lack of FGF-
4, FGF-8 and FGF-10 resulted in agenesis (absence of limb formation) in mouse models. 
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This further highlighted the importance of the development and maintenance of AER-FGF 
signalling during limb formation [20]. The research found that FGF-4 and FGF-8 are 
required for normal limb bud development and complete inactivation of FGF-4 and FGF-8 
resulted in SOX-9 expressing cells not being able to commit to osteochondral progenitors 
and failure to form any chondrogenic primordial [20]. Owing to distal mesenchymal 
defects, the AER or AER functions are not maintained at later stages and distal 
mesenchymal proliferation is inevitably reduced, which further reduces limb bud size 
[20].  
By understanding the signals and the sequence of signals involved in the patterning and 
developmental process of limbs the use of stem cells as a therapeutical regime for limb 
injuries and disease can become more realistic and a possible future option. Embryonic 
development holds many a key to the patterning of limbs and subsequent development 
of specific components of the musculo-skeletal system. 
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 Tendon Development 1.2.3
The molecular signalling and subsequent control of tendon synthesis has yet to be 
completely elucidated. Cell signal, cellular positioning and/or cellular polarity may play a 
role in the initial development of tendon with a transition from signal induced tendon 
development towards micro-movement maintenance of tendon development. To date, 
very little documentation in respect of the control and maintenance of tendon formation 
is available. Due to the close proximity of tendon to bone and muscle it is likely that the 
signalling patterns involved in bone and muscle formation may play a role in tendon 
formation. However, the role of collagen synthesis, secretion and subsequent extra 
cellular matrix formation plays a major role in tendon formation. The formation of the 
extra cellular matrix which contains collagen is vital in the provision of the mechanical 
properties observed in tendon [21]. Tendon development has been shown as early as 
E14.5 in the murine model and between days 6-9 in the chick embryo [22]. At this point 
the extra cellular matrix becomes populated with narrow-diameter collagen fibrils [22]. 
The majority of early embryonic tendon formation studies have been performed using 
chicks and between the days 6-9 in embryonic tendon, the tendon mass is mainly made 
up from cells and very little extra cellular matrix (ECM) [15]. Early tendon formation is as a 
result of the tendon fibroblast synthesising and secreting ECM [23]. 
The majority of early tendon research has been conducted using animal models. However 
research conducted by Shaw et al.[24] described early foetal human samples ranging 
from 51 days old through to 138 days old [24].  
However, pre 45 days gestation there is little documentation of Achilles tendon 
initiation/differentiation and early formation. During foetal development (45-57mm) the 
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Achilles tendon is highly cellular with little sign of fibril genesis [24]. The Achilles tendon is 
indirectly attached to the cartilaginous anlagen of the calcaneus by a thick perichondrium 
[24]. It was also noted that the fat cells that are present in both the Kager’s triangle and 
the plantar fascia had yet to develop and were only visible post 110mm (98 -100 days 
gestation). The formation of the fat pad within the Kager’s triangle conveys a mechanical 
advantage in that the fat pad increases the lever arm of the tendon which leads to 
mechano stimuli of the developing tendon [24]. 
More recently the role of mechanical stimuli during embryonic Achilles tendon 
development is gaining attention. A delicate and essential relationship between 
development progression and mechanical stimuli is gaining favour. Research conducted 
by Vogel and Koob [25] and Gao et al. [26] showed mechanical loading induced 
metaplasia of tendon fibroblasts into fibrocartilage cells. The importance of mechanical 
loading was then further highlighted by Thomopoulos et al. [27] who showed that 
paralysis of the supraspinatus muscle in a murine model resulted in delayed development 
of the Achilles tendon and enthesis fibrocartilage. The relationship between tendon 
development and adjacent musculosketal components which transfer mechanical forces 
to the tendon were highlighted in 1949 by Wood Jones [28] and more recently by 
Benjamin et al. [29]. 
The development of a fully functional tendon structure requires not only chemical cues 
but also mechano-stimulation. However, to date the relationship between chemical cues 
and mechano-stimulation has yet to be elucidated in embryonic human development. 
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1.3 Tendon Structure 
Healthy tendons are bright white in colour with a fibroblastic appearance. Tendons 
demonstrate a marked variation in form; they can be rounded chords, strap-like bands, or 
flattened ribbons. Within the extracellular matrix of the tendon, tenocytes and tenoblasts 
constitute 90% - 95% of the cellular element of the tendon [6]. The remaining 5% - 10% of 
the cellular element of tendons consists of chondrocytes at the region of bone 
attachment/insertion sites, synovial and vascular cells, including capillary endothelial cells 
and smooth muscle of the arterioles [6]. Tenoblasts are immature tendon cells, and are 
spindled-shaped with numerous cytoplasmic organelles, which reflect their high 
metabolic activity [6, 30]. Tenoblasts have a spindle morphology with an ovoid nucleus 
and size ranges from 20-70µm in length and 8-20 µm in width [31]. They contain large 
numbers of organelles like Golgi bodies, endoplasmic reticulum (ER) and also contain 
myosin and actin filaments [31]. As the tenoblast matures, they become elongated and 
transform into tenocytes. Tenocytes have a lower nucleus/cytoplasmic ratio than 
tenoblasts[5]. They are thin and long with reduced metabolism [5].  
Tenocytes are metabolically adaptive and can generate energy via the aerobic Krebs 
cycle, anaerobic glycolysis, and the pentose phosphate shunt [32, 33]. As, tenocytes age 
the metabolic pathway choice shifts from an aerobic to an anaerobic preference [32, 33]. 
The oxygen consumption of tendons is approximately 7.5 times lower than that of 
skeletal muscle [33]. This lower metabolic rate and well-developed anaerobic energy 
generation capacity are essential to carry loads and maintain tension for long periods. 
This reduces the risk of ischemia and subsequent necrosis. However, the lower metabolic 
rate results in increase in time required for healing after injury [33]. 
W. R. Webb PhD Thesis Chapter 1 
12 
 
Another factor resulting in the metabolic shift from aerobic to anaerobic energy 
generation by the tenocytes is how tendon is supplied by nutrients, namely the perfusion 
of tendon. Mayer et al [34] , Ahmed et al. [35] and Theobald et al [36] who collectively 
demonstrated that the majority of tendon perfusion was delivered by vessels contained 
within the anterior paratenon, derived from the posterior tibial artery in rabbits. The 
consensus opinion is that the human tendon is primarily perfused by the paratenon which 
decreases with age especially the mid-tendon region [36].  
The tendon is composed of a collagen-tenocyte network and extracellular matrix, which 
contains proteoglycans, glycosaminoglycan, glycoproteins and other small molecules [5]. 
Adhesive glycoproteins such as fibronectin, tenomodulin and thrombospondin, 
participate in the repair and regeneration process in tendon [32, 37, 38]. The dry mass of 
human tendon is approximately 30% of the total tendon mass, with water accounting for 
the remaining 70%. Collagen type I is predominant (65% - 80%) but collagen Types III, IV, 
V and VI and proteoglycans, glycosaminoglycan, glycoproteins and other small molecules 
make up the remainder of tendon extracellular matrix (ECM) [31]. 
The collagen found within tendon is arranged in levels of increasing hierarchical 
complexity. This begins with tropocollagen, which is a triple-helix polypeptide chain, 
which unites into fibrils (primary bundles); fascicles (secondary bundles); tertiary bundles; 
and the tendon itself (Figure 1.3). The soluble tropocollagen molecules secreted by the 
tenoblast cross-link to create insoluble collagen molecules, which aggregate to form 
collagen fibrils. The collagen fibre is the smallest tendon unit that can be tested 
mechanically. Although collagen fibres are mainly orientated longitudinally, fibres also 
run transversely and horizontally, forming spirals and plaits [33]. 
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Figure 0.3 Normal Structure of Tendon  
Tendon tissue has a multi-unit structure composed essentially of the fibril-forming type I collagen 
molecules, which are organised into individual sub-fascicles and fascicles separated by the ECM of the 
epitenon. Groups of fascicles form the body of the functional tendon, within which is a rich, vascularised 
and innervated ECM that is synthesized and maintained by the tendon fibroblasts, which typically align 
longitudinally in rows along the collagen fibres. Numerical diameter values taken from Richardson et al 
2007 [39]. 
The other structural zones of the tendon are the epitenon and the endotenon which all 
contribute to the unique tendon properties. The epitenon, a fine, loose connective-tissue 
sheath containing vascular, lymphatic and nerve supply to the tendon, covers the whole 
tendon and extends deep within it between the tertiary bundles as the endotenon. The 
endotenon is a thin reticular network of connective tissue investing each tendon fibre 
[37]. The epitenon is surrounded by paratenon, a loose areolar connective tissue 
consisting of collagen fibrils Type I and Type III, some elastic fibrils and an inner lining of 
synovial cells [38]. Synovial tendon sheaths are found in areas subjected to increased 
mechanical stress, such as tendons of the hand and feet, where efficient lubrication is 
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required. Synovial sheaths consist of an outer fibrotic sheath and an inner synovial 
sheath, which consists of thin visceral and parietal sheets [3, 40, 41]. The inner synovial 
sheath invests the tendon body and functions as an ultra-filtration membrane to produce 
synovial fluid [42]. The fibrous sheath forms condensations, the pulleys, which function as 
fulcrums to aid the tendon function[43]. 
Tendons are linked to both bone and muscle through osteotendinous and myotendinous 
junctions, respectively. The osteotendinous junction is composed of four zones: a dense 
tendon zone, fibrocartilage, mineralised fibrocartilage, and bone [42]. The specialised 
structure of the osteotendinous junction prevents collagen or fibril bending, fraying, 
shearing and failure [43]. At the myotendinous junctions, tendinous collagen fibrils are 
inserted into deep recesses formed by myocyte processes, allowing the tension 
generated by intracellular contractile proteins of muscle fibres to be transmitted to the 
collagen fibrils [38]. This complex architecture reduces the tensile stress exerted on the 
tendon during muscle contraction and the complex interactions and arrangement of the 
collagen molecules and proteoglycans that convey the mechanical properties such as 
Young’s modulus to tendon tissue [38, 43]. The fine structure and interactions between 
collagen-cellular and proteoglycan components of the tissue structure are what give 
tendon its unique mechanical properties such as Young’s modulus However, the 
myotendinous junctions still remain the weakest point of the muscle-tendon unit and 
point of increased injury susceptibility.  
 Biochemical Components of Tendon Extra Cellular Matrix 1.3.1
The complex arrangements and interactions of the collagen fibres, elastin fibrils and 
proteoglycans deliver the unique mechanical properties of tendon [44]. Tendons are 
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composed of approximately 55 – 70% water of which a substantial part can be attributed 
to the association with the proteoglycans (PG) [45]. The most abundant collagen present 
in tendon is collagen I, and is organised into a helical arrangement along the largest axis 
of the tendon [46-49]. The micro structure of tendon is based around the helical structure 
of type 1 collagen with a typical helical protein of 270nm in length which is undergoes 
extracellular assembly resulting in a larger supra molecule of around 300nm diameter, 
which can eventually result in a helical collagen structure of up to several centimetres in 
length (Figure 1.2) [50]. Between 60 – 85% of the ECM component of tendons being made 
up of collagen [51]. This can then be further broken down to the exact types of collagen 
such as: ~60% Collagen type I [51], Collagen type II [52, 53],0 – 10% collagen III [54], ~2% 
Collagen type IV [55, 56], collagen type V and VI [45, 57-60], up to 1% Proteoglycans [61], 
~ 2% elastin [62] and up to 1%  cartilage oligomeric matrix protein (COMP) [63, 64].  
 Tenomodulin 1.3.1.1
The tenomodulin gene is located on the X-chromosome loci q21.33-q23. Tenomodulin is 
highly expressed in ligaments, tendon and eyes and some expression was also seen in 
liver, thymus, lungs, cartilage [65]. In tenomodulin deficient mice it was apparent that 
tenomodulin is involved in accelerating division of tenocytes and increasing the number 
of cells but that it did not affect synthesis of collagen type I and formation of blood 
vessels. It was also observed that in tenomodulin deficient mice the tendon’s surface was 
rough as compared to smooth in case of normal mice. Tenomodulin also affects the 
collagen VI network by causing changes in its epitopes [66]. During tenocyte culture when 
scleraxis was expressed expression of the tenomodulin also increased [67]. This shows 
that tenomodulin expression depends on expression of scleraxis [68] 
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 Tenascin –C 1.3.1.2
The tenascin-C gene can be found on chromosome 9q33.1. Tenascin C is expressed in the 
blastema, differentiated primordial and proximal tendons [69]. Tenascin-C has been used 
to mark primordial tendons. However, as it is also expressed in cartilage and nerves (glial) 
Tenascin-C cannot be used as a single tendon specific genetic marker[70]. 
 Thrombospondin-4 1.3.1.3
The thrombospondins are a family of extracellular proteins that bind calcium and 
modulate cellular phenotype during tissue genesis and remodelling [71]. All of the 
thrombospondin proteins have been reported to bind not only calcium, but also heparin 
[71]. The thrombospondin-4 (THBS-4) gene loci is 5q.13 [71] and the subsequent 
pentamer protein product has been shown to also bind to fibrinogen, fibronectin, laminin 
and type V collagen [68]. However, the exact function of THBS-4 has yet to be discovered 
[68]. Research conducted by Baumeister et al has shown THBS-4 to be present in tendon 
mesenchyme. Both TNMD and THBS-4 have been detected in tendon tissue. A recent 
study by Jelinsky et al [68] has shown THBS-4 in conjunction with TNMD to be very 
specific to tendon tissue. 
 Collagen 1A2 1.3.1.4
The collagen 1A2 gene can be found on Chromosome 7 loci q22.1. The COL1A2 gene 
provides instructions for making part of a large molecule called type I collagen. Collagens 
are a family of proteins that strengthen and support many tissues in the body, including 
cartilage, bone, tendon, skin, and the white part of the eye (the sclera). Type I collagen is 
the most abundant form of collagen in the human body [72]. 
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The COL1A2 gene produces a component of type I collagen called the pro-α2 (I) chain. 
Collagens begin as procollagen molecules, which must be processed by the enzymes 
outside the cell to remove extra protein segments from their ends (procollagen 
peptidase) and collagen cross-linking (lysyl oxidase). Each rope-like procollagen molecule 
is made up of three chains: two pro-α1(I) chains, which are produced from the COL1A1 
gene, and one pro-α2(I) chain, which is produced from the COL1A2 gene [72]. After 
procollagens are processed, the resulting mature collagen molecules arrange themselves 
into long, thin fibrils. Individual collagen molecules are cross-linked to one another within 
these fibrils. The formation of cross-links results in very strong type I collagen fibrils, 
which are found in the spaces around cells. 
 Collagen 3A1 1.3.1.5
The collagen 3A1 gene can be found on Chromosome 2 loci q31. Type III collagen is found 
in tissues such as the skin, lungs, intestinal walls, and the walls of blood vessels [73]. The 
COL3A1 gene produces the components of type III collagen, called pro-alpha1 (III) chains. 
Three copies of this chain combine to make a molecule of type III pro-collagen. These 
triple-stranded, rope-like procollagen molecules are then processed by the enzymes 
outside (procollagen peptidase) the cell to remove extra protein segments from their 
ends. Once these molecules are processed, the collagen molecules arrange themselves 
into long, thin fibrils. Within these fibrils, the individual collagen molecules are cross-
linked to one another by the enzyme lysyl oxidase. These cross-links result in the 
formation of very strong mature type III collagen fibrils, which are found in the spaces 
around cells [73]. 
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 Decorin 1.3.1.6
Decorin (DCN) is a proteoglycan gene which can be found on chromosome 12 loci q21.33 
and decorin belongs to the small leucine-rich proteoglycan family with an average size 
between 90 – 140 kDa [74]. Decorin consists of a protein core which contains leucine 
repeats and a glycosaminoglycan chain which may contain either chondroitin sulphate or 
dermatan sulphate [75]. Decorin has a structure similar to biglycan and can be either 
cellular or pericellular [74]. Decorin plays two major roles in tendon tissue: 1) matrix 
organisation and 2) fastening adjoining collagen fibrils together and the possible 
mechanical coupling of fibrils [76, 77]. Furthermore, decorin has also been shown to 
regulate the assembly of collagen fibrils and is a major contributor to the biomechanical 
properties of developing tendon [78].  
 Fibromodulin 1.3.1.7
The gene coding for the fibromodulin protein is FMOD and has the gene loci of 1q32. 
Fibromodulin is a member of the small interstitial proteoglycan family and has a 
molecular weight of 67 – 110 kDa [79]. Lack of fibromodulin in developing tendon has 
been shown to result in alterations in collagen fibrils resulting in joint instability and 
abnormal gait [80]. Further investigation using double knockout mouse models have 
shown thinner collagen fibrils resulting in abnormal fibres in tendon [81]. Also an 
increased deposition of lumican was observed in the fibromodulin knockout mouse model 
leading to subtle changes in collagen architecture and mechanical properties in the 
collagen matrix which would account for the observations in gait change made by Ameye 
et al. [80, 81]. 
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 Scleraxis 1.3.1.8
The Scleraxis gene (SCX) can be found on chromosome 8q24.3 and codes for a 60-100 
amino acid protein which functions as a DNA-binding protein/transcription factor. SCX has 
been shown to be expressed from early stages of tendon development in limb bud 
tendon progenitors and in the syndetome somatic compartment that contains tendon 
progenitor cells during mouse embryogenesis [69]. Its expression in the buds of the limb 
was observed in four different phases. In the first phase (stage 21) both ventral and dorsal 
parts of limb showed scleraxis expression, in the second phase (25-27) the scleraxis 
expression was highly complex, in the third phase (28) formation of fibres occurred 
followed by their elongation and in the fourth phase (31) all the tendons of the limb were 
expressing scleraxis. It was also found that in order to maintain the expression of the 
scleraxis in the tendons, presence of FGF-4 was essential [70]. It was observed that in 
absence of (Fibroblast Growth Factor) FGF-4, tenascin and scleraxis expression was 
decreased in the limb of chick but on application of FGF-4 both these transcription factors 
showed an increment in their expression in the normal limbs and limbs of the chick that 
did not contain muscles [82]. Along with FGF4, FGF8 was also involved in increasing the 
expression of scleraxis but only at the last phase of development of the tendon. These 
factors (FGF-4 and 8) were released by the myogenic cells [4]. The expression of this 
protein can be stopped by BMPs but at the same time noggin can antagonize this effect 
[83]. It was also found that more collagen was produced by the activation of a promoter 
(COL1α1) due to attachment of SCX/E47 to the E box of the TSE2 so for the activation of 
COL1α1, TSE1 and 2 are essential. In fibroblast of the tendons, NFATc and SCX induce 
activation of the COL1α1 [84]. In mouse that were lacking this protein, the organization of 
the cells and matrix showed distorted geometry [85]  
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1.4 Mechanical Properties of Tendon 
Tendons are designed for the transmission of forces with minimal deformation and 
energy loss [86]. The two primary features of tendon are stress-relaxation (decreased 
stress over time with constant deformation) and creep (increased length over time with a 
constant load). These two properties give rise to load-deformation relationship of tendon 
that is dependent on the activities prior to assessment [86]. 
 Young’s Modulus of Tendon 1.4.1
The primary role of tendon is the transmission of force from the muscle to the bone to 
enable joint movement [87, 88]. Unlike bone, tendon does not behave as a rigid body but 
instead exhibits viscoelastic behaviour [87, 88]. The most vital characteristic of tendon is 
observed in its Young’s modulus when compared to other skeletal tissues. Young’s 
modulus describes the elastic properties of a solid undergoing compression or tension in 
only one direction, and can be summarised as the normal stress divided by the linear 
strain (Figure 1.4). The mechanical properties of tendon depend largely on its location 
within the body. A typical small adult human tendon (from the forearm) has a Young’s 
modulus of 1-2 GPa, an ultimate stress of around 100 MPa and an ultimate strain of 4-
10% [89]. Similarly, the estimated Young’s modulus for adult Achilles tendon has been 
reported to be 2 GPa , an ultimate stress of 80 MPa and an ultimate strain of 3.6-8.8% 
[90] and conversely for the human patella tendon an estimated Young’s modulus of 1.5-
1.7 GPa, an ultimate stress of 34-43MPa and an ultimate strain of 5.3-5.8% dependant on 
age [91] 
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Figure 0.4 Graph to Illustrate the Young’s Modulus for Tendon 
The load-deformation curve of tendon has four distinct features in relation to the anatomic 
microstructure. The initial “toe” region corresponds to the arrangement of the fibres with the direction of 
stress. The linear region of the curve is as a result of the helical structure. The end linear region is where 
unpredictable failure begins, leading to eventual rupture and the recoil of tendon at the ruptured end 
[92]. 
1.5 Tendon Injury 
As previously mentioned tendon injuries place a strain on the health care of many 
countries. Tendon injuries can be acute or chronic: the aetiology of tendon injuries can be 
classified as intrinsic or extrinsic factors. The intrinsic factors include: any anatomical 
predisposition, inability of the body’s biomechanics to absorb forces. Extrinsic factors can 
include environmental factors and poor training techniques [30, 93]. 
Chronic tendon disorders have a high level interaction between intrinsic and extrinsic 
factors [30]. The main pathological stimulus for tendon degeneration has been shown to 
be excessive loading during high level physical training [30] . The formation of micro-
trauma within the tendon structure over time and repeat excessive loading eventually 
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results in increased non-uniform stress and an increase in frictional forces resulting in 
partial or complete tendon rupture requiring medical intervention [30]. 
1.6 Tendon Healing 
The major studies into tendon healing have predominantly been performed on animal 
models. Therefore, the relevance to the healing of tendinopathic human tendon still 
remains unclear [30]. Tendon healing has been classified into two modes namely intrinsic 
and extrinsic healing [94]. Intrinsic healing includes the migration and proliferation of cells 
from both the endotenon and epitenon to the injury site. The migrated cells lay-down and 
establish an extracellular matrix and an internalised neo-vasculature. Extrinsic t healing 
consists of the migration and infiltration of cells from the tendon periphery and external 
tissue source [94] . Once the cells have invaded the injury site they further initiate and 
promote repair and regeneration[94]. 
The combination of extrinsic and intrinsic tendon healing has been described as a three-
phase process with each process having overlaps: - 
 First Phase: (inflammatory phase) erythrocytes and inflammatory cells 
(neutrophils) infiltrate the site of injury. During the first 24 hours necrotic tissue is 
phagocytosed by macrophage and monocyte cells. Around the site of injury 
vasoactive chemicals such as nitric oxide and chemotactic factors such as 
cytokines are released and result in an increase in vascular permeability, 
angiogenesis initiation and an increase in tenocyte proliferation and migration of 
tenocytes to the wound where type III collagen synthesis starts. 
 Second Phase: (Proliferative Phase) 2-4 days post injury the proliferative phase 
commences where synthesis of Collagen 3 is at highest and will last up to 2-3 
weeks. Also, the concentration of water and glycosaminoglycans are elevated 
during this time. 
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 Third Phase: (Remodelling Phase) Approximately 6 weeks post injury remodelling 
commences. A decrease in cell numbers and reduced collagen and 
glycosaminoglycan synthesis. The remodelling phase can be sub-divided into two 
stages of consolidation and maturation stage. The consolidation stage starts 
approximately 6 weeks post injury and can last up to 10 weeks in this time the 
repair tissue shifts from cellular to fibrous. Also tenocyte metabolism remains 
elevated and the alignment of collagen fibres and tenocytes occurs also a shift to 
type I collagen synthesis occurs. After 10 weeks, the maturation phase occurs, 
where there is a shift from fibrous tissue to scar-like tendon, which can take up to 
1 year. 
Further to the cellular response in both intrinsic and extrinsic healing the application of 
exercise in the form of physiotherapy has been shown to improve tendon repair in 
numerous biomechanical studies [95]. The regime of exercise requires strict monitoring 
and will differ between patients [95]. Immobilised tendons have been shown to have a 
higher risk of adhesion formation [95]. Forces such as friction have been calculated for 
tendon and can be used to calculate the amount of force required (such as tension) to 
induce tendon gliding and can be applied to healing tendon as to prevent complications 
such as adhesion formation [95]. 
 Current Treatments for Tendon Repair 1.6.1
Two major approaches are followed for the treatment of tendon injuries; conservative 
and surgical. However, both of these treatments regimes do not return tendon integrity 
or function to levels prior to injury [96].  
With the conservative route, relief from pain is achieved by rest, analgesia, anti-
inflammatory medication and physiotherapy (Table 1.1 that gives explanations for various 
conservative treatment regime/methods).  
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Treatment Putative Target or Mode of Action 
Rest or modification of activity Removal of precipitating factors and prevention of re-injury 
Orthotics (e.g. Heal inserts) As above 
Cryotherapy (e.g. Ice pack or baths) Reduction of acute inflammation and decrease in cell metabolism 
Heat Treatment Stimulation of cell activity and a localised increase in blood flow 
Physiotherapy (including massage and 
controlled motion) 
As above 
Electrical stimulation 
Reduction of pain perception, stimulation of blood flow and 
increase in cellular activity 
Laser treatment (pulsed or continued) 
Possible analgesic effects and unspecified (unknown) effects on cell 
activity 
Pulsed electromagnetic fields As above 
Ultrasound (0.75 - 3.0MHz, pulsed or 
continued) 
Thermal effects on tissue, stimulation of cell activity and increased 
blood flow 
Extracorporea; shock-wave therapy 
As above, with possible stimulatory effects on neovascularisation 
and inhibition of nociception 
NSAIDs 
Reduction of inflammation through inhibition of prostaglandin 
synthesis 
Corticosteroid injection 
(peritendinous) 
Reduction of inflammation  and other unknown effects (generally 
inhibitory to protein synthesis) 
Low-Dose Heparin Effects on tendon blood flow, possibly results in improved healing 
Actovegin (deproteinised extract of 
calf's blood) 
Unknown (suggested to promote glucose uptake and other effects 
on tendon cell metabolism that promotes repair and resolution) 
Glycoaminoglycan polysulphate 
Inhibition of inflammation, possibly also acting to inhibit 
metalloproteinase enzyme activity 
Eccentric exercise therapy 
Thought to promote restoration of normal tissue structure, possibly 
through an effect on cell activity and matrix remodelling 
Sclerosant injection (ultrasound - 
guided) 
Blocks tendon blood flow(targets neovascularisation and associated 
nerve in-growth) 
Platelet-rich plasma injection 
Contains growth factors (e.g. Transforming growth factor -β and 
platelet-derived growth factor that promote matrix synthesis and 
tissue repair 
Table 0.1 Conservative methods for treating tendinopathy  
Conservative treatment regime and putative target or mode of action for tendon injuries. Table 
replicated and adapted from Riley (2008) [37]. 
The conservative treatment of tendon injuries still requires a long period of time. This is 
due to the poor vasculisation and subsequent low rate of metabolism of the tendon cells, 
which results in a reduced healing capacity of tendon tissue [97].  
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To enhance the healing of the tendon, mechanical conditioning can be delivered by 
mechanical stimulus which is in turn converted into biochemical signalling via a process 
known as mechanotransduction [98]. Tendons can alter their composition and structure 
to adapt to load (mechanical) changes by up-regulating expression of those genes that 
code for growth factors which promote healing, such as platelet-derived growth factor 
(PDGF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor 
(bFGF/FGF-2) and transforming growth factor beta (TGF-β) [92].  
Other than the conservative route for tendon injuries the use of surgery is applied. The 
open technique may utilise suture or grafts [99]. If the injury is large, then grafts are 
utilised, but they have some drawbacks such as implants do not have a long practical life 
in situ. Also, poor biocompatibility which leads to an immune response which may lead to 
further or re-injury [100]. Allograft and autologous grafts may be used but both have 
some drawbacks such as the danger of immune rejection (allograft) due to immunological 
reactions [101], which may cause problems during remodelling [101, 102]. Further 
complications due to immune responses may occur. Such as adhesions that limit joint 
flexion, fibrosis and paucity of tendon differentiation signals during remodelling [103, 
104]. Also, the lack of adequate donors limits the use of allografts. The use of autografts is 
restricted by surgical induced morbidity of the donor site [98]. The damage induced at the 
point at of harvest may cause further tendonitis and pain, leading to long time periods of 
rehabilitation [105]. However, since the development of cell culture and bio-scaffolds, the 
use of autograft can be re-evaluated when using scaffold along with autologous cell 
harvest and expansion techniques. Rather than harvesting whole tissue for implantation 
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the harvest of cells to be expanded or differentiated and then re-implanted as part of a 
scaffold that can induce cellular attachment. 
 Synthetic Tendon Implants 1.6.2
A more recent strategy which employs a synthetic scaffold to bridge the tendon defect, 
have been employed by many research group. This strategy which uses scaffold only and 
has utilised materials such as: nylon, carbon fibres and dacron for tendon injuries repair, 
but the success is very much limited, with high rates of failure [96]. Therefore, another 
strategy is highly desired to provide a functional alternative. More recently, research has 
been focused on the use of synthetic and biological scaffolds that are capable of 
withstanding the physical properties endured by tendon. Once the physical requirements 
of the scaffold have been addressed the incorporation of a cellular component to the 
scaffold. The addition of a cellular component that can be incorporated to the scaffold 
and either induce cellular regeneration or actually become “new” tendon is highly 
desired. Cells such as tenocytes or mesenchymal stem cells could be introduced with the 
scaffold and mechanically stimulated. Mechanical stimulation has been shown to enhance 
development of matrix, improve structural properties and drive the differentiation 
process. Another component could be added to the tendon scaffold such as a growth 
factor delivery system which could further enhance differentiation and ultimately scaffold 
integration. However, to date such a scaffold system does not exist and limited success in 
tenocytes-scaffold fusion to the proposed scaffold [106].  
Synthetic Scaffolds require specific properties as they are exposed to various mechanical 
and biological factors after their implantation into the patient’s body. These properties 
should include as a prerequisite: 
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 Immunologically inert 
 The ability to withstand the mechanical properties endured by native tissue 
 Biodegradable or bioresorbable 
Ideally the synthetic scaffold should be metabolised by enzymes that are “natural” to the 
metabolic pathways of the specific tissue at point of implantation within the body. 
Furthermore, the rate of formation of new tissue and scaffold degradation should show 
an inverse relationship (as the tissue formation increases the mass of implant decreases 
until the new tissue completely replaces the implant/scaffold). 
 Acellular tendon implants 1.6.3
Acellular tissue grafts have been used in the repair of neglected tendon ruptures [107, 
108], graftjacket® being used in both the augmentation of mid-substance peroneal 
tendon defects [109] and the repair of lacerated anterior tibial tendon [110]. Graftjacket® 
has been shown to reduce pain and has also been shown to be tolerated well by 
recipients with the implant showing integration to the recipient tissue after 20 -30 
months [110]. Barber et al. showed graftjacket® to have favourable mechanical properties 
when implanted to augment rotator cuff repair [111, 112]. However, when repairing 
Achilles tendon defects the graftjacket® had an ultimate load failure of 50% of native 
tendon and a 33% stiffness when compared to native tendon [111, 112]. Due to the 
failure rates in mechanical properties the requirement for a tissue engineered approach 
especially for Achilles tendon is highly desired and may include the use of synthetic 
polymers. 
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 Synthetic Polymers Currently Being Researched as Tendon 1.6.4
Implants 
Many polymers have been investigated for their potential use in tendon repair. Examples 
of such polymers are shown below in Table 1.2.  
Polymer Repair Type Outcome Reference 
Polyglycolic Acid (PGA) Canine Rotator cuff Slight improvement in 
mechanical properties 
compared to the control 
group. 
Derwin et al.[113] 
Polylactic Acid (PLA) Rabbit Rotator cuff Fibroblast alignment and 
tissue pattering in 
compared to control. 
Yokoya et al.[114] 
Poly (lactic-co-glycolic) 
Acid (PLGA) 
Rabbit Achilles Tendon Cellular infiltration and 
polymer integration at 
point of attachment. 
Ouyang et al.[115] 
Table 0.2 Polymers implanted in a tendon repair model. 
Previous studies using implants to repair tendon injuries have employed polymers such as 
polyglycolic acid (PGA) and polylactic acid (PLA) [113]. Varying degrees of success have 
emerged ranging from histological indications of fibroblast alignment and patterning in 
PLA models when compared to the PLA control and slight improvement in mechanical 
properties of the repaired tendon in Japanese white rabbits with the PGA scaffold [114]. 
However, to date there are no commercially available polymer based scaffold available 
for the treatment of tendon injury. PLGA implanted to repair a tendon defect in the rabbit 
model showed cellular infiltration and integration at the point of attachment [115]. 
Although the implants researched have shown tissue integration, cellular alignment and 
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minimal immune response and improved mechanical function compared to control 
groups. PLA, PLGA and PGA implants have failed to return the mechanical properties 
observed in native tendon. 
One promising polymer group that has a potential use in tendon repair is the 
polyhydroxyalkanoates (PHAs). PHAs are a group of natural polyesters that can be 
biologically synthesised by a wide range of micro-organisms [116]. PHAs are synthesised 
via biosynthesis pathway (Figure 1.5) and form granules within the cytoplasm, Therefore, 
the PHA serves as an energy store much like lipids/glycogen in mammalian cells. PHAs can 
contribute up to 80% (w/w) of the cell dry weight matter of cell or even more. Due to the 
high percentage w/w ratio up scaling of the production of the PHAs is being highly 
researched. Large-scale production of PHA is based upon the industrial fermentation 
employed by pharmaceutical industry in the production of antibiotics in the early 1920s 
[117]  
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Figure 0.5 Metabolic pathway involved in the synthesis and breakdown of PHB in Eutropha  
When carbon source is plenty and the organism is stressed the PHB metabolic pathway for Europha is 
activated and Acetyl-CoA is channelled to towards P(3HB) synthesis which in turn is channelled towards 
D(-)-3-hydroxybutyrate [118]. 
Depending on the nutrient stress placed on to the organism can results in different PHA 
molecules being synthesised (Figure 1.6). This can allow manipulation of the growth 
environment to produce a range of polymers. 
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Figure 0.6 Structure of polyhydroxylalkanoates  
Basic carbon backbone structure of PHBHHx, with R indicating the position of the functional group with 
the polyhydroxyalkanoate polymer. The blending of a polyhydroxyalkanoate can be achieved by varying 
the functional group. The percentage ratio of different functional groups can convey different mechanical 
properties [118]. 
 Poly -3- hydroxybutyrate-co-3-hydroxyhexanoate 1.6.5
Polyhydroxybutyrate (PHB) was the first Polyhydroxyalkanoate (PHA) to be discovered 
and is the most extensively studied [118]. Poly-3-hydroxybutyrate-co-3-
hydroxyhexanoate (PHBHHx) is a co-polymer, which consists of 3-hydroxybutyrate and 3-
hydroxyhexanoate [119]. Both polymers are members of the PHA family and are 
produced by microorganisms when stressed due to unbalanced growth conditions with 
the presence of excess carbon source and are stored within the cytoplasm of the 
organism as insoluble inclusions [119, 120].  
PHBHHx has also been made in to fibres (Figure 1.7) and electro-spun microfibers making 
this material very pliable and adaptable for control of degradation rates dependant on 
surface area/volume ratio and molecular weight [119]. Furthermore, improvements in 
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some of the physical properties of the PHBHHx polymer have been achieved by adjusting 
the ratio of HB to HHx. The adjustments in the ratio of HB to HHx results in an alteration 
in both Young’s modulus and strength of the PHBHHx polymer, allowing the polymer to 
be used in a possible array of applications [119]. 
Recent research into the biocompatibility of PHBHHx and its blends, have been evaluated 
in-vitro by the use of murine fibroblast cell line L929. Results from this study showed PHB 
and PLA films to have poor biocompatibility ,whilst PHB - PHBHHx and PHBHHx showed a 
vast improvement in biocompatibility and the level of improvement was dependant on 
the amount of PHBHHx present in the blend [119].  
 
Figure 0.7 Scanning electron micrograph of PHBHHx fibres 
A) PHBHHx weave of 3 strands of 217um in width and B) Shows a single strand of PHBHHx used in A, C & 
D) show cross-section samples of PHBHHx porous filmsAll images were taken at the Department of 
Microscopy using Scanning Electron Microscopy, Tsinghua University, China. 
Also, by mixing blends alterations in young’s modulus and strength have been reported 
[119]. Therefore, PHBHHx is a good choice for investigation into its potential use as a 
biodegradable implant in the treatment and repair of tendon using cell based therapies 
and developmental biology. 
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1.7 Vitamin C 
Vitamin C (ascorbic acid) has been shown to be vital in many biological processes. Early 
research into collagen synthesis has shown Vitamin C to be vital in the synthesis of 
healthy collagen [121, 122]. Research performed by Elster showed that collagen did not 
require ascorbic acid [123]. Whereas, Robertson and Schwatrz showed that precollagen 
increased when guinea pigs were nutritionally supplemented with ascorbic acid in a 
wound healing model [121].  
The requirement for ascorbic acid for collagen synthesis is vital in connective tissue 
development as ascorbic acid is required for enzyme activity in the synthesis of both 
hydroxyproline and hydroxylysine [124, 125]. The major function of hydroxyproline is to 
serve as a molecular stabiliser in that hydroxyproline stabilises the collagen triple helix 
and the absence of this molecule leads to unstable collagen [125]. Hydroxylysine is 
required for not only the intercellular crosslinking of collagen but also the glycosylation of 
collagen which is thought to be important in the crosslinking of collagen and further 
adding to the mechanical properties of collagen [125]. 
The major modulation of collagen synthesis is achieved by ascorbic acid through its 
effects on prolyl hydroxylation via prolyl hydroxylase (Figure 1.8) [125]. Murad et al also 
noted and increase in lysyl hydroxylase activity when human fibroblast cells were 
supplemented with ascorbate [125]. Lysyl hydroxylase is vital in the cross link formation 
of collagen and ascorbic acid has been shown to increase intracellular hydroxylation and 
inhibit extracellular oxidation of collagen residues [126]. Furthermore, Murad et al 
postulated that due to collagen levels continuing to rise even after optimum levels of 
ascorbate had been achieved that the influence of ascorbate on collagen synthesis could 
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not be only attributed to hydroxylation. However, ascorbic acid is a key component for 
collagen synthesis [125] 
 
Figure 0.8 Effects of Vitamin C on the biosynthesis of collagen flowchart. 
Biosynthetic pathway for collagen indicating the point of cofactor interaction by Vitamin C adapted from 
Sharma et al [124]. 
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1.8 Oxygen Tension 
The most critical component for aerobic cell survival is the presence of oxygen [127]. A 
reduction in oxygen availability can lead to not only loss of cellular functionality, but also 
cell death [127]. 21% Oxygen culture environment is widely considered to be the 
normoxic condition, however, physiological normoxia is actually within the range of 2% -
9% for the majority of cell types within the adult mammalian system [128].Due to the 
requirement of oxygen over the course of animal evolution, both special and sensitive 
mechanisms have developed to minimise the possible disastrous effects of low oxygen, 
such as transcriptional profile alteration [129]. 
The importance of oxygen gradients within the stem cell niche can be traced to early 
research conducted on endometrial and trophoblastic tissues in early pregnancy [130]. 
Prior to the formation of a circulatory system, the delivery of oxygen to the developing 
embryo is subject to the limitations of diffusion, with the estimated diffusion distance for 
oxygen being 150μm [131, 132]. Therefore, early mammalian development actually 
occurs in a relatively low oxygen environment.  
Hypoxic culture environments have been shown to maintain the undifferentiated state of 
stem cells such as hematopoietic stem cells [133], mesenchymal stem cells [134], neural 
stem cells [135] and human embryonic stem cells [136]. Furthermore, hypoxic conditions 
have also been shown to influence quiescence, proliferation, differentiation leading to 
cell fate commitment [127]. Stem cells are primarily defined by their ability to self-renew 
and maintain a production of mature cells, which has been found to reside predominantly 
within a hypoxic niche [137, 138]. 
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The hypoxia inducible factor (HIF) group of gene products play a major role in the 
maintenance of stem cell potency [129]. Currently, there are six known HIF genes which 
code for six transcription factors (Table 1.3). 
Recent observations in the hypoxic cultivation of hMSCs not only prevents their 
differentiation, but also increases their proliferation potential [139]. Further research by 
Grayson et al (2007) showed that cultivation in hypoxic conditions leads to an increase in 
the expression levels of the HIF-2α protein and the Oct4 protein which is associated with 
not only undifferentiated phenotype but also the self-renewal of stem cells [140]. 
Member Protein Gene 
HIF-1α Hypoxia-inducible factor 1, alpha subunit HIF1A 
HIF-1β Aryl hydrocarbon receptor nuclear translocator ARNT 
HIF-2α Endothelial PAS domain protein 1 EPAS1 
HIF-2β Aryl hydrocarbon receptor nuclear translocator 2 ARNT2 
HIF-3α Hypoxia-inducible factor 3, alpha subunit HIF3A 
HIF-3β Aryl hydrocarbon receptor nuclear translocator 3 ARNT3 
Table 0.3 Members of the HIF transcription factors and genes. 
HIF are sub divided into 3 groups of 2 members namely α and β. The table above shows the HIF member 
and associated protein along with gene name [129]. 
An array of studies have been undertaken to investigate the effects of low oxygen 
environments on ESCs which employed the use of ESCs derived from many species (e.g. 
human, and ovine), where an increase in the inner cell mass size has been observed in 
ovine research [141]. Low oxygen tension has also shown an enhancement in hESC clonal 
recovery and a reduction in chromosomal abnormalities [142]. HIF-2α has also been 
shown to be up-regulated in hESC which results in the suppression of p53 and ultimately 
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enhances the stemness and regenerative potential when cultured under hypoxic 
conditions [143]. 
Therefore, the differentiation of both mesenchymal and embryonic stem cells towards a 
tenocyte lineage should be investigated at both 21% and 2% oxygen environments due to 
the effects of HIF proteins on differentiation. 
1.9 Stem Cell Therapy 
Since the discovery and subsequent isolation for embryonic stem cells, which Nobel Prize 
was awarded to Sir Martin Edwards, Mario R. Capeechi and Oliver Smithies. Stem cells 
and their potential application have held hope for those afflicted with incurable and 
degenerative disease. To date, the treatments and/or therapies that employ embryonic 
stem cells that have been translated from the laboratory to the clinical application have 
been very few. 
Stem cells were first studied by Becker et al. in 1963 with the injection of bone marrow 
cells into irradiated mice and subsequent nodule development in the spleens of the mice 
in proportion to the number of bone marrow cells injected. From this research, they 
concluded that each nodule arose from a single marrow cell. Subsequently, they 
determined that these cells were capable of infinite self-renewal, a central characteristic 
of stem cells [144]. Thus, stem cells by definition have two essential properties, i.e. the 
capacity of self-renewal, giving rise to more stem cells, and the capacity to differentiate 
into different cell lineages under appropriate conditions. Broadly speaking, there are two 
main types of stem cells, embryonic and non-embryonic. Embryonic stem cells (ESCs) are 
pluripotent and, accordingly, they can differentiate into all three embryonic germ layers 
[145]. Non-embryonic stem cells (non-ESCs) derived from marrow, fat or cord-blood are 
W. R. Webb PhD Thesis Chapter 1 
38 
 
multipotent; their potential to differentiate into different cell types seems to be more 
limited [146]. 
 Human Embryonic Stem cells 1.9.1
Alexis Carrel was a Nobel laureate and an innovative surgeon, his experiments with the 
transplantation and repair of body organs led to advances in the field of surgery and 
tissue culture. In January 1912, he placed part of a chicken’s embryo heart in a culture 
containing fresh nutrient medium. He found that every 48hrs the tissue doubled in size. 
This continued for 34 years, outliving Carrel himself. Even though these cells were unlikely 
to be embryonic stem cells but more likely related to chord-derived or foetal cells, this 
experiment showed the future potential of embryonic/foetal cells and tissue culture [147, 
148]. 
Murine Embryonic Stem (ES) cells were first described in 1981 [145, 149]. The 
development of ES cells evolved from the work on murine teratocarcinomas, which are 
tumours that arise in the gonads and consist of an array of somatic tissue arranged in a 
disorganised fashion [150]. In 1995 primate ES cells were derived from rhesus monkey 
pre-implantation blastocysts and later from the marmoset [151, 152]. It was not until 
1998 when expanding the previous primate studies that Thompson and co-workers 
derived human ES cells from surplus blastocysts donated by couples undergoing fertility 
treatment and it was at this point at which embryonic stem cell research evolved [150, 
153]. 
Many of the advances in stem cell science are based on developmental studies of mouse 
embryogenesis. The first stage of life, the fertilized egg, has the potential to generate an 
entire organism. This capacity is defined as totipotency and is retained by the early 
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progeny of the zygote up to the eight-cell morula. Subsequently, cell differentiation 
results in the formation of a blastocyst composed of the outer trophoblast cells and 
undifferentiated inner cells, commonly referred to as the inner cell mass (ICM) (Figure 1.9 
differential pathway from zygote to blastocyst).  
 
Figure 0.9 Post fertilisation blastocyst development prior to embryonic stem cell extraction. 
The fertilised egg from 2 cells to 4 to 8 cells to become the early morula. When the morula reaches 16 to 
32 cells there are distinctive inner and outer cells, as the morula continues to develop a distinct late 
cavitation. The morula can be observed until the early blastocyst has developed. The early balstocycst 
continues to develop through to the late blastocyst were the PE-Primitive endoderm and  EPI-Pluripotent 
epiblast are found [150]. 
Cells of the ICM are no longer totipotent but do retain the ability to develop into all cell 
three germ layers and subsequently the specific tissue types (Figure 1.10). The cells within 
the blastocyst then become the one of three germ layers (Ectoderm, Endoderm and 
Mesoderm) that will eventually give rise to all the cellular components and tissue of a 
fully developed foetus. 
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Figure 0.10 ESC differential potential of embryonic stem cells 
The early zygote develops into the blastocyst from which all three germ layers will arise and eventually 
develop in to a fully developed foetus [150]. 
 Human Mesenchymal Stem Cells 1.9.2
The concept of mesenchymal stem cells (MSCs) is a term first coined by Arnold Caplain 
(1991) and can be traced to experiments demonstrating that the transplantation of bone 
marrow (BM) to heterotrophic anatomical sites resulted in de novo generation of ectopic 
bone and marrow [154]. Further examples of such studies date back to the 19th century 
by Goujon, and also the work of Tavassoli and Crosby (1968), which clearly established 
proof of an inherent osteogenic potential associated with BM. The Tavassoli and Crosby 
experiments were conducted with entire fragments of bone-free BM, the precise identity 
of any cell functioning as a progenitor of differentiated bone cells and therefore of non-
haemopoietic, mesenchymal cells could not be delineated. 
It was not until a series of seminal studies conducted by Friedenstein and co-workers in 
the 1960s and 1970s, who demonstrated that the osteogenic potential, as revealed by 
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heterotrophic transplantation of BM cells, was associated with a minor subpopulation of 
BM cells [154, 155]. These cells were distinguishable from the majority of haemopoietic 
cells by their rapid adherence to tissue culture vessels and also by the fibroblastic-like 
morphology of their progeny in culture, which indicated their origin from the stromal 
compartment of BM [155]. Further work by Friedenstein and co-workers provided a 
second major breakthrough by showing that seeding of BM cells suspensions at clonal 
density resulted in the establishment of discrete colonies initiated by single cells (known 
as the colony-forming unit fibroblastic, CFU-Fs) [155]. In vivo transplantation led to the 
recognition that multiple skeletal tissues (bone, cartilage, adipose tissue, and fibrous 
tissue) could be experimentally generated, in vivo, by the progeny of a single BM stromal 
cell [155]. Friedenstein and Owen called this cell an “Osteogenic stem cell”, and later in 
1988 called the cell a “Stromal stem cell”. The implications of these discoveries were 
initially only appreciated by experimental haematologists, only later was the relevance to 
tissue biology and disease appreciated.  
In 1978 Schofield conceptualised the “Stem cell niche hypothesis” with the notion that 
haemopoietic stem cells (HSCs) are regulated by their physical association with discrete 
cellular microenvironment within the BM. This hypothesis was substantiated by further 
experimental observations by Dexter et al., 1977; Allen, 1978; Dexter and Testa, 1976 
[155]. 
The pioneering works by Tevassoli,  Friedenstein, and Owen revealed that a second type 
of stem cell could be present in the BM and, specifically, in the haematopoiesis-
supporting stroma [155]. The concept of non-haemopoietic stem cells in BM did not 
resonate worldwide until the additional work of Pitttenger in 1999. Combined with the 
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timing of the isolation of ES cells, the term mesenchymal stem cells (MSCs) gained wide 
popularity and in the minds of many, MSCs became one kind of postnatal human stem 
cell with a differential properties broader than originally envisioned and possibly as broad 
as ES cells (Figures 1.11). 
 
Figure 0.11 Mesenchymal stem cell differentiation potential  
Differentiation properties and cell lineage arising from MSCs which include: bone, cartilage, muscle, 
stromal, tendon/ligament, fat and dermal tissues [155-157].  
Currently BM derived MSCs are being used in an array of research topics in tissue 
engineering including tendon repair [156], tendon and ligament engineering [157], 
myocyte generation [158] and neuronal differentiation [159] to mention a few. 
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  Tendon Progenitor Cells 1.9.3
Present in the extracellular matrix of the tendons are tendon stem progenitor cells (TSPC) 
[160]. Comparison of TSPC with cells of the human bone marrow demonstrated that the 
TSPC showed increased expression of tenomodulin, scleraxis and collagen type I, which 
are all markers of tendon cells in comparison to bone marrow cells and type II collagen 
(expressed in case of cartilage and bone) was not expressed by either of these cells. The 
extracellular matrix was responsible for regulating the renewal and differentiation 
capacity of TSPC and it was subsequently found that fibromodulin (Fmod) and biglycan 
(Bgn) was present in the matrix and were highly expressed in TSPC and were responsible 
for converting TSPC into tendon tissue [160]. These findings have been supported by the 
fact that when these two proteins were not expressed in the matrix or when their 
expression was inhibited then bone tissue was formed. This evidence highlighted that the 
two proteins were playing a very important role in the extracellular matrix (Niche) by 
regulating the signalling pathway of the BMP in order to give rise to tendons by 
differentiating TSPC and this conversion of TSPC into tendons often got disturbed in the 
absence of Bgn and Fmod, leading to the disruption of collagen fibre organisation which 
lead to big gaps in the tendon followed by an increment in the collagen type II and 
aggrecan (marker for chondrocyte) and a marked decrease in the expression of collagen 
(Type I) and scleraxis, ultimately leading to formation of bones [160]. However, the key 
limitation to the use of TSPC is that tendon contains a reduced number of cells than other 
tissue meaning a vastly lower number of TSPC within the tendon. Also the process of 
harvesting the cells would induce further trauma to the tendon [160]. 
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1.10 Growth Factor Induced Tendon Regeneration 
Growth factors can engage in autocrine, juxtacrine, paracrine and endocrine stimulation. 
If the receptor resides on the same cell where the ligand is expressed, the resulting 
cellular stimulation is autocrine; when the growth factor diffuses from cell to 
neighbouring cells in the same organ/tissue, stimulation is paracrine, and juxtacrine 
stimulation is a mode of signalling reserved for those membrane-anchored growth 
factors, which interact with receptors located on the neighbouring cells. When a factor is 
transported through the bloodstream from the place of synthesis to other tissues 
equipped with a receptor that can recognise the factor, stimulation is endocrine, as in the 
case of hormones such as insulin and human growth hormone (hGH) [161] 
Recently many papers have been published in regards the use of growth factor induced 
tendon regeneration. An array of growth factors and combination of growth factor 
cocktails have been investigated and include members of the Transforming growth factor 
super family (TGF), Platelet derived growth factor (PDGF), Bone morphogenic proteins 
(BMP) and vascular endothelial growth factor (VEGF) with varying degrees of success 
(Table 1.4). 
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Growth Factor 
Type of treatment 
and species 
Results and References 
bFGF 
 
ACL in Canine [162] 
MCL in Rabbit [163] 
PT in Rat [164] 
Flexor tendon in 
Canine[165] 
Enhanced tendon healing was observed in 
ACL canine[162] . Early formation of tissue 
repair was observed in MCL in rabbits 
[163]. Increased expression of Collagen 3 in 
PT repair in the rat model [164]. No 
improvement was observed in flexor 
tendon canine model with increased scar 
tissue formation was observed [165]. 
GDF-5 
Flexor tendon in Rabbit All repairs failed. Increased early maximum 
load observed in GDF-5 treated samples 
compared to control [166] . 
GDF-6 
Achilles tendon in Rat Increase in tendon strength compared to 
control [167]. 
IGF-1 
Achilles tendon in Rat Reduction in immune response resulting in 
increased rate of repair [168]. 
PDGF-ββ Achilles tendon in Rat Increased healing observed [169]. 
SDF-1 Achilles tendon in Rats 
Larger collagen fibrils compared to control 
and physiological structures [170]. 
TGF-β1 ACL in Rabbits 
Rapid and continuous proliferation of 
fibroblasts with elevated collagen 1 and 3 
[171]. 
TGF-β2 MCL in Rabbit 
Elevated Collagen 1 expression with rapid 
proliferation [172]. 
Table 0.4 Growth Factors used in Tendon Repair  
The Above table shows growth factors investigated in tendon repair table is adapted from Lui et al [173]. 
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 Transforming Growth Factor-β 1.10.1.1
The transforming growth factor β (TGF-β) superfamily consists of over 30 members and 
many subgroups such as Bone Morphogenic Proteins (BMPs), Growth and Differentiation 
factors (GDFs), Activins and Nodals, all of which have a major function is the development 
of the foetus [174, 175]. The TGF-β superfamily and the downstream pathway 
components are a well conserved in vertebrates [174]. The TGF-β superfamily have been 
shown to have an array of diverse cellular responses which include: growth, adhesion, 
migration, apoptosis and differentiation [174]. 
The sub-group of proteins within the TGF-β superfamily, BMPs have been shown to be 
highly involved in bone and skeletal tissue development. BMP-4 has been shown to be 
involved in the regulation of bone formation [175], whilst BMP-12 has been shown to be 
involved in tendon generation [176]. 
 Bone Morphogenic Proteins 1.10.1.2
Bone morphogenic proteins (BMPs) are a sub group of the TGF-β growth factors with 20% 
– 30% amino acid homology to other members of the TGF-β superfamily [177]. BMPs are 
considered to be pleiotropic, affecting many different tissues in subtly different ways 
[177]. BMPs have also been shown to play a role in tissue healing and embryonic 
development [178]. Currently over 30 BMPs have been identified with some also falling 
under the growth and differentiation factors group (GDF7 also being known as BMP-12). 
Recently, BMP-12 has been researched as having a role to play in tendon differentiation 
by means of gene transfection [176, 179, 180]. Also, BMP-13 has also been implicated in 
tenogenic differentiation [181]. However, tenogenic differentiation is not limited to just 
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BMP-12 and 13, as both BMP-2 and BMP-7 have also been shown to have a role in tendon 
repair [182]. 
To date the use of gene transfection has been employed to induce increased repair of 
damaged tissue and the differentiation of mesenchymal stem cells towards a tendon-like 
tissue [176, 180]. A study by Fu et al showed that BMP-12 was expressed in healthy 
human patellar tendons and located in clusters of tenoblasts in active remodelling sites 
and also perivascular mesenchymal cells [183]. However, expression of BMP-12 was not 
apparent in tenocytes found sitting on intact collagen [183]. This research showed that 
BMP-12 does actively play a role in certain physiological processes in healthy adult 
tendon and may be related to tissue regeneration due to the up-regulation of matrix 
proteins such as procollagen I and II [183]. The data obtained from the study by Fu et al 
lead to the hypothesis that BMP-12 is involved in the remodelling of tendon tissue that 
has micro-injuries induced by normal activities due to hyper-cellular areas correlating to 
increased BMP-12 expression. Further findings included the culture of human tendon 
fibroblasts in the presence of rhBMP-12 showed a marked increase in procollagen types I 
and III [183].  
 Fibroblast Growth Factor 1.10.1.3
Fibroblastic growth factor-4 (HST-1, FGF-4) was originally identified as fibroblastic-specific 
growth factors [184]. Fibroblastic growth factors (FGFs) are a large family of signalling 
polypeptide growth factors that are evolutionary conserved between species. Currently, 
there have been 23 members identified within this large family within vertebrates, with a 
molecular mass ranging from 17 – 34kDa, with a 13 – 71% conservation of amino acid 
identity [185, 186]. 
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From the 22 genes responsible for the coding of the FGF proteins, the function of FGF-16 
still remains unknown [185, 187]. Several of the FGF genes have been shown to be 
located in clusters, FGF-3, FGF-4 and FGF-19 being a good example of such clustering 
which can be found on chromosome 11q13 and these individual genes have been shown 
to be separated by as little as 10 – 40kb [185]. The apparent clustering of FGF genes and 
the work undertaken by Kelley et al. 1992 which showed that a transcriptionally active 
portion of FGF-7 could be amplified to 16 copies which were dispersed throughout the 
human genome along with sequence conservation, could be due to chromosomal 
duplication and truncation during evolution [185, 187, 188]. 
Fibroblast growth factor -4 (FGF-4) was originally identified by Sakamoto et al., 1986 and 
Deili-Bovi et al., 1987 as HST-1 gene from human stomach cancer and Kaposi’s sarcoma 
by a NIH3T3 transforming assay. The deduced amino acid sequence for FGF-4 has been 
shown to have 43%, 38% and 40% homologous sequences to fibroblastic growth factor -2 
(FGF-2), fibroblastic growth factor -1 (FGF-1) and fibroblastic growth factor -3 (FGF-3), 
respectively [186]. The gene loci for FGF-4, was located on chromosome 11q13 along with 
FGF-3 and FGF-19 as a clustered region of FGFs [189-191]. After protein synthesis FGF-4 is 
cleaved and glycosylated to produce a mature protein of 176 amino acids, which excludes 
the cleaved 30 amino acids of the signal peptide [192, 193]. 
Delli-Bovi et al. 1988 investigated the effects of inhibition of glycosylation and impaired 
secretion of FGF-4; it was also found that the stability of FGF-4 was increased by the 
presence of heparin in the culture media. It was also found that FGF-4 in the un-
glycosylated form was cleaved into two NH2-terminally truncated peptides, which were 
13 and 15 kDa [194]. These two peptides were investigated and found to be more active 
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than the wild-type protein and also showed increased affinity for heparin-binding [195, 
196]. Kosaka et al. 2009 proposed, “That these two proteins could represent a novel 
mechanism for regulation of FGF-4 mediated biological activity”. FGF-4 is expressed in 
pre-implantation murine blastocysts and is also present in the inner cell mass (ICM) [197, 
198]. 
The FGF-6 gene is located on chromosome 12p13.32 and encodes for 18.7kDa protein, 
which consists of 206 amino acids and has been shown to bind to the FGFR-1c, 2c and 
4.The FGF-6 gene was first cloned by low stringency hybridization to an FGF-4 probe in 
1989 by Marcias and co-workers [199]. De Lapeyriere et al. reported in 1990 that FGF-6 
transcripts were present in adult muscles and during embryogenesis. Further 
investigations into the action of FGF-6 by Zhao & Hoffman (2004) in regards embryonic 
myogenesis revealed FGF-6 was the likely ligand for FGFR-4 and positional cues that 
dictate the cell determination, proliferation and differentiation into adult muscle[200]. 
Furthermore, antagonists of Wnt signalling, sFRP1, SFRP2 and sFRP4 (secreted frizzled-
related proteins) were significantly up-regulated, which suggested active inhibition of not 
only the Wnt pathway (Wnt1, 3a, 7a and 11), but also shh (sonic hedgehog) pathway and 
BMP pathway were not induced in muscle regeneration [200]. Recently, in-situ 
hybridization studies conducted by Amand et al. had shown FGF-6 expression to be 
restricted to developing skeletal muscle [201, 202]. Studies conducted using the murine 
model has shown FGF-6 presence at E9.5 and to be exclusively present in the myotomal 
compartment of the somite [201, 202]. Due to the interaction between muscle and 
tendon is the transmission of forces between muscle and bone it is also feasible that FGF-
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6 could play an integral role in the development of tendon and muscular-tendon 
junctions. 
The FGF-8 gene is located on chromosome 10q25-q26 and encodes for 22.4 kDa protein 
consisting of 193 amino acids. Early investigation into the role of FGF-8 in limb 
development was conducted by Moon and Capecchi in 2000 where they undertook 
experimental work to assess the role of FGF-8 during mouse limb development [203]. As 
with FGF-4 and FGF-6 the AER provided the signals to maintain mesenchymal cells in the 
proliferative state in the PZ during limb development.  
The research showed that exogenous FGF-8 was capable of inducing ectopic limb 
development and also used to replace the AER to support continued limb development. 
The limb patterning along the anterior/posterior axis was also shown to require 
interactions between the zone of polarising activity (ZPA) and the AER, where Shh (sonic 
hedgehog protein) was the proposed mediator of polarisation [203]. Moon & Capecchi 
went further in the research to say BMP-2 may be responsible for FGF levels in the AER 
rather than Shh due to asymmetrical expression of downstream genes such as Hoxd 
genes and BMP-2 [203]. Further research conducted by Park et al. showed that FGF-8 as 
with other FGF family members has a role to play in not only limb development but also 
organogenesis in this case the heart [204]. This would indicate the combined effect of 
cellular positioning due to polarisation (local polarisation) and FGF signalling may be the 
key in development specification. Meaning cell positioning is the primary determining 
factor in the fate of tissue to develop when FGF signalling initiates and maintains 
proliferation and differentiation. 
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Reciprocal interaction between muscle and tendon has been reported in numerous 
studies, which is vital for their respective tissue development [14, 205-208]. 
Experimentally generated muscle-less limb models in both the chick and mouse models 
have shown initial tendon development to be independent from muscle. However, 
continued tendon development requires the presence of muscle. This requirement was 
shown by the failure of tendon segregation and differentiation in the absence of muscle 
[82, 205, 209].  
 Bone Morphogenic Protein Receptor 1.10.1.4
The BMP12/13 molecule binds first to a type II receptor. The receptor-ligand complex 
then combines with a type I receptor, forming an oligomeric signalling receptor complex. 
Both the type I and type II receptors have cytoplasmic serine/threonine kinase domains. 
With TGF-β (which BMPs are a member) signalling is transmitted via SMADs, which are a 
family of signal transducers and transcriptional activators [161]. TGF-β receptor activation 
is a good example of the mutual dependency of dimerization and trans-phosphorylation. 
Type I receptors have a highly conserved, 30 amino acid long region which precedes the 
kinase domain. This region is the GS (glycine-serine) domain because it contains the 
protein sequence GSGS. On interaction with the liganded type II receptor, the GSGS 
sequence in receptor I is trans-phosphorylated by the type II receptor. Phosphorylation of 
ser165 in the GSGS sequence is crucial and determines the intensity of signalling [161]. 
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Figure 0.12 BMP-BMPR signal cascade  
BMP binds to either BMPR I or BMPR II dependant on ligand specificity. Both BMPR I and II result in the 
phosphorylation of SMAD-1, 5 and 8 combinations which bind with SMAD-4. Post binding with SMAD 4 
the newly formed SMAD complex translocates to within the nucleus and activating co-factors that result 
in target gene transcription. Activation of both BMPRs can also result in activation of Ras and MAP3K7IP3 
and result in further signal transduction with results still to be elucidated [178, 181].  
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 Fibroblast Growth Factor Receptors 1.10.1.5
All FGFs have been shown to contain an internal core with 28 highly conserved amino 
acids and 6 invariant amino acid residues [187]. Plotnikov et al [210], where ten of these 
conserved amino acids are responsible for the interaction between FGF and its receptor 
(FGFR). Structural studies by Zhu et al. [211] and Eriksson et al. [212] both showed that 
FGF1 and FGF2 contained 12 anti-parallel β strands which were located in the highly 
conserved protein core region. Faham et al [213] went on to show that FGF1 and FGF2 
both have a β trefoil structure, which has the presence of 4-stranded β sheets, which 
were arranged in a triangular array. Furthermore, the 2 β strands (strands β10 and β11) 
were shown to contain several amino acid residues that formed the primary FGF2 
heparin-binding site [210-213]. 
The four known Fibroblast growth factor receptors (FGFR) FGFR1 through FGFR4 sharing 
between 55% and 72% homology at the protein level [214, 215] and are a vital 
component of signalling cascades, which have been shown to control embryonic pattern 
formation in animals [216]. The general structure of the FGFR family are characterised by 
a modular structure with seven domains [214]:- 
 N – terminal signal sequence 
 The presence of usually 3 extracellular Ig-like loops (Ig I to Ig III) 
 An acidic domain IgI and IgII 
 Single transmembrane domain 
 Split tyrosine kinase domain 
During FGF and heparin sulphate proteoglycan binding it has been shown that of the 3 Ig-
like loops, only the juxtamembrane IgII and IgIII domains are required. Olsen et al. 2003 
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[217] showed the IgI domain is neither essential for FGF binding or receptor activation, 
but does exert a modulatory, auto-inhibitory function by the folding back to IgII and IgIII 
[217-219]. 
The FGF receptors show a high level of conservation in homology between each receptor 
type (Table 1.5) [220]. Although there are many types of FGFs and they convey a diverse 
range of effects on target cells, this is achieved by the high level of variance in the 
receptor[220]. This level of diversity is best demonstrated with FGF-7, which has a 
mitogenic effect on keratinocytes, however, this effect is not observed with fibroblast or 
endothelial cell lines [221]. This observation in regards FGF-7 implies that different cell 
lines will react differently to the same FGF signal and this reaction is dependent upon the 
cellular expression of receptor and which variant of the receptor the cell expresses [220]. 
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Name Synonym(s) Receptors Reference 
FGF-1 Acidic FGF, aFGF FGFR-1, IIIb & IIIc; FGFR-2, IIIb 
& IIIc; FGFR-3, IIIb & IIIc; FGFR-
4 
Ornitz et al [222] 
 
FGF-2 Basic FGF, bFGF FGFR-1, IIIb & IIIc; FGFR-2, IIIc; 
FGFR-3, IIIc, FGFR-4 
Ornitz et al [222] 
FGF-3 Int-2 FGFR-1. IIIb; FGFR-2, IIIb Ornitz et al [222] 
FGF-4 kFGF, Kaposi FGF, 
hst-1 
FGFR-1, IIIc; FGFR-2, IIIc; FGFR-
3, IIIc; FGFR-4 
Ornitz et al [222] 
FGF-5  FGFR-1, IIIc; FGFR-2, IIIc Ornitz et al [222] 
FGF-6 hst-2 FGFR-1, IIc; FGFR-2, IIIc, FGFR-4 Ornitz et al [222] 
FGF-7 KGF FGFR-2, IIIb Ornitz et al [222] 
FGF-8 AIGF FGFR-1, FGFR-2, IIIc, FGFR-3, 
IIIc, FGFR-4 
Ornitz et al [222] ,Koga et al 
[223] 
FGF-9 GAF FGFR-2, IIIc; FGFR-3, IIIb & IIIc, 
FGFR-4 
Ornitz et al [222] 
FGF-10 KGF-10 FGFR-1, IIIb; FGFR-2, IIIb Ornitz et al [222], Miralles et al. 
[224] 
FGFs 11 – 14 FGFs UNKNOWN Ornitz et al [222] 
FGF-15  UNKNOWN Ornitz et al [222] 
FGFs 16 – 19  FGF-17; FGFR-1, IIIc; FGFR-2, 
IIIc 
Ornitz et al [222], Xu et al.[225] 
FGF-20 XFGF-20 UNKNOWN Ornitz et al [222] 
Table 0.5 FGF groups and Associated Receptors  
The above table was adapted and reproduced from Powers et al [220] and shows each FGF molecule and 
its associated receptors [222-225]. 
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There are possible mechanisms of expression of different forms of FGFR: 
1. FGFR gene splice variants 
2. Expression of different FGFR genes. 
With the employment of splice variants it becomes possible for the same FGFR gene to 
encode for a variety of different receptor protein isoforms [220] and this kind of diversity 
is due to the structure of the respective FGFR genes [220]. Genetic analysis of the FGFR-1, 
FGFR-2 and FGFR-3 genes has shown a remarkably high level of conservation in the 
arrangement of the intro/exon boundaries [185, 220, 222, 226]. 
 Heparin and FGF 1.10.2
Heparin and HS are heterogeneously linear sulphated polymers consisting of repeating 
sub-units of the disaccharide hexuronic acid and D-glucosamine [227]. Heparin sulphate 
(HS) can be found in the interstitial spaces within the extracellular matrix of most tissues 
and on the surface membrane of most cells  
A large volume of evidence implies that the FGF pathways are required for vertebrate and 
invertebrate development [228-230]. Interactions between FGF and heparin have been 
shown to stabilise both FGF1 and FGF2 to terminal denaturing and protects FGF2 from 
proteolysis [187, 231]. The affinity of FGFs for Heparin sulphate (HS) proteoglycans 
severely limits their diffusion and release into interstitial spaces; therefore FGFs function 
in a paracrine fashion when bound to heparin [232-234]. 
The binding of FGFs to heparin or heparin sulphate results in the formations or 
stabilisation of dimers and higher order oligomers along the proteoglycan chain [221, 231, 
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235]. It has also been shown that FGFs can form “Trans” dimers with a heparin molecule 
bound between two FGF molecules [236]. The concept of heparin/HS-FGF dimer being an 
essential component/step in the transduction of FGF/FGFR signalling complex still 
remains controversial [237]. Although, it is well established that heparin is essential for 
high affinity binding of FGF to FGFR when cells are unable to synthesis cell-surface HS, 
cells pre-treated with heparin degrading enzymes or cells exposed to sulphation inhibiting 
agents [238, 239]. Also studies by Szebenyi et al (1999) [240] and Ornitz (2000) [187] 
showed that heparin/HS complex increased not only FGF/FGFR affinity but also the half-
life (T½) of the FGF-FGFR complex. 
 FGF-FGFR Signal Transduction 1.10.3
FGF binding to the cell surface induces the dimerisation of the FGFR, this then results in 
the activation of tyrosine kinase and the auto phosphorylation of the cytoplasmic domain 
of the cognate receptor [241]. The phosphorylated tyrosine’s are subsequently 
recognised by the SH2 domain, which contains signal transducers such as 
phosphotyrosine phosphatase (SHP-2) which is vital in the downstream activation of 
target proteins [242]. With FGF-2 signal transduction SHP-2 has been shown to associate 
with FRS2 were the SH2 domain in the N-terminal has been shown to be important for 
Ras signalling pathway [243]. Rho GTPase is a member of the Ras super family and plays 
an opposite role to general Ras proteins and may be involved in JNK/SAPK pathway [243]. 
Rasp21 is an important intermediate in the FGF-2 induced activation of the Ras/MAPK 
signalling pathway [243]. Grb2 has been shown to activate Rasp21 which can activate 
MAPK via the activation of MAPKKK which then activates the level of transcription factor 
Elk-1 [244-250]. Phospholipase C-gamma (PLC-γ) is phosphorylated by FGFR-1 at position 
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Y766. Tyrosine phosphorylation of PLC-γ results in activation and subsequent hydrolysis of 
phosphatidylinositol 4, 5 bisphosphate to inositol 1, 4, 5 triphosphate and diacylglycerol. 
The generation of two inositol 1, 4, 5 triphosphate, leads to the release of Ca2+ from 
intracellular stores, whereas diacylglycerl accumulation leads to activation of member of 
the protein kinase C family [251, 252]. 
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Figure 0.13 FGF-FGFR signalling Cascade 
Post FGF-FGFR binding results in an array of signal transduction pathways which can result in transcription factor activation which in turn can result in mitogenic 
responses via ERK1/2 activation, FGF inhibition (negative feedback) via ERK1/2 activation, stress response via JNK and p38 activation, anti-apoptosis response via Akt 
activation, cytoskeleton reorganisation and proliferation via phospho kinase C (PKC) activation [241-243, 251-253]. 
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1.11 Drug Delivery Systems 
The use of drug delivery systems as a means of delivering a controlled and sustained 
release of drugs or growth factors has received much attention in recent years [254]. 
However, tailoring the size and properties of the particle to deliver the growth factor to 
the desired cell/tissue type has yet to be fully documented. To date the majority of 
research groups focus upon the encapsulation efficiency of a desired drug/growth factor 
or hormone without fully exploring the full spectrum of nanoparticle production variables 
that can control the nanoparticle properties such as size and possibly polydispersity index 
and charge? 
Many polymers have been investigated and are currently being employed for their 
potential use as a vehicle to deliver drug or growth factors such as lysosomes, synthetic 
polymers (Table 1.6) and natural polymers (Table 1.7) [255-258].  However, the control of 
nanoparticle size as a key factor in drug/growth factor delivery has yet to be investigated. 
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Synthetic Polymer Main Application Reference 
Poly (glycolic acid); Poly (Lactic acid)  
and their copolymers 
Used in Sutures, drug delivery 
systems and tissue engineering. Co-
polymerized to regulate degradation 
rate 
Mooney et al. [259] 
Polyhydroxybutyrate Biodegradable, used as a matrix for 
drugs. 
Holland et al. [260] 
Poly (carpolactone) and copolymers Delivery system, Cell 
microencapsulation 
Lee et al. [261] 
Poly (alkylene succinate) Properties that can be tuned by 
chemical modification, 
copolymerization and blending 
Bikiaris et al. [262] 
Polyanhydrides Biodegradable, used in tissue 
engineering for the release of 
bioactive molecules 
Gunatillake & Ahikari [263] 
Polyacrylonitrile Dialysis Membranes Stoilova et al. [264] 
Polyamides Used for sutures and hemofiltration 
membranes. Inhibitors of DNA 
transcription 
 
Poly (ortho esters) Surface-eroding polymers. 
Applications in sustained drug 
delivery, ophthalmology. 
Kellomaki et al.[265] 
Polyphosphazenes Can be tailored with versatile side-
chain functionality. Applications in 
drug delivery 
Peach et al. [266] 
Table 0.6 Synthetic polymers and application in drug delivery systems  
The table above shows the synthetic polymers used for drug delivery along with their main application 
and references [259-266]. 
Natural Polymer Main Application References 
Collagen Sutures, Drug release Friess [267] 
Gelatin Used in the preparation of gels 
and in drug release 
DiTizio et al. [268] 
Albumin Drug stabilizer and drug release Elzoghby et al.[269]  
Carboxymethylcellulose Drug release, dialysis membranes. Barbucci et al. [270] 
Starch Drug delivery Tuovinen et al. [271] 
Agarose Used in clinical analysis and as a 
matrix 
Wang & Wu [272] 
Alginate Used in the release of bioactive 
molecules 
Tonnesen & Karlsen [273] 
Heparin and glycosaminoglycan  Used in ionotropic gelation and in 
capsules preparation 
Liu et al. [274] 
Dextran and derivatives Used in drug delivery Miyazaki et al. [275] 
Chitosan and derivatives Used in film preparation and 
applied in drug delivery 
Prabaharan & Mano [276] 
Table 0.7 Natural Polymers and application in drug delivery systems  
The table above shows the natural polymers used for drug delivery along with their main application and 
references [267-276]. 
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 Polymer Drug delivery systems 1.11.1
Polymer (Polymeric) based drug delivery systems are a versatile class of materials and 
have the potential to have a vast effect on pharmacological based therapies. Over recent 
years the two major classes of polymers namely synthetic and natural have been both 
investigated and utilised as carriers for controlling drug release [258]. Originally the 
polymer based drug delivery system (DDS) was based on non-degradable polymer matrix. 
However, the major disadvantage of such a system was that the release kinetics were 
uncontrollable and dependant on the diffusive properties (behaviour) of the loaded drug 
through the polymer matrix [258]. As the design of DDS developed combinations of 
natural and synthetic biodegradable polymers allowed for the controlled release of 
encapsulated agents. Therefore, allowing for the possibility to address the targeting of 
the active agent to the target site (cell/tissue) [258]. 
The primary concern for DDS is the choice of polymer to be employed in the controlled 
release delivery system, as controlled release depends on the physical, chemical and 
biological properties of polymer and the DDS constituents (active agent and 
encapsulation agent) [277]. The most recent generation of DDS are currently under 
investigation. These systems are designed using multi-component materials which are 
specifically engineered to avoid biological barriers and stimulate cellular responses such 
as direct cell proliferation and differentiation [278] 
Controlled drug delivery devices can be classified based on the nature of the carriers and 
can be divided into two major categories: diffusion controlled release systems and 
degradable delivery systems. With diffusion controlled release systems, the active agent 
is released from an aqueous solution and is inhibited by the insoluble polymer matrix. The 
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active agent is released either by passing through pores or between polymer chains and it 
is these processes that controls the release rate of the active agent [258, 277, 278]. 
Diffusion controlled systems are divided into two types: reservoir (membrane systems) 
and matrix systems (Figure 1.14) [258, 277, 278]. 
 
Figure 0.14 (A) Schematic of reservoir drug delivery system and (B) matrix based drug delivery 
system. 
In membrane DDS, the drug is contained in a core, which is surrounded by a polymer membrane, and it is 
released by diffusion through this rate-controlling membrane. Reservoir DDS have a coating that controls 
the release rate [258].  
 A reservoir based DDS is generally cylindrical, disk-like or spherical in shape and 
constitutes an agent core in either liquid or powdered form and is contained 
within a polymeric film. The polymeric layer which is non-biodegradable 
represents the only barrier through which the agent slowly diffuses. The diffusion 
rate of the agent is dependent upon the properties of both the agent and the 
polymer. The reservoir can be either microporous or macroporous polymer film. 
The composition of which changes from one component to a mixture of polymers, 
or a heterogeneous matrix in which hydrophilic polymer particles are dispersed in 
a hydrophobic polymer matrix [279]. 
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 With matrix based diffusion control systems, the agent is uniformly distributed 
throughout the polymer matrix and is subsequently released from the matrix at a 
uniform rate as the agent particles disassociate from the polymer network. The 
agent can be physically embedded into the polymer at large enough 
concentrations as to create interconnecting pores throughout the matrix which 
allow for the agent to slowly diffuse out of. The use of such systems allows for 
hydrophobic and/or viscous hydrophilic polymers to incorporate solid agent 
dispersal. The release rate is based on the diffusion of the agent molecule to the 
device surface where they are delivered. This process takes place as long as the 
higher concentration of the agent in the system core affords a constant flow of 
agent molecules through the matrix. With this dissolution-diffusion process, the 
interface between agent reservoir and the release moiety progressively contracts 
and moves towards the core of the device [280]. 
 
Figure 0.15 Schematic Drug Release Profile for Nanosphere and Nanocapsules 
The nanocapsule has an initial burst release followed by continuous release, whilst the nanosphere has a 
reduced burst release followed by prolonged increased release. 
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In degradable DDS the agent molecules are initially dispersed in the polymer and are 
released as the polymer undergoes eroding or degradation. Similar to the reservoir 
system, the degradable reservoir system has an agent-loaded core which is surrounded 
(encapsulated) by a polymer coating which undergoes erosion or degradation. These 
systems combine the advantages of the long-term constant rate of agent release with 
bio-erodabilty or biodegradability. With a surface-degrading polymer, degradation is 
confined to the outer surface of the device. With a bulk-degrading polymer, degradation 
occurs homogeneously throughout the material. With most polymers hydrolysis is a 
major factor and therefore water intrusion into the device is of significant importance for 
the study if degradation kinetics as well as agent release kinetics [281]. 
 Polymeric Nanoparticles 1.11.2
Polymeric nanoparticles (NPs) have drawn much attention within the pharmaceutical field 
as a potential delivery method for pharmaceutical agents. NPs have been defined as solid, 
colloidal particles within a size range of 10 – 1000nm with a capability to carry an agent to 
the target site or to release an agent in a controlled manner [282]. The original particulate 
DDS was primarily based on liposomes and polymer-drug conjugates. Liposomes were 
originally discovered in the 1960’s and can be defined as a spherical vesicle with a lipid 
bilayer membrane structure, which can encapsulate both hydrophobic and hydrophilic 
agents [283]. Polymer-drug conjugates have been extensively investigated after first 
appeared in the 1970’s where the drug or bioactive agent is covalently linked to the 
macromolecular backbone [284]. Today, both liposomes and polymer-drug conjugates 
provide the foundation for the field of advanced drug delivery systems based on 
nanotechnologies. However, these systems have many disadvantages and are 
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characterised accordingly, such as poor encapsulation efficiency and bioavailability of the 
agents, difficulty in targeting a desired target site and relatively high production costs. 
Polymeric NPs offer the capability to achieve controlled release of bioactive agents, 
improvements in the stability of the active agents (the polymeric shell acts as a protective 
shield against factors such as pH, enzymes and light) and their relatively small size can 
allow for the manufacture of a size of NP that may provide a higher cellular uptake than 
other particulate systems. Another advantage of NP as active agent carriers can include 
higher encapsulation efficiency, lower polymer content when compared to other DDS and 
the possibility of utilising polymers with a greater degree of biocompatibility and 
biodegradability [285]. NPs can be classified as nanocapsules and nanospheres. Polymeric 
nanospheres may be defined as a matrix based particle with the entire mass is solid and 
molecules may be adsorbed at the sphere surface or encapsulated within the particulate. 
Polymeric nanocapsules are a vesicular system, which may act as a reservoir, in which the 
entrapped agent are confined to a cavity made from a liquid core (which can be oil or 
water) surrounded by a polymer shell [286]. 
The design of polymeric NPs depends on the therapeutic application, target site (organs, 
tissues, cellular or subcellular organelles) and the route of administration. Although 
injection (subcutaneous or intravenous) is the most common route of administration, 
these nanocarriers can be also delivered through dermal and oral routes to name a few 
[287]. For every administration route of drug delivery that the use of a NP delivery vehicle 
is to be utilised many physical barriers need to be breached. The NPs have to be able to 
deliver beyond the biological barriers, such as skin, mucus, blood, extracellular matrix and 
cellular or subcellular barriers. With respect to these factors, the correct selection of the 
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polymer can affect the NPs intracellular fate, safety, biocompatibility, release kinetics and 
the capability to overcome biological barriers [288]. Biocompatibility and biodegradability 
of NPs are essential concerns for the safety of the patients and should be vigorously 
tested both in vivo and in vitro.  
The use of biodegradable polymers would avoid the concerns in relation to physiological 
excretion or mechanical removal of the delivery device after agent depletion. The 
application of biodegradable matrix (Figure 1.16) could provide a further mechanism for 
release rate control, by combining typical diffusive mechanisms with tuneable polymer 
degradation [289]. 
Nanocapsule
Entrapped agents Surface adsorbed agent
Nanosphere
Entrapped agents Surface adsorbed agent  
Figure 0.16 Structure of Nanocapsule and Nanosphere. 
Shows nanocapsule with the matrix found between the polymer shell and core. The nanosphere with the 
matrix as a component of the core [290]. 
The most commonly used biodegradable polymers being utilised for NP production are 
poly (lactic acid) (PLA), poly (glycolic acid) (PGA), poly (ε-caprolactone) (PCL) and the co-
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polymer poly (lactic-co-glycolic acid) (PLGA) of PLA and PGA. Along with the natural 
hydrophilic polymers, such as chitosan, sodium alginate and gelatin have also been 
utilised to produce drug loaded NPs. However, the aliphatic polyesters based on lactic 
and glycolic acids are the most widely employed polymers and have been approved for 
use in humans by the FDA [291]. Furthermore, lactide/glycolide polymer chains are 
cleaved by hydrolysis to form natural metabolites (lactic and glycolic acids), which are 
metabolised, utilised and subsequently eliminated from the body via the Krebs cycle 
[292]. 
 Nanoparticle Preparation Techniques 1.11.3
The properties of NPs have to be optimised according to the particular application. In 
order to achieve this, the properties of interest, the method of preparation play a key 
role. Therefore, it is highly advantageous to have several preparation techniques to 
obtain the NPs with the desired properties. There are several methods for NP production 
which are outlined briefly below:- 
 Emulsion solvent: is the most employed method of NP production. The 
preparation utilised in this method follows the general protocol of dissolving the 
polymer in a water immiscible, volatile organic solvent which is then emulsified 
with an aqueous phase to stabilise the system. The organic solvent is then 
evaporated which induces the formation of polymer particles from the organic 
phase droplets [282, 286, 288]. 
 Salting out: this is an emulsion based approach, with the advantage that this 
method avoids surfactants and chlorinated solvents. Briefly, a saturated salt 
solution containing a stabilising agent such as polivinilalcool (PVA) is added under 
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stirring to an acetone to diffuse into the external aqueous solution of the polymer. 
An organic/water (o/w) emulsion forms as the salt prevents the water and 
acetone mixing. Sufficient water is then added to allow the acetone to diffuse into 
the external aqueous phase and induce nanoparticle formation [282, 286, 288]. 
 Dialysis: The dialysis method is a simple and effective preparation method for 
small and narrow size distributed NPs. In this method, the polymer is dissolved in 
an organic solvent and placed within a dialysis tube with a specific molecular 
weight cut-off. Dialysis is performed against a non-solvent miscible with the 
former miscible solvent. The displacement of the solvent inside the membrane is 
followed by the progressive aggregation of polymer due to the decrease in 
solubility which leads to formation of homogenous suspension of NPs. The solvent 
used in such a preparation of the solvent solution has a direct effect on the 
morphology and particle size of the NPs [282, 286, 288]. 
Therefore, the choice of NP production method is highly dependent upon the agent being 
encapsulated and the chemical properties such as solubility of the agent to be 
encapsulated. By employing a design of experiment approach to nanoparticle production 
the variables of the procedure can be identified to control nanoparticle size and 
subsequently the concentration of drug delivered. 
1.12 Design of Experiment 
Design of experiments (DOE) utilises applied statistics which are capable of dealing with 
conducting, planning, along with the analysis and interpretation of controlled tests. The 
primary purpose is to evaluate the factors that control the value of a parameter or group 
of parameters. 
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A well-executed DOE can reveal a high volume of data in regards an effect on a response 
variable due to one or multiple factors, along with their subsequent interactions. Many 
experiments currently employ the holding of one factor constant whilst varying levels of 
another factor, basically a one-factor-at-a-time (OFAT). However, this process is 
inefficient and more costly (in regards time), when compared to changing factor levels 
simultaneously [293]. 
By utilising a DOE can reveal: 
 Key factors in a process 
 Optimum settings (Full factorial 23) 
 Key and main interactions within a process 
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1.13 Thesis Aims 
The three primary aims of this thesis are: 
1. To investigate whether PHBHHx can be used as a scaffold in tendon repair 
(Undertaken at Tsinghua University, Beijing, China). 
2. To Investigate the potential of FGF-4, FGF-6 and FGF-8 and subsequent 
combinations are capable of initiating human stem cell differentiation towards a 
tenocyte lineage (Undertaken at Keele University, U.K.) 
3. Investigate the controlled manufacture of PHBHHx nanoparticles and whether 
controlled manufacture results in control of nanoparticles properties utilising a 
DOE (Undertaken at West China School of Pharmacy, Sichuan University, Chengdu, 
China & Keele University, U.K.).  
The three primary aims of this thesis are to bring together three topic areas of Scaffold 
design for use in tendon repair, growth factor induced differentiation of both hESC’s and 
hMSC’s and finally the controlled production of PHBHHx nanoparticles for use in the 
delivery of growth factors at a range of concentrations The findings of the topic areas may 
lead to a self-contained implant that will comprise of three major components: a cellular 
component (stem cells) with the capability of differentiating towards a tenocyte cell 
lineage, polymer scaffold to provide structural support and integrity for tissue 
replacement/cellular delivery and a nanoparticle growth factor delivery vehicle capable of 
delivering a growth factor cocktail capable of inducing stem cell differentiation. 
  
 
 
 
 
 
 
Chapter 2: Poly 3-
hydroxybutyrate- co-3-
hydroxyhexanoate Scaffolds for 
Tendon Repair in the Rat Model 
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2.1 Introduction 
This Chapter is an expansion on the publication in Biomaterials Webb et al. 2013 [294] 
Tendon injury is an increasing problem in medicine, with over 300,000 tendon procedures 
performed annually in the United States alone [295]. Tendon is characterised by poor 
repair following injury or disease, is relatively acellular and has poor blood supply [6]. 
Treatment can involve many different types of surgical intervention, such as xenograft or 
allograft to treat large tendon defects, however potential problems with this method 
(such as foreign body reaction) can occur [296]. A lack of adequate strategies for tendon 
repair has led to the development of engineered replacement tendon tissue for use in 
surgical implantation[297]. Tissue engineering could be used to develop a regenerative 
medicine solution to tendon tissue repair [156]. 
A range of different materials have been investigated as possible scaffolds for tendon 
tissue engineering. These include natural materials such as collagen [298] and silks [299] 
or manufactured materials such as polymers [300]. One current approach is to blend 
natural and manufactured materials to form a hybrid design which would encourage 
cellular in-growth and provide mechanical support during the remodelling stage of 
tendon recovery [3]. 
An appropriate tendon tissue engineered scaffold would mimic the structure and 
mechanical properties of the natural tissue. The mechanical properties of tendon depend 
largely on its location within the body and can vary. For instance a typical small adult 
human tendon (from the forearm) has a Young’s modulus of 1-2 GPa, an ultimate stress 
of around 100 MPa and an ultimate strain of 4-10% [89] whereas the human patella 
tendon an estimated Young’s modulus of 1.5-1.7 GPa, an ultimate stress of 34-43 MPa 
and an ultimate strain of 5.3-5.8% ,the estimated Young’s modulus for adult Achilles 
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tendon is 2 GPa with an ultimate stress of 80 MPa and an ultimate strain of 3.6-8.8% 
[90],[91]. The tendon extracellular matrix is composed mainly of collagen type I arranged 
in hierarchical levels of increasing complexity, beginning with the triple-helix polypeptide 
tropocollagen which forms primary bundles (fibrils); secondary bundles (fascicles); 
tertiary bundles; and the complete tendon itself, which is surrounded by several layers of 
loose connective tissue sheaths [3, 30, 92, 301-303]. This complexity presents substantial 
difficulties to the generation of artificially produced structures which mimic tendon 
anatomical structure. 
Polyhydroxyalkanoates (PHA) are a family of biopolymers consisting of polyesters of many 
different hydroxycarboxylic acid molecules produced by microorganisms as energy and 
carbon storages in response to unbalanced culture conditions [304]. PHBHHx is the 
designation of molecules consisting of random copolymers of 3-hydroxybutyrate and 3-
hydroxyhexanoate [305] and is one of the few PHA molecules that can currently be 
produced on a sufficiently large scale for use in both scientific research and medical 
device construction [306]. PHBHHx has substantial potential as a material for tissue 
engineering owing to its adaptable mechanical properties, biodegradability and apparent 
compatibility with many different mesenchyme derived cell types [307-311].  
Previous studies using implants to repair tendon injuries have employed polymers such as 
polyglycolic acid (PGA) and polylactic acid (PLA) [113]. Varying degrees of success have 
emerged ranging from histological indications of fibroblast alignment and patterning in 
PLA models when compared to the PLA control and slight improvement in mechanical 
properties of the repaired tendon in Japanese white rabbits with the PGA scaffold [114]. 
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However, to date there are no commercially available polymer based scaffold available 
for the treatment of tendon injury. 
The aim of this study was to explore the use of PHBHHx, PHBHHx-collagen and PHBHHx-
collagen-tenocyte hybrid scaffolds for the in vivo treatment of damaged tendon. Here we 
have demonstrated that the use of PHBHHX and collagen/tenocyte combinations resulted 
in the absence of any adverse immunological response, return of load bearing and 
function (as evaluated through the Achilles Functional Index (AFI)), and cell alignment 
within the scaffold along with scaffold degradation without compromising functionality. 
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2.2 Materials and Methods 
 Animals 2.2.1
20 male Sprague-Dawley (SD) rats weighing between 180-200g were obtained from the 
Centre for Biomedical analysis, Tsinghua University, Beijing, China. Animals were treated 
kept in authorised, licensed facilities and under local ethical and handling guidelines 
throughout the experiment. 
 PHBHHx Fibre Construct 2.2.2
PHBHHx fibres were prepared by melt-spinning using a laboratory-size extruder (Ruojiang 
Chemical Fibre Machinery Co. Ltd., Beijing, China) with a single nozzle with an inner 
diameter of 300 µm. Briefly, PHBHHx powder (87.9% HB, 12.1%HHx) was melted, 
extruded, isothermally crystallized, drawn and annealed under tension (Chinese patent 
application No. 200810052461).  
 Porous Tube fabrication 2.2.3
PHBHHx tubes were prepared by dissolving 10% w/v PHBHHx powder (87.9% HB, 12.1% 
HHx) in 20 mL chloroform (Beijing Chemical Works, 20100303). Following polymer 
dissolution, 0.04 g NaCl crystals (<100 µm diameter) were suspended in the solution and 
homogenised by shaking/stirring. To fabricate the tube, a 2.5 mm diameter stainless steel 
mandrel was dipped into the homogenised solution, then removed and the solvent 
evaporated in a flow hood for 2 minutes. This process was repeated 5 times after which 
the mandrel was placed vertically and left for a further 20 minutes to allow the solvent to 
fully evaporate and the polymer to become rigid. The polymer tube formed around the 
steel was then removed by hand. The tube was then immersed in deionised H2O 
overnight to dissolve the NaCl crystals present in the structure prior to use. 
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 Collagen Gel 2.2.4
Briefly, collagen gels were formed by first neutralising type I rat tail collagen (Sigma 
Aldrich, C3867-1VL) with 1 M NaOH, and combining 9 parts collagen solution with 1 part 
10x DMEM to produce a final collagen concentration of 3mg/mL with the samples placed 
in an ice bath until required [312, 313].  
 Scanning Electron Micrograph Analysis of PHBHHx Fibres 2.2.5
Scanning electron microscopy was undertaken at the School of Medicine, Tsinghua 
University, China. Using a range of magnification (x200 – x2000), Samples were pre-
coated with gold particles in a vacuum unit for 10 minutes prior to visualisation. 
 Mechanical Testing 2.2.6
Maximum force testing was undertaken at the School of Chemical Engineering, Tsinghua 
University, China. Prior to testing the MTS tension/compression tester was calibrated by 
staff at Tsinghua University as per manufactures guidelines using 20kip and 50 kip load 
cells. Post calibration, Samples were placed onto a MTS tension/compression load cell 
tester (MTS, Canada) (Figure 2.1A) and elongated at a rate of 10mm per second until 
failure, were the maximum load is recorded under dry conditions, using factory fitted 
sample clamps (Figure 2.1B).  
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Figure 0.1 MTS Tension Compression load cell tester (NTS, Canada) 
A) shows MTS compression load unit, B) Factory fitted sample clamps. 
 Rat Tendon Harvest 2.2.7
Fresh rat tendon was harvested from 8 weeks old, adult Sprague-Dawley (SD). The rat was 
sacrificed and the Achilles tendons harvested 24hrs prior to mechanical testing and stored 
at 4oC in DMEM supplemented with 10% FBS, 5% NEAA, 5% L-Glutamine and 5% 
streptomycin/penicillin (Lonza) to prevent infection that could affect the outcome of 
mechanical testing. 
 Rat Tenocyte isolation 2.2.7.1
Fresh rat tendon was harvested from 8 week old, adult Sprague-Dawley (SD) which were 
sacrificed in accordance with University policy (Tsinghua University, Sichuan University 
and Keele University). The rat Achilles tendons were then surgically removed from both 
hind legs. The tendons were then placed in a universal bijou bottle containing a solution 
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of PBS supplemented with 1000 IU/ml penicillin, 1000μg/ml streptomycin and 
transported to the laboratory. The tendon was then removed from the transport solution 
in a Biological Safety Cabinet and placed into a sterile petri dish were the tendon was 
then subsequently dissected into smaller sections and minced using a scalpel. The petri 
dishes containing the tendon samples were then placed into an incubator for one hour, 
allowing the tendon samples to loosely adhere to the petri dish surface. DMEM media 
supplemented with 1% L-glutamine, 1% NEAA, 10% FBS was then carefully added drop 
wise to the petri dish until the tendon samples were immersed. After, approximately five 
days, cells were observed to migrate out of the tendon onto the surface of the petri dish.  
The cells in the petri dish were then removed by trypsinisation (1% trypsin/PBS solution) 
for five minutes, pelleted by centrifugation (three minutes, 200g), then re-seeded into 
two T-25 tissue culture flasks. One flask was then cultured at 2% O2 and one flask in 21% 
O2 (Keele University). All flasks were cultured at 21% O2 at Tsinghua and Sichuan 
Universities. 
 Rat Tenocyte Expansion 2.2.7.2
Rat tenocytes (rt-tenocytes) were cultured in T-75 culture flasks in Dulbecco’s Modified 
Eagle’s Medium High glucose (Invitrogen) supplemented with 10% foetal bovine serum 
(FBS), 1% Non-essential amino acids (NEAA) (Gibco), 1% L-glutamine (10mM) (Gibco) until 
confluent. When confluent the cells were passaged with a brief PBS wash before adding 3 
ml of 1% Trypsin/PBS solution and standing until detached. The cell suspension was then 
pipetted into a centrifuge tube, centrifuged (200g, 2 minutes), media aspirated and cell 
pellet re-suspended and distributed across 5 x T-75 flasks and cultured until 80% - 90% 
confluent.  
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 Rat Tenocyte Cryo preservation 2.2.7.3
After isolation of rt-tenocytes a substantial number rt-tenocytes cultured at 21% O2 at 
passage 1 were cryopreserved for future use. Confluent T-75 flasks of rt-tenocytes were 
harvested by aspirating the culture media from the T-75 and washing twice with 10ml 
PBS. Once the PBS was aspirated from the T-75, 3ml of 1% trypsin/PBS solution was 
added to disassociate the cells from the culture plastic. Once the cells had disassociated 
from the T-75 flask, 3ml of rt-tenocytes culture media (differentiation media) was added 
to the trypsin-cell suspension to quench the effects of trypsin. The media-cell-trypsin 
suspension was then placed into a 15ml centrifuge tube and centrifuged for 3 minutes at 
200g. After 3 minutes had elapsed the media- trypsin solution was aspirated from the 
centrifuge tube to leave a cell pellet. The cell pellet was then re-suspended in 1ml of 90% 
FBS and 10% DMSO at room temperature. The DMSO-FBS-cell suspension was then 
placed into a 1.5ml cryovial and placed in a ‘Mr Frosty’ (C1562 Sigma Aldrich, UK) and 
placed into a  -80oC freezer for 24hrs.. After 24hrs had elapsed the cryovial was then 
transferred into liquid nitrogen.  
 Surgical Implantation of PHBHHx Tendon Scaffold 2.2.8
15 male Sprague-Dawley (SD) rats 180-200 g were obtained from the Centre for 
Biomedical Analysis, Tsinghua University, China. Animals were returned to the centre post 
operation and held there for the duration of the experiment. The animals were sacrificed 
at 40 days post operation, with the Achilles tendons from both hind legs being removed 
for analysis. This study was conducted following the guidelines and requirements of the 
local ethical committee at Tsinghua University, Beijing, China and in collaboration with 
Peking Number 1 Hospital, Beijing, China. 
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Surgical procedures were carried out by experienced (consultant) orthopaedic surgeons 
at the Surgical Training Centre, Peking University Hospital Number 1, Beijing, China. 
Animals were anesthetised using 50 mg/Kg sodium pentobarbital. Once anesthetised, a 
lateral incision was made parallel to the Achilles tendon on the distal side of the right hind 
leg (Fig. 2.5B) and the tendon exposed (Fig. 2.5C). In the control group, a 5 mm section 
was removed from the centre of the tendon (Fig. 2.5D), then the incision closed using 3 
cross stitches using dissolvable sutures (Fig. 2.5I). Experimental groups had a 5 mm 
section removed from the tendon, which was then bridged using the scaffold. This was 
done by first knotting together the 3 fibres and passing each individually through one end 
of the damaged tendon (Fig. 2.5E). The tube was then passed along the open end of the 
fibres, and manoeuvred into position (Fig. 2.5F). The remaining open ends of fibre were 
then passed through the other damaged end of tendon, and the ends bought together to 
leave a 5 mm gap between the tendon ends. The fibres were then knotted together as 
previously, fixing the scaffold in place and the leg at the correct anatomical position (Fig. 
2.5G). In one experimental group, collagen gel was injected into the scaffold after it had 
been fixed in place using a syringe (Fig. 2.5H). The surgery was again then closed using 3 
cross stitches using dissolvable sutures. Animals were separated until all had recovered 
from anaesthesia, and then divided according to experimental group.  
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Figure 0.2 Implant Schematic  
A) shows the anastomosis where normal silk sutures were used to join the osteo-tendon and muscular 
tendon ends to repair the induced defect in the control group. B) Shows the components of the PHBHHx 
scaffold (PHBHHx fibres, PHBHHx porous tube, collagen gel with/without cells. C) shows how the PHBHHX 
scaffold was used to bridge the 3mm induced defect and the PHBHHx fibres replacing sutures to anchor 
the implant to both the muscular tendon and osteo tendon ends. 
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Figure 0.3 Implantation Procedure for Rat Tendon Repair  
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 Immune Response Analysis using C-Reactive Protein 2.2.9
Immune response was monitored by measuring C-Reactive Protein (CRP) levels in the rat 
serum from day 0 – day 40. Blood was taken from the tail vein of rats on days -2, 2, 5, 10, 
20 and 40. Day 0 blood samples were not possible due to blood loss during surgery. Once 
collected samples were centrifuged at 1500 rpm for 15 minutes and the serum (clear 
liquid level at the top) collected and stored at -80oC. CRP was measured using a Rabbit 
anti Rat CRP ELISA kit (BD Bioscience, 557825) according to the manufacture's protocol 
and read using a Molecular Devices' VersaMax' Micro plate Reader.  
 Achilles Functional Index 2.2.10
Achilles tendon functional recovery was quantitatively assessed using a modification of 
Murrell’s AFI method [314], similar to Kurtz et al [168]. A walkway approximately 80 cm 
long by 20 cm wide was lined with white paper (Figure 2.4A). A rat’s hind paws were then 
coated with water based ink and the rat placed at the start and allowed to proceed down 
the walkway. Footprints were scanned and print length, print width (distance from first to 
fifth toe) and intermediate toe width (distance from second to fourth toe) measured 
using Image J [315] analysis software. The AFI was then determined using Murrell’s 
formula:  AFI = 74(PLF) + 161(TSF) + 48(ITF) -[314] where PLF (print length factor), TSF (toe 
spread factor) and ITF (intermediate toe factor) represent the difference between the 
experimental and contralateral print measurements. Prints were obtained pre-operatively 
at day -2 and for post-operative days 2, 5, 10, 20 and 40 for n=3 rats from each 
experimental group (Figure 2.4B). 
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Figure 0.4 AFI Setup 
A) Paw pad print required for AFI calculations and Walk Way for acquiring paw pad print, B) Complete 
experimental Paw pad print during experimental time course excluding day 0. 
 Explanted Scaffold Mechanical Testing 2.2.11
Stretch to break testing was carried out on 3 separate extracted scaffolds from each 
experimental group after 40 days. Non-operated tendons were used as control. Following 
removal, tendons and scaffolds were loaded into the servo controlled system universal 
testing machine (AI-7000S, GOTECH, Taiwan) where tendon ends were secured by 
clamps, and stretched at a rate of 10 mm/min until complete failure was observed. 
 Gel Permeation Chromatography 2.2.12
PHBHHx scaffolds were separated from remaining hind leg tissue by suspending the 
tissue/tube explant in 3 ml of Trypsin/EDTA (0.01g/l, 0.004g/l) (Lonza (02-007E)) for 24 
hrs. After 24hrs the separated tube was washed twice using PBS (Lonza (17-516F)) and 
allowed to air dry at room temperature. Once dry the PHBHHx tube was dissolved in 
chromatography grade Chloroform (J.T. Baker, USA) at a ratio of 20% w/v PHBHHx 
chloroform solution and filtered using 0.22µm organic solution filters (Membrana, 
Germany) prior to GPC injection. 
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Molecular weights were studied using GPC (RID-10A, Shimadzu, Japan). Measurements 
were performed at 40oC using a GPC-804C column (Shimadz, Japan) where all samples 
were referenced against 10% w/v chloroform solutions of high molecular weight 
polystyrene standard (Mw 300,000 Da and 150,000 Da) (Fluka, Sigma-Aldrich, Germany) 
and low molecular weight polystyrene standard (Mw 50000 Da, 30000 Da, 9000 Da and 
4000 Da) (Shimadzu, Japan). 
 Haematoxylin and Eosin 2.2.13
Structural analysis of two samples from each group was performed using Haematoxylin 
and Eosin (H & E) (Gene Research Lab. Co. PS003) according to standard procedures. Prior 
to staining the sample was first fixed using 70% methanol for 24 hrs, then embedded in 
paraffin wax before sectioning into 8 µm sections and placing onto a glass slide. Sections 
from the injury site and healthy areas of tendon were analysed. Images were taken using 
a Nikon Eclipse 90i 
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 Experimental Plan 2.2.14
Design PHBHHx Synthetic Tendon
Designs Taken Forward to Implantation
C-Reactive Protein Testing
Achilles Functional Index 
Testing
Histological 
Examination of 
Explants
Test Mechanical Properties against Native Tendon
Does the Implant Match Native Tendon
Yes No
PHBHHx OnlyControl PHBHHx + 
Collagen
PHBHHx + 
Collagen + 
Tenocytes
Continuous 
Testing
Post 40 Day 
Testing
Mechanical Properties 
Examination of 
Explants
Molecular Weight 
Examination of 
Explants
 
Figure 0.5 Experimental Plan 
Experimental work plan showing scaffold selection and continuous monitoring of implant performance 
and immunological response. Post re-sectioning of scaffold for histological, mechanical and molecular 
weight analysis post re-sectioning. 
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2.3 Results 
 Scaffold Design 2.3.1
PHBHHx Scaffold components were characterised utilising SEM and mechanical force 
testing. The individual PHBHHx components namely: PHBHHx fibre and PHBHHx tubes 
were tested individually and in combination along with the addition of collagen to the 
scaffold core. 
 SEM PHBHHx Fibre Examination 2.3.1.1
SEM analysis of the PHBHHx tubes and fibres was undertaken to measure the tube pore 
size and diameter of the fibres. From the SEM images and measurements taken average 
pore size and fibre width were calculated to be: 175.4µm ± 2.4 µm for fibre diameter 
(Figure 2.6) and 46.01 µm ± 19.21 µm for pore size (Figure 2.7). 
 
Figure 0.6 Scanning Electron Micrographs (SEM) of the PHBHHx Fibres. 
A) Shows PHBHHx fibre prior to measurement, B & C) Show PHBHHx fibre measurements. 
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Figure 0.7 Scanning Electron Micrographs (SEM) of Porous PHBHHx Tubes. 
A) PHBHHx tube section prior to measurement (sample 1), B) PHBHHx tube section prior to measurement 
(sample 2) and C) PHBHHx tube section prior to measurement (sample 3). 
 Mechanical Force Testing 2.3.1.2
After SEM analysis comparisons between native tendon and complete scaffold constructs 
and scaffold components was undertaken utilising MTS tension/compression load cell 
tester (MTS, Canada) and elongated at a rate of 10mm per second until failure 
Rat Achilles tendon has an average breaking load of 17.35 ± 1.76 N (Figure. 2.8). A porous 
PHBHHX scaffold with varying number of fibres was evaluated to determine which had an 
approximate mechanical performance to natural tendon (Figure. 2.8). From this it was 
apparent that: 3 fibres running through the centre of a PHBHHx porous tube had 
comparable breaking loads with (23.46 ± 4.81 N) and without a collagen core (26.70 ± 
1.05 N), were both were significantly stronger than the native rat tendon (p<0.006), 
whilst both the single fibre and tube were significantly weaker than native tendon 
(p<0.004) (Figure 2.8). The 3 fibre construct without a porous tube had a comparable, 
though weaker value when compared to rat Achilles tendon (13.53 ± 5.37), and displayed 
wide standard deviations. This design was therefore ruled out for implantation due to the 
unacceptable degree of variation. From the data described above the scaffold featuring 3 
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fibres, a porous PHBHHx tube and 3 fibres in a collagen lumen design was applied in the 
Achilles tendon wound model described in Section 2.2.8.  
 
Figure 0.8 Mechanical Testing of Scaffold Designs 
Native rat tendon was measured and used as a minimal properties required for scaffold implantation. 
Scaffold components: PHBHHx tube, Single Fibre, 3 x fibres, 3 x fibres and tube and hybrid scaffold (3x 
fibres, tube and collagen core) were compared to the native tendon. 
From the data obtained in mechanical testing of the scaffold designs and the constituent 
parts, the hybrid scaffold was selected for implantation. 20 SD rats were subdivided into 4 
experimental groups. These groups were: Control (induced tendon defect with no repair), 
Group SO (Scaffold Only), Group Hybrid Scaffold (Scaffold with collagen core) and the 
final Group Hybrid scaffold containing Collagen core and the addition of rat tenocytes. 
Prior to implantation all 20 rats were treated as a single group so a baseline for C-reactive 
protein and Achilles Functional Index were obtained for comparison of data collected post 
implantation.   
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 Immunological Response 2.3.2
Prior to implantation the 20 rats were treated as one group. 300μl of blood was taken 
from each rat for base line CRP values. Post implantation each experimental group 
contained five animals (n=5). At time points 2, 5, 10, 20 and 40 days post implantation 
300μl of blood was taken from each rat in all experimental groups for CRP comparison 
prior to implantation. We were then able to monitor immune response to the implanted 
PHBHHx scaffold and also possible infection during implantation. 
The immune response was quantified by measuring C-reactive protein (CRP) 
concentration in blood serum. Samples were taken at time-points pre and post-surgery. 
Prior to surgery all rats were considered as one group (n=20) where an initial CRP 
concentration at day -2 of 1251.48 ± 31.42 µg/L (Figure. 2.9) was noted. Surgery was 
performed on day 0 and blood samples were not taken to minimize discomfort. CRP had 
increased significantly in all groups at day +2 after surgery, ranging in level from the 
scaffold only group (1502.25 ± 45.46 µg/L), the tenocyte-PHBHHx-collagen group 
(1437.38 ± 44.11 µg/L) to the control group (1357.58 ± 82.91 µg/L) (p<0.02). CRP levels 
were significantly elevated in all groups in comparison to Day -2 (p<0.04). By day +5, CRP 
levels ranged from 1244.39 ± 136.09 µg/L (PHBHHx-Collagen), 1160 ± 57.00 µg/L 
(PHBHHx), 1132.58 ± 23.21 µg/L (Control) to the tenocyte-PHBHHx-collagen group 
(985.46 ± 20.75 µg/L (p<0.05 vs. day-2; p<0.0007 vs. all other groups). All groups 
displayed reduced CRP levels at day +5 in comparison to Day +2 with a significantly lower 
value for CRP being observed in the PHBHHx only group (p<0.03) and in the tenocyte-
PHBHHx-collagen group (p<4.05E-08) when compared to pre-surgery CRP levels. CRP 
levels continued to fall further at day +10 where all groups had lower concentrations than 
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pre-implantation values. The tenocyte-PHBHHx-collagen only group recorded the lowest 
level at 960.89 ± 20.07 µg/L and all groups were lower than pre-implantation CRP levels 
(p<0.02) and post implantation day +2 (p<0.04). CRP levels in the control group stabilised 
at Day+10 levels while CRP levels for all other groups continued to decrease. CRP levels 
stabilised from Day+20 onwards through to Day +40 when final analysis was performed. 
All CRP levels for all groups remained significantly below the pre-implant values and post 
implantation levels (Day -2) (p<0.05). 
 
Figure 0.9 Immune Response to Implanted Scaffold. 
CRP base values were obtained prior to implantation (n=20). Post implantation, all experimental groups 
were sampled (n=5) and measured at time points 2, 5, 10, 20 and 40, and then compared to previous time 
points and day. 
 Restoration of Function  2.3.3
Prior to implantation Achilles functional index scores were calculated for the healthy 
animals prior to implantation. Further analysis was taken at 0, 2, 5, 10, 20 and 40 days 
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post implantation and compared against the pre-implantation values which were used as 
baseline scores. 
 Achilles Functional Index 2.3.3.1
Initial AFI scores were taken 2 days prior to surgery (-24.83 ± 1.29) (Figure 2.10). At day +2 
all groups displayed a dramatic decrease in AFI (Control -86.32 ± 14.05), PHBHHx only (-
95.36 ± 9.56), PHBHHx-collagen (-84.21 ± 12.50) and tenocyte-PHBHHx-collagen (-103.31 
± 12.04) where all groups had a significantly lower AFI when compared do day -2 (p<0.05). 
All groups showed a continuous improvement from day +5 to day + 10 excepting the 
PHBHHx-collagen group at day +5  (-84.90 ± 14.90). The greatest improvement was noted 
in the PHBHHx-collagen group at day +10 (-47.42 ± 33.68), and the tenocyte-PHBHHx-
collagen group (-49.44 ± 13.81). The least improved group at day +10 was the scaffold 
only group (-67.25 ± 11.03) (with all groups having a significantly lower AFI when 
compared to day -2, p<0.04). By day +20 the tenocyte-PHBHHx-collagen group had 
improved over the pre implantation AFI score (-18.95 ± 17.00). By day +40 the tenocyte-
PHBHHx-collagen group had improved further (-5.16 ± 6.95) followed by the scaffold only 
group (-14.79 ± 3.97), PHBHHx-collagen group (-15.22 ± 5.12) and finally by the control 
group (-19.67 ± 23.12). 
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Figure 0.10 AFI Data Against Time 
AFI analysis was undertaken on pre implantation rats to produce a baseline for comparison. All implant 
groups were then compared to the control group, with all implant groups showing a return of function to 
pre-implantation values by day 40 (* p<0.05). 
 Molecular Properties of Explanted Scaffolds 2.3.4
Prior to implantation the molecular properties of the scaffolds were analysed using GPC. 
This data formed the baseline for comparison. After 40 days post implantation each 
implant group had the scaffold removed for GPC analysis and the molecular properties 
were compared to the original scaffold properties prior to implantation. 
Pre-implant tubes had a molecular weight (Mw) of 224,742 ± 23,975 Da (Figure 2.12), 
Mean chain length (Mn) of 399,732 ± 73,540 Da (Figure 2.13) and Polydispersity Index 
(Mw/Mn) of 0.58 ± 0.042 (Figure 2.14). After 40 days all groups displayed reduced Mw 
and slightly elevated Mn; tenocyte-PHBHHx-collagen (212,381 ± 10,515 Da and 412,412 ± 
19,433 Da, respectively), scaffold only (212,623 ± 11,879 Da and 416,436 ± 46,612 Da, 
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respectively), and PHBHHx-collagen (222,204 ± 16,415 Da and 442,200 ± 22,054 Da, 
respectively). However, PDI was reduced after 40 days in scaffold only group (0.51 ± 
0.043) and significantly reduced in the PHBHHx-collagen (0.50 ± 0.012), and tenocyte-
PHBHHx-collagen group (0.52 ± 0.021) in comparison to non-implanted scaffold (p<0.03)  
 
Figure 0.11 Re-sectioned Scaffold Degradation Measurement of Molecular Weight. 
Molecular weight analysis was performed on pre and re-sectioned implants and showed no significant 
decrease in values obtained when compared to the pre-implantation values. 
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Figure 0.12 Re-sectioned Scaffold Degradation Measurement of Mean Chain Length Molecular 
Weight (Mn) 
Mean Chain analysis was performed on pre and re-sectioned implants and showed no significant 
decrease in values obtained when compared to the pre-implantation values. 
 
Figure 0.13 Re-sectioned Scaffold Degradation Measurement of PDI 
PDI analysis was performed on pre and re-sectioned implants and showed significant decrease in values 
for re-sectioned hybrid scaffold and explanted hybrid scaffold that contained tenocytes when compared 
to the pre-implantation values (*p<0.05). 
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 Re-sectioned Mechanical Properties of implanted scaffolds 2.3.5
Mechanical testing, namely stretch to break (force to break) and elastic modulus 
determination was performed after the implant removal on day 40 (Figure 2.14 and 
Figure 2.15). Pre-implanted scaffold had a maximum force of 9.4 ± 2.2N and elastic 
modulus of 24.3 ± 13.2 MPa. All explanted scaffolds had a reduction in both maximum 
force and elastic modulus (PHBHHx only: 7.5 ± 1.1N and 18.7 ± 2.7 MPa, PHBHHx and 
Collagen: 5.6 ± 2.4N and 14.0 ± 6.0 MPa, and tenocyte-PHBHHx-collagen: 4.8 ± 0.1N and 
12.1 ± 0.2MPa). All groups had a significantly lower force to break (PHBHHx only, p<0.05; 
PHBHHx and collagen, p<0.05; and tenocyte-PHBHHx-collagen, p<0.003) with no observed 
difference in elastic modulus.  
 
Figure 0.14 Re-sectioned Scaffold Mechanical Testing 
Comparison of ultimate tensile strength (N) of pre implantation scaffold and re-sectioned scaffolds 
removed after 40 days implantation (*p<0.05). 
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Figure 0.15 Re-sectioned Scaffold Young’s Modulus. 
Comparison of elastic modulus (MPa) of pre implantation scaffold and re-sectioned scaffolds removed 
after 40 days implantation. 
 Histological Analysis 2.3.6
One re-sectioned scaffold was taken from each experimental group for histological 
analysis. Each section underwent paraffin wax imbedding and sectioned to a thickness of 
10μm. Post sectioning each sample was stained using Haematoxylin and Eosin staining 
protocol as outlined in Section 2.2.13 and imaged for analysis. 
 Haematoxylin and Eosin Staining 2.3.6.1
Microscopic evaluation of the damaged tendon sites with Haematoxylin and Eosin 
demonstrated evidence of cellular infiltration and partial structure regeneration to 
varying degrees dependent upon the scaffold implanted. Cellular migration into the 
defect site was apparent throughout where increased migration was observed where a 
PHBHHx-collagen only implant had been introduced to the wound site when compared to 
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either healthy tendon (Figure. 2.16) or a wound site with PHBHHx scaffold only (Figure. 
2.16). A characteristic of tendon tissue is the crimp pattern which is presented by the 
elongated sinusoidal wave like patterning of the nuclei and cytoplasm of the cells as 
apparent in the undamaged tendon sample .The emergence of the wave-like patterning 
was observed in both the PHBHHx-collagen and tenocyte-PHBHHx-collagen implants, 
however a greater structural organisation was observed in the tenocyte-PHBHHx-collagen 
implants. The tenocyte-PHBHHx-collagen implant displayed increased cellular alignment 
along the force-bearing axis; this feature was also observed in all other implants with less 
organisation along the fibre axis (Figure. 2.16). Cells formed a consistent wave pattern 
when in contact/close proximity to the fibre or tube component of the implant. This 
demonstrates that tendon-like tissue was being created around the implant, rather than 
just overlaying fibrous tissue. This was less evident in the scaffold only group (Figure 
2.16), indicating that tendon regeneration was more efficient in the tenocyte-PHBHHx-
collagen and PHBHHx-collagen implant groups. The implant was not discernible in the 
scaffold only group, providing further evidence of weaker interaction, leading to slight 
detachment from the tissue resulting in reduced integration This finding shows the use of 
collagen within the implant construct plays a vital role not only for remodelling of the 
implant but also integration  
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Figure 0.16 Histological Staining of Explanted Scaffold (H&E staining) 
Shows microscopic images of Control (healthy rat tendon), PHBHHx Scaffold only group (S), PHBHHx Scaffold and Collagen (SC) and PHBHHx Scaffold, Collagen and rat 
tenocytes (SCT) using 10x and 20x magnifications. Red arrows indicate PHBHHx fibres, Orange arrows indicate cellular alignment (error bars=500μm) 
  
 
2.4 Discussion 
The aim of this investigation was to identify a PHBHHx scaffold design that could be used 
to facilitate repair of damaged tendon tissue while not initiating an immune response or 
prolonging inflammation. A composite scaffold was developed which featured a PHBHHx 
tube, a collagen core, and PHBHHx fibres which would facilitate cellular migration and 
tissue remodelling, while at the same time allowing for limited restoration of movement. 
The design was mechanically similar to the rat Achilles tendon and to other commercially 
available human tendon repair materials [117, 297]. Furthermore, this study has shown 
that PHBHHx scaffold encourages cellular infiltration, proliferation and cellular 
alignment/organisation along the force barring fibre without initiating a prolonged 
immune response. 
C-reactive protein (CRP) is a well conserved member of the pentraxin family of proteins 
and is secreted by the liver in response to an array of inflammatory cytokines [316, 317]. 
CRP binds to damaged tissue and increases rapidly in response to trauma, infection and 
inflammation and also decreases rapidly with the resolution of the condition [318-320]. 
CRP also has the ability to activate the complement pathway and has been shown to bind 
to the Fc receptors used by IgG (FcγRI and FcγRII) [317, 319-321]. CRP-Fc receptor binding 
leads to a pro-inflammatory response similar to that observed with IgG complexes[321]. 
Not only does CRP activation precede IgG antibodies by approximately one week, CRP has 
also been shown to play a crucial role in the activation of the adaptive immune response 
early in the inflammatory and infectious process [318]. CRP has been used to measure an 
array of immune responses such as inflammation in implanted biomaterials in animals 
and both total knee replacement and hip replacements in humans [322]. This study 
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employed multiple time point analysis which included pre and post implantation levels of 
serum C-reactive protein (CRP) in response to the 40 day exposure of PHBHHx implanted 
scaffold in the rat model. CRP level grossly elevated on Day +2 which agrees with previous 
studies [323] However, by day +5 CRP levels had rapidly decreased to below pre-
implantation levels in all experimental groups and continued to remain below pre-
implantation levels in all experimental groups throughout the remainder of the study, 
which agrees with previous studies in both rodents and humans [324]. The decrease in 
CRP to below pre-implantation levels indicates that no long term 
immunological/inflammatory reaction was occurring due to the presence of the 
implanted PHBHHx scaffold and its components; improving on similar conclusions made 
by previous studies [325]. This study has also shown for the first time prolonged exposure 
to PHBHHx or PHBHHx breakdown products does not prolong an 
immunological/inflammatory response in the rat model when monitored using CRP.  
AFI testing showed a continued improvement for all groups over the 40 day investigation, 
with complete return of function being as early as day +20 in the tenocyte-PHBHHx-
collagen group which was a full 20 days prior to the PHBHHx only and PHBHHx-collagen 
group, with the control group remaining below pre-surgical implantation levels. These 
results show the implanted scaffolds are capable of withstanding the forces which are 
exposed to native tendon and the implantation of a scaffold returns function to the limb 
faster than the absence of an implant which agrees with previous studies [314]. 
Mechanical testing of tube samples recovered from the rats at day +40, found that all 
group had a reduced mechanical load capability of the scaffold tubes when compared to 
pre-implanted scaffold tube, suggesting that the fibre component of the scaffold was the 
W. R. Webb PhD Thesis Chapter 2 
103 
 
major contributor to the delivery of the mechanical properties displayed in the AFI. 
Histological examination showed cellular infiltration into the PHBHHx lumen, which would 
show PHBHHx provides favourable conditions for cellular migration and proliferation 
which adds to the findings in previous studies [307-311]. Cellular infiltration into the 
scaffold was observed in both the PHBHHx only and Collagen-PHBHHx scaffold designs 
with sinusoidal cellular alignment which is a key marker in the histological analysis of 
tendon tissue, signifying the presence of crimp angles between collagen fibrils [33, 43]. 
However, the collagen-PHBHHx scaffold showed a denser cellular presence with limited 
sinusoidal morphology along the surface of the PHBHHx fibre, this would imply a more 
favourable environment for cells is produced when a collagen lumen is present within the 
scaffold design [114, 300, 312]. The tenocyte-PHBHHx-collagen scaffold cells appeared to 
be more elongated and sinusoidal in morphology, when compared to the other implanted 
scaffold designs, as with the PHBHHx only and collagen-PHBHHx scaffold designs, when 
cells were in direct contact with the scaffold, especially the fibre component this feature 
was more apparent and the sinusoidal-elongated morphology could possibly indicating 
that force transmission resulting in mechanotransduction from the fibre to the cells 
promoted tendon cell proliferation and alignment [90, 301, 312]. However, the cellular 
density observed in the tenocyte-PHBHHx-collagen group was less apparent than that of 
the PHBHHx only and collagen-PHBHHx containing scaffold which would imply the 
addition of tenocytes cells had proliferated and become organised earlier, resulting in 
decrease in time required for functionality to return to the tendon and would account for 
the results in AFI measurements. Earlier studies have highlighted the addition of collagen 
within the scaffold design can aid integration within the implanted tissue. This further 
highlights the importance of collagen not only in the tissue integration and remodelling of 
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tendon but in a means of delivering cells to a point of repair and further adds to previous 
studies suggesting collagen is a beneficial inclusion in tendon graft material [114, 300, 
326].  
GPC analysis of explanted tube component of the scaffold showed an increase in number 
average chain length (Mn) and lower molecular weight (Mw). These findings suggest that 
the shorter chain length and low molecular weight component of the scaffold (namely the 
hydroxybutyrate) component may be being metabolised/broken down, which would 
account for the decrease in overall molecular weight which agrees with an earlier 
PHBHHx study [310]. The increase in Mn indicates that the polymer has a greater ratio of 
longer chain lengths than shorter chain lengths, which would correspond with the shorter 
chain length component of the polymer being metabolised/broken down. This is further 
evident in the changes of polymer dispersity index (PDI) (calculated by Mw/Mn) which is 
attributed to the dissolution of degraded polymer chain from the polymer bulks [327].The 
scaffold only group which lacked the presence of collagen, showed the greatest decrease 
in the Mw, we hypothesis the collagen component does in-fact delay the breakdown of 
the polymer [328]. The tenocyte-PHBHHx-collagen implant (212,381 Da ± 10,515 Da, after 
40 days) already contained a cellular component and therefore the requirement for 
cellular infiltration is removed and cells were able to actively proliferate, remodel the 
collagen component and breakdown the polymer at an earlier stage with similar values to 
that of the PHBHHx only (212,623 Da ± 23,975 Da after 40 days) than the PHBHHx-
collagen scaffold lacking the cellular component. Furthermore, the decrease in molecular 
weight would convey mechanical changes in the scaffold observed in explant mechanical 
testing of the scaffolds tube component, such as ultimate tensile strength and Young’s 
modulus [327].  
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When considered together, these results suggest that this scaffold is biocompatible; 
inferring ability to perform its desired function without eliciting any undesirable local or 
systemic effects whilst facilitating a regenerative cellular response capable of contributing 
mechanical properties of the scaffold [329]. 
2.5 Conclusion 
This study has demonstrated for the first time that PHBHHx in conjunction with collagen 
and tenocytes can be used as a scaffold material for the treatment of damaged tendon 
tissue in vivo, and with no prolonged immunological/inflammatory response in the rat 
model. It has also shown that cells not only migrate into, but implanted tenocytes 
proliferate within the PHBHHx scaffold in vivo and are capable of remodelling damaged 
tissue, with a tenocyte-PHBHHx-collagen scaffold aiding regeneration and the recently 
generated tissue being able to contribute to mechanical properties of the implant 40 days 
post implantation. 
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Chapter 3: Growth Factor induced 
Tenogenesis of Human Stem Cells 
  
W. R. Webb PhD Thesis Chapter 3 
108 
 
3.1 Introduction 
Tendon injury due to ageing tendon and over use continues to be a burden on western 
health care. The current shortage in donor tissue and inadequate synthetic implants 
provides a niche for the development of a tissue engineered approach for the treatment 
of damaged tendons. 
Tendon injuries and the subsequent repair continues to be an under researched topic 
area. Currently, the treatment options employed are limited to two major options, 
namely: conservative approach and surgical approach. Both methodologies have 
produced limited degrees of success with no consensus on which approach produces the 
best outcome for the patient. 
Surgical repair is restricted to the size of injury with the use of xenobiotic implants also 
producing limited success. Autologous implants are limited by the induced morbidity at 
the donor site. The use of allograft is also limited to donor availability and also the age of 
the donor material. Therefore, an alternative approach to the treatment of tendon 
ruptures is highly desirable. In the previous chapter we have identified a PHBHHx based 
scaffold which is capable of restoring function of an induced tendon injury in the rat 
model. This chapter aims to identify a unique combination of growth factors capable of 
inducing and maintaining stem cell differentiation towards a tenocyte lineage. 
A stem cell based approach to the treatment of tendon ruptures may provide a unique 
treatment opportunity. This can be patient specific by the utilisation of the patients’ 
mesenchymal stem cells or a broader “off-the-shelf” approach which may utilise 
embryonic stem cells 
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Growth factors have been shown to be powerful mediators and initiators of tissue 
formation [174].The utilisation of embryogenesis as a means of mapping tendon 
development has been limited to species such as rats, murine and chicks [197, 198, 201, 
202]. 
However, observations of such developmental pathways may not be conserved to human 
development [330]. One possible example is in tendon development in humans. To date 
there is very little evidence to the tendon transcription factor scleraxis activity in growth 
factor initiated human tendon development. However, there is evidence indicating 
scleraxis activity post mechanical stimulation [331]. 
This chapter will focus on the possibility of: FGF-4, FGF-6, FGF-8 and there combinations 
as being candidates for initiating stem cell differentiation towards a tenocyte-like cell 
lineage. Also, this chapter will build upon previous studies within the group in regards the 
potential of the combination of BMP-12 and BMP-13 as initiators of hESC differentiation 
towards a tenocyte-like cell lineage  
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3.2 Materials and Methods 
The primary cells used in the experiments are described below (Table 3.1). 
Cell Lines Description Origin Age Sex 
MEFs Mouse Embryonic 
fibroblasts isolated 
from 12.5-13.5 days 
gravid uteri of Black 
CB1 hybrid mice 
Keele University 
Small Animal 
Facility 
11 – 14 day 
old pups 
M/F 
SHEF-1 Human Embryonic 
Stem cell line 
Sheffield 
University, UK; 
used under license 
from the UK Stem 
Cell Bank 
n/a Male 
hMSC Human 
mesenchymal stem 
cells isolated from 
bone marrow 
aspirates 
Human bone 
marrow aspirates 
from Lonza, USA 
32 Year old M 
rtTenocytes Rat tenocytes 
isolated from 8 week 
old Sprague-Dawley 
rats 
Keele University 
Small Animal 
Facility 
8 weeks Old M/F 
rtTenocytes(TU) Rat tenocytes 
isolated from 8 week 
old Sprague-Dawley 
rats 
Tsinghua University 
Small Animal 
Facility 
8 Weeks Old M/F 
rtTenocytes(SU) Rat tenocytes 
isolated from 8 week 
old Sprague-Dawley 
rats 
Sichuan University 
Small Animal 
Facility 
8 Weeks Old M/F 
rtMSC(SU) Rat mesenchymal 
stem cells isolated 
from bone marrow 
aspirates 
Sichuan University 
Small Animal 
Facility 
8 Weeks Old M/F 
Table 0.1 Cell lines
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The following materials were used in cell culture unless otherwise stated (Table 3.2) 
Material Details 
DMEM Dulbeccos Modified Eagles media (4.5g/L glucose) (12-604F, Lonza, UK) 
FBS Foetal Bovine Serum (12-501F, Lonza, UK) 
bFGF basic Fibroblast Growth Factor (FGF-2) (100-18B, Peprotech, UK) 
BMP-12 Bone Morphogenic Protein -12 (recombinant mouse GDF-7,CF, R5240 
A572, R &D Systems, UK) 
BMP-13 Bone Morphogenic Protein-13/CDMP-2 (120-04, Peprotech, UK) 
FGF-4 Fibroblast Growth Factor -4 (100-31, Peprotech, UK) 
Dorsomorphin 6-(4-(2-Piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-
a)pyrimidine (P5499-5mg, Sigma-Aldrich, UK) 
FGF-6 Fibroblast Growth Factor -6 (100-30, Peprotech, UK) 
FGF-8 Fibroblast Growth Factor -8 (100-25, Peprotech, UK) 
NEAA Non-Essential Amino Acids (13-114E, Lonza, UK) 
L-Glut L-Glutamine (17-605E, Lonza, UK) 
PSA Penicillin, Streptomycin and AmphotericinB (15240112, Invitrogen, UK) 
Typsin Trypsin/EDTA Solution (CC-5012, Lonza, UK) 
KO DMEM Knockout DMEM (03382, Gbico, UK) 
Matrigel™  354277, SLS, UK 
Fibronectin F0895, Sigma Aldrich, UK 
SR Serum Replacement (10828-028, Gibco, UK) 
DMSO Dimethyl Sulphoxide (R00550, Invitrogen,UK) 
PBS Phosphate Buffered Saline (17-516F, Lonza, UK) 
BME β-Mercaptoethanol (31350010, GIBCO, UK) 
ASC L-Ascorbic Acid (A4403-100MG, Sigma-Ardich, UK) 
T-25 Corning 25cm2 tissue culture flask 430639 (43021, SLS, UK) 
T-75 Corning 75cm2 tissue culture flask 4306 (354639, SLS, UK) 
6 well plates Costar 3516 (SLS, UK) 
96 well Plates Costar 96 (SLS, UK) 
Centrifuge tube 15ml SLS8002 (SLS, UK) 
Centrifuge tube 50ml SLS8110 (SLS, UK) 
IMS Industrial Methylated Spirit (64-17-5, Genta Medical, UK) 
PFA Paraformaldehyde (P6418, Sigma-Aldrich, UK) 
BSC Biological Safety Cabinet Class II (W05318, Envair, UK) 
Table 0.2 General cell Culture Consumables 
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 Mouse Embryonic Fibroblast 3.2.1
 Mouse Embryonic Fibroblast Harvest 3.2.1.1
Mouse embryonic fibroblasts were harvested from 12.5 – 13.5 days pregnant black CB1 
hybrid mice. The hybrid mice were sacrificed and the embryos were harvested and eight 
to ten embryos collected from each pair of uteri. Post collection the Viscera and head 
were identified and removed from the embryos using aseptic techniques by Keele 
University animal house staff. The resulting embryos were then placed in PBS containing 
1% PSA and transferred to ISTM facilities at the Guy Hilton Research Centre. 
Once at the Guy Hilton research centre, the embryos were then washed three times in 1% 
PSA containing PBS to remove remaining fragments of the viscera and blood clots. 
Embryo fibroblasts were then isolated from the embryos by placing 5 embryos into a 7ml 
Bijou bottle containing 5ml of trypsin/EDTA. 
Trypsinised embryos were then vortexed twice at 5 minute intervals during the 
incubation process. Post incubation, cell supernatants were collected and re-suspended in 
10ml of DMEM supplemented with 10% FBS, 1% L-Glutamine, 1% NEAA and 1% PSA in 
15ml centrifuge tubes. The cell suspensions were then centrifuged at 200g for 3 minutes. 
The supernatants were discarded and the cell pellets re-suspended in 10ml of DMEM 
media mentioned above. 2 ml of MEFs cell suspension was then seeded into T75 culture 
flasks in 18 ml of media and incubated at 37oC in the presence of 5% CO2 and 95% air in a 
humidified cell culture incubator. 24 hours later the media was replaced with antibiotic-
free complete culture media, with media changes twice weekly until the MEFs became 
confluent. 
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 Mouse Embryonic Fibroblast Cryopreservation 3.2.1.2
After isolation from the mouse embryo and post expansion, MEF at passage 1 were 
cryopreserved for future use. Confluent T-75 flasks of MEF were harvested by aspirating 
the culture media from the T-75 and washing twice with 10ml PBS. Once the PBS was 
aspirated from the T-75, 3ml of 1% trypsin/PBS solution was added to disassociate the 
cells from the culture plastic. Once the cells had disassociated from the T-75 flask, 3ml of 
MEFs culture media was added to the trypsin-cell suspension to quench the effects of 
trypsin. The media-cell-trypsin suspension was then placed into a 15ml centrifuge tube 
and centrifuged for 3 minutes at 200g. After 3 minutes had elapsed the media- trypsin 
solution was aspirated from the centrifuge tube to leave a cell pellet. The cell pellet was 
then re-suspended in 1ml of 90% FBS and 10% DMSO at room temperature. The DMSO-
FBS-cell suspension was then placed into a 1.5ml cryovial and placed in a ‘Mr Frosty’ 
(C1562 Sigma Aldrich, UK) and placed into a -80oC freezer for 24hrs.. After 24hrs had 
elapsed the cryovial was then transferred into liquid nitrogen.  
 Mouse Embryonic Fibroblast Expansion 3.2.1.3
Mouse embryonic fibroblast cells (MEF) were cultured in T-75 culture flasks in MEF media 
(DMEM, 10% FBS, 1% NEAA and 1% L-glutamine) with a media change twice weekly until 
confluent.  Once confluent MEFs were washed twice with PBS, the PBS aspirated from the 
T-75 and 3ml of 1% trypsin/PBS solution was added to disassociate the cells from the 
culture plastic. Once the cells had disassociated from the T-75 flask, 3ml of MEFs culture 
media was added to the trypsin-cell suspension to quench the effects of trypsin. The 
media-cell-trypsin suspension was then placed into a 15ml centrifuge tube and 
centrifuged for 3 minutes at 200g. After 3 minutes had elapsed the media-cell-trypsin was 
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aspirated from the centrifuge tube to leave a cell pellet. The cell pellet was then re-
suspended in 5ml of MEFs media and 1ml of the cell suspension was added to five, T-75 
with a further 14ml of MEF media added. MEFS were then cultured with a twice weekly 
media change until 50 -60 % confluent. 
 Mouse Embryonic Fibroblast Preparation of Conditioning 3.2.1.4
Media for use with Embryonic Stem Cells 
Once the MEFs reached 50-60% confluent the T-75 flasks were washed twice with PBS 
and media changed to Conditioning Media (KO-DMEM, 20% SR, 1% NEAA, 1% L-Glut, 
4ng/ml bFGF (1µl per ml) and 910 l BME for 24hrs. After 24hrs media was removed and 
4ng/ml FGF-2 was added prior to filtration using Millipore ExpressTM Plus 0.22 m vacuum 
filter. The filtered media (CM+) is then ready for use for the culture of hESC. 
 Human Embryonic Stem Cell Culture 3.2.2
 Matrigel Coating of T-25 Culture Flasks 3.2.2.1
Culture surfaces of T-25 tissue culture flasks were coated with 1:100 diluted ice cold KO-
DMEM. Coating was undertaken by adding 4ml matrigel/KO-DMEM solution to each T25 
flask (160μl/cm2) and incubated at room temperature for 2 hours. Before use, matrigel 
containing flasks were incubated at 370C for 30 minutes in the incubator, after incubation 
the matrigel media was discarded and hESC culture media was added. Prepared matrigel 
coated culture flasks were stored at 40C for later use. 
 Human Embryonic Stem Cell Expansion 3.2.2.2
SHEF-1 embryonic stem cells were then cultured on matrigel-coated T-25 culture flasks in 
conditioned media (CM+) changed every 24hrs. Once confluent the media was aspirated 
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from the T-25 and subsequently washed with PBS. After washing 1% Trypsin/PBS solution 
was added to induce cell detachment. Once the cells had detached the trypsin was 
quenched with 1ml of CM+ media. The cell suspension was then pipetted into a 
centrifuge tube, centrifuged (200g, 2 minutes), media aspirated and cell pellet re-
suspended in 1ml CM+ and 500ul pipetted into 2 x T-25 flasks. 
 Human Embryonic Stem Cell Cryopreservation 3.2.2.3
80-90% confluent T-25 flasks of hESC were harvested by aspirating the culture media 
from the T-25 and washing twice with 3ml PBS. Once the PBS was aspirated from the T-
25, 1ml of 1% trypsin/PBS solution was added to disassociate the cells from the culture 
plastic. Once the cells had disassociated from the T-25 flask, 1ml of CM+ culture media 
was added to the trypsin-cell suspension to quench the effects of trypsin. The media-cell-
trypsin suspension was then placed into a 15ml centrifuge tube and centrifuged for 3 
minutes at 200g. After 3 minutes had elapsed, the media –trypsin solution was aspirated 
from the centrifuge tube to leave a cell pellet. The cell pellet was then re-suspended in 
1ml of 90% SR and 10% DMSO at room temperature. The DMSO-SR-cell suspension was 
then placed into a 1.5ml cryovial and placed in a ‘Mr Frosty’ (C1562 Sigma Aldrich, UK) 
and placed into a -80oC freezer for 24hrs. After 24hrs had elapsed the cryovial was then 
transferred into liquid nitrogen.  
 hESC BMP- Driven in vitro Differentiation 3.2.3
Sub-confluent (80-90%) T-25 of hESC were trypsinised, centrifuged (200g, 3 minutes), re-
suspended and distributed evenly across matrigel-coated 6-well plates and 2 ml of CM+ 
media added to each well. The following day the CM+ media was aspirated from each of 
the six wells and differentiation media (DMEM, 10% FBS, 1% NEAA and 1% L-Glut) 
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supplemented with 10ng/ml BMP-12, 10ng/ml BMP-13 and 10mM ASC. Media was 
replenished twice weekly and RNA lysates collected or cells fixed for 
immunocytochemistry or histology at multiple time points (Days 0, 1, 5, 10, 20 and 40). 
 hESC FGF-Driven in vitro Differentiation 3.2.4
Sub-confluent (80-90%) T-25 of hESC were trypsinised, centrifuged (200g, 3 minutes), re-
suspended and distributed evenly across matrigel-coated 6-well plates and 2ml of CM+ 
was added. The following day the CM+ was aspirated from the wells and differentiation 
media (DMEM, 10% FBS, 1% NEAA and 1% L-Glut) supplemented with either FGF4 +/- 
10mM Ascorbic acid, FGF6 +/- 10mM ASC, or FGF8 +/- 10mM Ascorbic acid. Growth 
factors were supplemented to final concentrations of 0, 20, and 50ng/ml. Media was 
replaced with fresh twice weekly and RNA lysates collected or cells fixed for 
immunocytochemistry or histology at multiple time points (Days 0, 1, 5, 10, 20 and 40). 
 Human Mesenchymal Stem Cells 3.2.5
 Fibronectin Coating of Tissue Culture Flasks 3.2.5.1
10ml of 10ng/ml fibronectin/PBS solution was added to each T-75 tissue culture flask and 
incubated at room temperature for 2 hours. Prior to use the fibronectin solution was 
aspirated from the T-75 tissue culture flasks.  
 Human Mesenchymal Stem Cell Isolation 3.2.5.2
hMSCs were isolated and expanded from human bone marrow aspirates (BMA) using the 
plastic adherent technique following the previously published protocols [332, 333]. The 
whole bone marrow was seeded at a density of 1 x 105 mononuclear cells/cm2 on 
fibronectin coated T-75 flasks in 20ml of DMEM supplemented with 10% FBS, 1% NEAA, 
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1% L-glut and 1% PSA. The whole bone marrow containing non-adherent (mononuclear 
cells) and adherent (MSC) were maintained in a continuous co-culture for three weeks in 
a humidified incubator at 37oC in the presence of either 2% O2 or 21% O2. After seven 
days of culture 50% of the DMEM supplemented with 10% FBS, 1% NEAA, 1% L-glut and 
1% PSA was aspirated from the T-75 flask and replenished with DMEM supplemented 
with 5% FBS, 1% NEAA, 1% L-glut and 1% PSA media (10ml). After 14 days, a complete 
media change was undertaken, the 20ml of media was aspirated and the T-75 tissue 
culture flask was rinsed once with PBS and 20ml of fresh DMEM media supplemented 
with 5% FBS, 1% NEAA, 1% L-glut and 1% PSA was added to the T-75 tissue culture flask. 
After, three weeks the adherent hMSC populations were either cryopreserved. 
 Human Mesenchymal Stem Cell Expansion 3.2.5.3
hMSC were cultured in T-75 culture flasks in hMSC media (DMEM, 5% FBS, 1% NEAA and 
1% L-glutamine) with a media change twice weekly until confluent.  Once confluent hMSC 
were washed twice with PBS, the PBS aspirated from the T-75 and 3ml of 1% trypsin/PBS 
solution was added to disassociate the cells from the culture plastic. Once the cells had 
disassociated from the T-75 flask, 3ml of hMSC culture media was added to the trypsin-
cell suspension to quench the effects of trypsin. The media-cell-trypsin suspension was 
then placed into a 15ml centrifuge tube and centrifuged for 3 minutes at 200g. After 3 
minutes had elapsed the media-cell-trypsin was aspirated from the centrifuge tube to 
leave a cell pellet. The cell pellet was then re-suspended in 2ml of hMSC media and 1ml of 
the cell suspension was added to two, T-75 with a further 14ml of hMSC media added. 
hMSC were then cultured with a twice weekly media change until confluent. 
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 Human Mesenchymal Stem Cell Cryopreservation 3.2.5.4
After isolation from the Bone marrow aspirate a substantial number of hMSC cultured at 
2% and 21% O2 at passage 1 were cryopreserved for future use. Confluent T-75 flasks of 
hMSCs were harvested by aspirating the culture media from the T-75 and washing twice 
with 10ml PBS. Once the PBS was aspirated from the T-75, 3ml of 1% trypsin/PBS solution 
was added to disassociate the cells from the culture plastic. Once the cells had 
disassociated from the T-75 flask, 3ml of hMSC culture media was added to the trypsin-
cell suspension to quench the effects of trypsin. The media-cell-trypsin suspension was 
then placed into a 15ml centrifuge tube and centrifuged for 3 minutes at 200g. After 3 
minutes had elapsed the media- trypsin solution was aspirated from the centrifuge tube 
to leave a cell pellet. The cell pellet was then re-suspended in 1ml of 90% FBS and 10% 
DMSO at room temperature. The DMSO-FBS-cell suspension was then placed into a 1.5ml 
cryovial and placed in a ‘Mr Frosty’ (C1562 Sigma Aldrich, UK) and placed into a  -80oC 
freezer for 24hrs.. After 24hrs had elapsed the cryovial was then transferred into liquid 
nitrogen.  
 hMSC FGF-Driven in vitro Differentiation 3.2.6
Sub-confluent (80-90%) T-75s of hMSC were trypsinised, centrifuged (200g, 3 minutes), 
re-suspended and distributed evenly across Fibronectin-coated 6-well plates and 2ml of 
hMSC media was added. The following day the hMSC was aspirated from the wells and 
differentiation media (DMEM, 10% FBS, 1% NEAA and 1% L-Glut) supplemented with 
either FGF4 +/- 10mM ASC, FGF6 +/- 10mM Ascorbic acid, or FGF8 +/- 10mM ASC. Growth 
factors were supplemented to final concentrations of 0, 20, and 50ng/ml. Media was 
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replaced with fresh twice weekly and RNA lysates collected or cells fixed for 
immunocytochemistry or histology at multiple time points (Days 0, 1, 5, 10, 20 and 40). 
 Dorsomorphin Supplementation Optimisation 3.2.7
Dorsomorphin was reconstituted to a concentration of 10mM using 1.25ml DMSO. 750ul 
of stock solution was added to 15ml of differentiation) to produce a secondary stock 
solution of 500ug/ml. Subsequent serial dilutions were undertaken to produce 
experimental concentrations of 500 μM/ml, 200 μM/ul, 100 μM/ml, 10 μM/ml and 1 
μM/ml.  hESC (hMSC in the absence of Matrigel™)  were seeded at a density of 3x105 cells 
per well and cultured on matrigel™ coated 6 well plate. hESC (hMSC in the absence of 
Matrigel™) C were cultured for 7 days with a media change being undertaken after 3 
days. On day 7 the wells were fixed using 95% methanol (Sigma) and Giemsa’s staining 
was undertaken to evaluate cell survival. 
 hESC Growth Factor Inhibition by Dorsomorphin 3.2.7.1
hESC were seeded at a density of 3x105 cells per well and cultured on matrigel™ coated 6 
well plate. hESC were cultured for 40 days with differentiation media (10% FBS, 1% L-
glutamine, 1% NEAAand 10mM ASC) which was supplemented with 10ng/ml BMP-
12/BMP-13 and 1µM Dorsomorphin or 50ng/ml of FGF-4 and 1µM Dorsomorphin, 
50ng/mL of the combination of FGF-4 & FGF-8 and 1µM Dorsomorphin or FGF-4, FGF-6 & 
FGF-8 and 1µM Dorsomorphin) and cultured at 2% O2 environment. Cell lysates were 
collected at time points: Day 0, Day 2, Day 5, Day 10, Day 20 and Day 40 along with cells 
being fixed at the same time points for immunocytochemistry. 
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 hMSC Growth Factor Inhibition by Dorsomorphin 3.2.7.2
hMSC were seeded at a density of 6 x 105 cells per well and cultured on fibronectin 
coated 6 well plate. hMSC were cultured for 40 days with differentiation media (10% FBS, 
1% L-glutamine, 1% NEAA and 10mM ASC) which was supplemented with 50ng/mL of the 
combination of FGF-4 & FGF-8 and 1µM Dorsomorphin or FGF-4, FGF-6 & FGF-8 and 1µM 
Dorsomorphin and cultured at 2% O2 environment. Cell lysates were collected at time 
points: Day 0, Day 2, Day 5, Day 10, Day 20 and Day 40 along with cells being fixed at the 
same time points for immunocytochemistry. 
 Rat Tenocyte Harvest and Culture 3.2.8
Please refer to previous sections 2.2.7.1 – 2.2.7.3 
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3.3 Ribonucleic Acid Extraction and Processing 
Listed below are the materials used for RNA extraction: 
Reagent/Kit Supplier 
QIA Shredder 79654, Qiagen, UK 
RNesay minikit 74104, Qiagen, UK 
Superscript III one-step hi-fi RTPCR 12574030, Invitrogen, UK 
RNAse ZAP R2020-250ml, Sigma Aldrich, UK 
β-mercaptoethanol 3150010, Invitrogen, UK 
Ethidium Bromide Solution E1510-10ML, Sigma Aldrich, UK 
Agarose (High resolution electrophoresis 
quality) molecular biology grade 
A4718, Sigma Aldrich, UK 
Directload Wide Range DNA marker D7058, Sigma Aldrich, UK 
Gel loading Solution G2526-5ml, Sigma Aldrich, UK 
50x TAE B9-0030, Geneflow, UK 
Table 0.3 Molecular Biology Reagents 
 
 Cell Lysis and RNA Extraction 3.3.1
RNA lysates were obtained by aspiration of media from the 6 wells followed by a PBS 
wash, followed by the addition 700μl of lysis buffer (contained in the RNEasy kit) to the 
well and samples scraped using a well scraper to encourage detachment of the cells from 
the well. The lysis buffer-cell suspension was then transferred in to a QIAshredder spin 
column, which was placed into a collection tube. The column/ collection tube was then 
centrifuged for 2 minutes at 16000g. After 2 minutes the shredder column was removed 
and the collection tube capped and stored at -80oC until RNA extraction could be 
undertaken. 
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RNA was extracted using the RNeasy kit (Qiagen). Samples were retrieved from the -80oC 
and thawed at room temperature. Once thawed, 350μl of 70% ethanol (EtOH) was added 
to the eppendorff containing the lysed sample and mixed well by pipetting. The sample 
was then decanted into a spin column which sits on a 2ml collection tube. The collection 
tube/column was then centrifuged at 9000g for 15 seconds and the flow-through was 
discarded. 700μl of buffer RW1 (supplied as part of the Qiagen RNeasy Kit) was placed 
into the RNeasy spin mini column; this was then centrifuged for 15 seconds at 9000g and 
the flow-through was discarded. 500μl of RPE buffer was then added (supplied as part of 
the Qiagen RNeasy Kit) to the RNeasy spin column and centrifuged for 15 seconds at 
9000g discarding the flow-through and repeated. The spin column was then placed into a 
new collection tube and centrifuged at 9000g for 2 minutes to remove excess EtOH. The 
RNeasy mini spin column was then placed into a new 1.5ml collection tube and 15μl of 
RNase-free water added and left to stand for 3 minutes prior to being centrifuged on full 
power for 1 minute at 9000g. The flow through was then pipetted directly back onto the 
RNeasy mini column and allowed to stand for a further 3 minutes and then centrifuged at 
full power for 1 minute at 9000g. The RNeasy mini spin column was then discarded and 
the flow through retained for quantification and subsequent gene expression analysis. 
Samples were frozen at -80oC until analysis could be undertaken. 
 Quantitative Analysis of RNA Extraction 3.3.2
After RNA extraction quantitative analysis of the RNA sample was performed using 
Nanodrop (ND-200) spectrophotometer to enable correct RNA sample concentration for 
RT-PCR (30ng/µl).Briefly 1μl of RNA sample was loaded onto the pedestal analysis stand 
and read using the RNA quantification tool as part of the ND-2000 software. RNA 
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concentration (ng/ml), 260/280 260/230 measurements were recorded. Pre and post 
sample analysis the Nanodrop pedestal was cleaned before each sample run (all samples 
were kept on ice whilst RNA quantitative analysis was performed). 
The following calculation was applied to each reading to calculate the dilution of RNA 
samples to the 30ng/µl required for RT-PCR. 
The following calculation was applied to each reading to calculate the dilution of RNA 
samples to the 5ng/µl required for RT-PCR (Figure 3.1). 
 
 
 
Figure 0.1 RNA Dilution Calculation 
 Reverse Transcription Polymerase Chain Reaction 3.3.3
The PCR reaction solution: were set up as below: 
Chemical 
Sample Mix Blank Mix 
Volume Volume 
Reaction Mix 6.75μl 6.75 μl 
RNA free H2O 2.5 μl 2.5 μl 
Forward Primer 1 μl 1 μl 
Reverse Primer 1 μl 1 μl 
Enzyme 0.25 μl 0.25 μl 
Sample 1 μl 0 μl 
RNA free H2O 0 μl 1 μl 
Table 0.4 PCR Reaction Mix Volumes 
 
1. Desired RNA = (sample reading)/5 = X 
2. Dilution = 1*y + (1*y)*X) 
Where y= volume of RNA 
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 Primer Sequences Design 3.3.4
The primers for this thesis were designed using human gene sequences from NCBI Map 
Viewer or Ensemble Genome Browser and Primer 3. Designed primers were evaluated in 
NCBI Primer-BLAST to check binding specificity. Customised primer sets were purchased 
from Invitrogen, UK. Primers are show below (Table 3.5). RT-PCR was performed with a 
one-step protocol. 
 
Table 0.5 Table of Primers sequences, annealing temperatures and amplicon size 
 
 
 
 
 
 
Gene Primer (5' - 3') Annealing Temp (
oC) Amplicon Size (bp)
F GCAATTTGCCAAGCTCCTGAAGCAG
R CATAGCCTGGGGTACCAAAATGGGG
F GGTGGCAGAAAAACAACTGGC
R TGCAGGACTGCAGAGATTC
F GCAGCTCCCATTTCATCAGC
R CAGGATGGTCTTGAAGTCTG
F GACTTTGTTGCTGCTTGC
R CAAGTCCAACTCCTTTTCC
F AAGGACACAGAGGCTTCG
R CTGGTTGACCATCAATGC
F GCACTGATGAAACATTGG
R ATCCAATACATGGTCAGG
F CCCCAGGTCTTTGACCTTCTCCC
R ACCTTCCCATCGTTCTTCAGGT
F AAGAGCATTCCTGTCAGC
R CAGTTTGCCGGTAAGAGG
F CTGCTTGCACAAGTTTCC
R TTCCAACTTCACCAAAGG
F GCCACGGCTGCTTCCAGC
R AGGGTGTAACGCAACTAAGTC
TERT (hTERT) 53 343
ACTB (β-actin) 55 504
TENC (Tenascin C) 50 217
DCN (Decorin) 48 372
TNMD 
(Tenomodulin)
47 274
THBS-4 
(Thrombospondin-4)
59 245
COL1A2(Collagen 1) 50 242
COL3A1 (Collagen 3) 51 210
POU5F1 (Oct-4) 55 536
NANOG (Nanog) 55 300
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 Thermocycler Set Up 3.3.5
The gene amplification were run on the DNA Engine thermal cycler (PTE-200) the table 
below shows the cycle temperature, time and number of cycles used in the amplification 
of the specific genes shown in Table 3.6. 
Table 0.6 PCR Thermal Cycler gene amplification Reagent Set up 
The PCR reaction tubes are set up using 1µl of sample to be amplified along with 11.5µl of 
the reaction mix (including enzyme, gene specific primers and reaction mix). The reaction 
tubes are then capped and placed in the thermal cycler for the PCR reaction to be 
initiated. 
Once the PCR reaction is complete the reaction tubes are removed from the thermal 
cycler and 2µl of gel loading solution using a fresh pipette tip for each of the samples. 
Sub Cycle Temperature Time Number of Cycles 
cDNA Synthesis and 50
o
C 30 mins 1 
pre-denaturing 94
o
C 2 mins 1 
Denaturing 94
o
C 15 secs 
40 Cycles Anneal Gene Specific * 30 secs 
Extend 68
o
C 30 secs 
Extend 68
o
C 5 mins 1 
* Gene specific temperature for annealing  
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 Agarose Gel 3.3.6
The agarose gel was prepared 1 hour prior to the electrophoresis run by adding 2g 
agarose (electrophoresis quality) to 1 x TAE (20ml 50xTAE buffer is added to 980ml of 
dH2O to get a working concentration of 1 x TAE buffer. This was heated using a laboratory 
microwave set to full power until the agarose was fully dissolved and the solution was 
completely clear. Once the agarose was dissolved 5μl of Ethidium bromide solution  was 
added, and the solution poured into the gel mould and allowed to set with a gel comb in 
place for 45mins to allow the gel to set. 
 Electrophoresis 3.3.7
The gel was removed from the mould and placed in the electrophoresis tank containing 
excess 1 x TAE buffer ensuring the buffer completely covers the gel to a depth of around 
5mm. The comb was removed from the gel and the wide range ladder loaded into the 
first well and samples are loaded in all other wells allowing for a blank and second wide 
range ladder to be placed in the final 2 wells. Samples and blanks were loaded at a 
volume of 6μl per well with fresh pipette tips for each sample and blank. The wide range 
ladders were loaded at a volume of 5μl. The electrophoresis tank was then connected to 
the Biorad Powerpac 300 (92Volts/400mAMPS/37W) and allowed to run for 45 minutes. 
 Gel Imaging 3.3.8
After the allotted 45 minutes for electrophoresis the power pack was switched off and 
the gel removed from the tank. Gels were imaged on the Syngene Gel UV illuminator and 
focused using Genimage™ software. Once the gel was focused the image was printed and 
saved.   
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3.4 Immunocytochemistry 
 hMSC (BMA-12) Characterisation 3.4.1
hMSC (P-1) were seeded at a density of 5 x 104 cells to each well of a 24 well plate and 
cultured until 80-90% confluent prior to immunophenotyping. Once 80-90% confluency 
was achieved each well was fixed with 4% PFA for 5 minutes. After 30 mins had elapsed 
the PFA was aspirated from each well and each well was subsequently washed twice with 
2mL of PBS before adding 0.5% Triton-X 100 for 5 mins to induce membrane permeability. 
After 5 mins had elapsed the 0.5% Triton X 100 was aspirated from the wells and the 
wells washed twice with PBS. After which, 3% BSA and allowed to stand for 1 hour at 
room temperature to block non-specific antibody binding. After 1 hour had elapsed each 
well was washed twice with PBS and cells were characterised using human MSC 
characterisation kit which contained anti-human mouse anti-CD-44, anti-CD90, anti-
CD146, anti-CD14 and anti-STRO-1 primary antibodies at 1:500 dilutions (Cat. No. SCR067, 
Millipore). Cells were then incubated at 4oC overnight. Secondary antibodies used were 
anti-mouse IgG-NL557 for anti-human mouse anti-CD-44, anti-CD90, anti-CD146 and anti-
CD14, with anti-mouse IgM-NL493 for STRO-1(both sets of secondary antibodies dilutions 
of 1:200. DAPI was used at a dilution of 1:500 as a nuclear stain. Once staining was 
complete the samples were immediately imaged using a fluorescent microscope (Nikon 
Eclipse Ti-ST, Japan). 
 
 
W. R. Webb PhD Thesis Chapter 3 
128 
 
 hESC (SHEF-1) Characterisation 3.4.2
SHEF-1 (hESC (P-37)) were seeded at a density of 2.5 x 104 cells to each well of a 48 well 
plate and cultured to 80-90% confluency prior to immunophenotyping. Once 70-80% 
confluency was achieved each well was fixed with 4% PFA for 5 minutes. After 30 mins 
had elapsed the PFA was aspirated from each well and each well was subsequently 
washed twice with 2mL of PBS (Lonza, Belgium) before adding 0.5% Triton-X 100 for 5 
mins to induce membrane permeability. After 5 mins had elapsed the 0.5% Triton X 100 
was aspirated from the wells and the wells washed twice with PBS. After which, 3% BSA 
and allowed to stand for 1 hour at room temperature to block non-specific antibody 
binding. After 1 hour had elapsed each well was washed twice with PBS and cells were 
characterised using “human embryonic stem cell marker antibody panel” kit which 
contained anti-human mouse anti-alkaline phosphatase (ALP), goat anti-OCT-4, goat anti-
Nanog, mouse anti-SSEA-1 and mouse anti-SSEA-4 primary antibodies at 1μg/100μL 
concentration (each well was covered with 150μL) (Cat. No. SC008, R&D systems). Cells 
were then incubated at 4oC overnight. Secondary antibodies used were anti-goat IgG-
NL493 (1:200, Northern Lights, R & D Systems) for OCT-4 and Nanog. TRITC-conjugated 
anti mouse IgG (1:200, ab6787, Abcam) was used for ALP and SSEA-4. DAPI was used at a 
dilution of 1:500 as a nuclear stain. Once staining was complete the samples were 
immediately imaged using a fluorescent microscope (Nikon Eclipse Ti-ST, Japan). 
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 Tenomodulin Staining 3.4.3
PBS was aspirated and the wells were washed twice using fresh PBS (Lonza). After 
washing, 1ml of 0.5% triton X 100 (Sigma) was added to each well for 5 minutes to 
permeate the cell membrane. After the 5 minutes had elapsed, the triton X 100 was 
aspirated and the wells washed twice with PBS. Once washed, the PBS was aspirated and 
each well was covered with 500µl of 3% Albumin (A8806, Sigma Aldrich, UK)/PBS solution 
for 1 hour at room temperature then washed twice with PBS. After washing, 500µl of 
Primary tenomodulin antibody (SC98875, Santa Cruz Biotechnologies, Germany, 1:500 
dilution in PBS) was added to each well and left overnight at 4oC. The next day the 
primary antibody was aspirated off and each well washed twice with PBS (and the 
secondary (detection) antibody was added (SC2090 Santa Cruz Biotechnologies, Germany, 
1:500 dilution in PBS) and left for 1 hour at room temperature. After 1 hour had elapsed, 
the secondary antibody was aspirated off and each well washed twice with PBS (Lonza) 
and 500ul of 4’, 6-diamidoino-2-phenylindole (DAPI) (D9542 Sigma Aldrich, UK) (1:500 
dilution.) and left for 5 minutes room temperature. After 5 minutes had elapsed the DAPI 
solution was aspirated and then each well was washed twice with PBS and imaged 
immediately on the Nikon Eclipse T1 microscope. 
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3.5 Histological Staining 
 Giemsa’s Staining 3.5.1
Cells were fixed using 95% EtOH and then washed twice with PBS. After wash 750µl of 
Giemsa’s stain was placed into each well and placed for 2 hours on a motorised rocker. 
After 2 hours had elapsed the Giemsa’s stain was aspirated off and each well was washed 
with PBS until clear. The 6 well plates where then allowed to dry overnight before 
imaging. 
 Alcian Blue Staining 3.5.2
PBS was aspirated from the wells and then 50µl of Alcian Blue stain (A3157-10G, Sigma 
Aldrich, UK) was placed into each well and kept at room temperature for 24hrs on an 
R100 Rotateck shaker (Luckham) to maximise stain uptake. 
After 24hrs had elapsed the Alcian Blue stain was aspirated off each well and each well 
washed with 150µl of sterile double filtered H2O until excess Alcian Blue stain was 
removed (if required, a third wash with sterile double filtered H2O was performed). Once 
all the excess Alcian Blue stain was removed the plates were left for 24hrs to dry before 
imaging and image analysis was performed using Image J. 
 Masson’s Trichrome Staining 3.5.3
PBS was aspirated from the wells and then 50µl of Bouins Solution (Sigma Aldrich HT15-
1KT) to completely cover the cells at the case of the wells and placed on the R100 
Rotateck shaker (Luckham) for 24hrs to maximise stain uptake. 
After 24hrs had elapsed the Bouins solution was aspirated from all the wells and each 
well was washed with 150µl of double filtered H2O (multiple washes if required) as to 
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remove the residual Bouins solution. The wells were then counterstained with 50µl 
Haematoxylin (Sigma HT15-1KT). After 5mins had elapsed the Haematoxylin was 
aspirated from the wells which were then washed with 150µl of double filtered H2O 
(multiple washes if required) to remove excess residual red colour. The wells were then 
stained with 50µl of Biebrich Scarlet-Acid Fuschin solution (Sigma Aldrich HT15-1KT) and 
allowed to stand at room temperature for 5 mins. 
After 5 mins had elapsed the Biebrich Scarlet-Acid Fuschin solution was aspirated from 
the wells and the wells washed with 150µl of double filtered H2O (multiple washes if 
required). The wells were then stained with 50µl of Phosphotugstic/Phosphomolybdic 
Acid solution (Sigma HT15-1KT freshly constituted by adding 25% (v/v) Phosphotungstic 
Acid, 25% (v/v) Phosphomolybdic Acid and 50% (
v/v) dH2O) and allowed to stand for 5 
mins. After 5 mins had elapsed the Phosphotugstic/Phosphomolybdic Acid solution was 
aspirated from the wells and 50µl of Aniline Blue Solution (Sigma HT15-1KT) was added to 
cover the base of the wells and allowed to stand at room temperature for 5 mins. 
After a further 5 mins had elapsed the Aniline Blue solution was aspirated from the wells 
and 50µl of 1% Acetic Acid (8.8ml of 1M Acetic (Ethanoic) Acid was added to 41.2ml of 
dH2O) and allowed to stand for 2 minutes. After an additional 2 mins had elapsed the 1% 
Acetic acid was aspirated from the wells and the wells were washed with 150µl double 
filtered H2O. The H2O was then aspirated for the wells and the 96 well-plate was allowed 
to stand and dry for 24hrs, prior to imaging. 
 Image Analysis 3.5.4
After air drying (24 hrs) the individual wells were imaged using X4 magnification on a 
Nikon Eclipse TD100 inverted microscope. Once the cells/colony had been located an 
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image was taken using a Canon EOS400D digital camera and saved as a TIF file, this 
process was repeated for all wells stained with Alcian Blue and Masson’s Trichrome. 
 Image J Software Set-up 3.5.5
Image J software was obtained as a free download and for Alcian Blue analysis the 
following settings were used to extract colour analysis which were part of the analysis 
pack. 
COLOUR SETTING 
Red 0.6371708 
Green 07683354 
Blue 0.06061394 
Table 0.7 Colour Settings for Alcian Blue Data Analysis 
To Undertake Alcian blue analysis we open the image J software package and choose the 
image to be analysed (Figure 3.2A). Once the image opens, we then choose Plugin, 
analyse and then Alcian blue (Figure .2B). From the choices made 4 small windows will 
open we close the windows named “Colour 3” and “Colour 2” (Figure 3.2C). We then 
choose the window “Colour 1” and select measure which will produce a table window 
containing the data (Figure 3.2D). This data is then transferred to Excel for future analysis. 
this process is utilised for all Alcian Blue Images. 
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Figure 0.2 Image J Alcian Blue Analysis set up 
For Masson’s Trichrome Analysis the following Macro was used: 
To Undertake Masson’s Trichrome analysis we open the image J software package and 
choose the image to be analysed (Figure 3.3A). Once the image opens (Figure .3.3), we 
then choose measure which will produce a table window containing the data (Figure 
3.3C). This data is then transferred to Excel for future analysis. This process is utilised for 
all Masson’s Trichrome Images. 
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Figure 0.3 Image J Masson’s Trichrome Set up 
 Statistical Testing 3.5.6
The significance of difference between groups (n=3 per group) was determined by one-
way ANOVA two factor two tailed comparison analysis. A p value less than 0.05 was 
considered to indicate statistical significant. Data are presented as mean ± standard 
deviation (SD). All statistical analysis was performed using Minitab® 16 (Minitab Inc., 
Pennsylvania, USA).  
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 Experimental Plan 3.5.7
Cultured 
for 20 days 
with FGF 
without 
Vitamin C
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for 20 days 
with FGF 
with 
Vitamin C
Tenomodulin Negative = END
Cultured 
for 20 days 
with FGF 
without 
Vitamin C
2% Cultured hESC/hMSC 21% Cultured hESC/hMSC
Cultured 
for 20 days 
with FGF 
with 
Vitamin C
RT PCR for Tenomodulin
Tenomodulin Positive
Tenomodulin 
Immunocytochemistry
Alcian Blue 
Histology
Masson’s Trichrome 
Histology
Further RT-PCR for 
Tendon marker
Dorsomorphin Inhibition of FGF/Vitamin C 
Cell Culture
 
Figure 0.4 FGF driven human MSC and hESC differentiation experimental plan 
Flow chart of work plan showing initial screening for TNMD gene expression. After identification of 
TNMD gene expression, Dorsomorphin inhibition of BMP signalling and full tendon gene expression for 
growth factor supplementation of differentiation media along with TNMD immunocytochemistry and 
histological analysis.  
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3.6 Results 
 hESC Characterisation 3.6.1
Prior to experimental set up we sought to confirm the expression of pluripotent markers 
for human embryonic stem cells (SHEF-1) utilising immunocytochemistry previously 
described in Section 3.4. This was undertaken by expanding a 2 x T-25 and seeding the 
confluent T-25 to a 6 well plate. The remaining T-25 was then utilised for RNA extraction 
using the Qiagen RNEasy kit previously described in Section 3.3. 
 hESC Phenotyping  3.6.1.1
hESC cell line SHEF-1 was utilised for this experimental chapter and cultured in a feeder-
free, culture condition using MEFs-CM media following the protocol described in the 
Section- 3.2.2. SHEF-1 cells grew in a steady manner and did not show any apparent sign 
of senescence.  
Immunocytochemistry (Figure 3.5) SHEF-1 cells were highly positive for alkaline 
phosphatase (ALP) and stage-specific embryonic antigen-4 (SSEA-4) markers [336]. 
Supplementary to the immunocytochemistry, RT PCR analysis showed SHEF-1 cells 
displayed high levels of hTERT gene expression as detected by RT-PCR (Figure 3.6) 
(Section- 3.3), a common criterion for hESC (Thomson et al., 1998). Cells were also 
positive for pluripotent nuclear markers Octamer-binding protein-4 (Oct-4) and Nanog 
again detected by RT-PCR (Figure 3.6). 
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Figure 0.5 Immunocytochemistry Profiling of Human Embryonic Stem cells (SHEF-1) 
Pluripotent characterisation for embryonic stem cell markers produced positive for NANOG, Alkaline 
Phosphatase (ALP), OCT-4 and Stage specific embryonic antigen-4 (SSEA-4) protein markers for SHEF-1 
cells, during cell expansion. 
 
Figure 0.6 RT-PCR Pluripotent gene expression of SHEF-1.  
RT-PCR was undertaken during expansion (passage 32) and on seeding (passage 35) the hESCs on the day 
prior to the addition of FGF supplemented media. 
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 hESC Tenomodulin Expression After FGF Driven 3.6.2
Differentiation 
After identifying the SHEF-1 (hESCs) expressed pluripotent markers the next phase of the 
investigation was to investigate the effects of FGF-4, FGF-6 and FGF-8 supplementation of 
differentiation media (DMEM supplemented with 10% FBS, 1% L-GLUT and 1% NEAA) in 
the presence and absence of Vitamin C (10μM) at two different oxygen environments (2% 
and 21%). SHEF-1 cells were seeded as shown in Section 3.2.4.  
This phase of the investigation utilised the time points 0, 2, 5, 10 and 20 days for RT-PCR 
to detect the presence of Tenomodulin (a known tendon marker). 
Preliminary RT-PCR showed. FGF-4 & 8 when cultured in the presence of Vitamin C and 
cultured at 2% O2 was capable of maintaining TNMD expression through to day 20 (Figure 
3.7). However, the expression post day 10, did appear to reduce. FGF-4, 6 & 8 when 
cultured at 2% O2 and supplemented with Vitamin C were capable of sustaining TNMD 
gene expression in hESCs (Figure 3.7) with no apparent reduction in expression. 
Conversely, FGF-4, FGF-6, FGF-8 FGF-4 & 6, FGF-4 & 8 and FGF-4, 6 & 8 when cultured for 
20 days at 21% O2 were incapable of sustaining TNMD gene expression in hESC when 
cultured in the presence or absence of Vitamin C (Figure 3.8). 
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Figure 0.7 Tenomodulin expression of FGF driven differentiation of hESC (SHEF-1) cultured at 2% 
O2 supplemented with or without Vitamin C 
RT-PCR analysis for Tenomodulin (TNMD) showed that combinations of FGF-4 & 8 and the combination of 
FGF-4, 6 & 8 induced and maintained the expression of TNMD for 20 days when supplemented with 
Vitamin C at 10µM per mL. FGF supplemented media which was not supplemented with Vitamin C was 
unable to initiate and subsequently maintain the expression of TNMD. 
 
Figure 0.8 Tenomodulin expression of FGF driven differentiation of hESC (SHEF-1) cultured at 21% 
O2 supplemented with or without Vitamin C 
FGF supplemented media with/without Vitamin C was unable to initiate transcription of TNMD when 
hESC’s are cultured at 21% O2. 
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Having now identified the FGF growth factor combination capable of initiating and 
maintaining TNMD expression the next phase was to be initiated. The next investigation 
was to identify the concentration of Dorsomorphin that allowed cell survival. Then 
supplement the FGF/Vitamin C differentiation media with Dorsomorphin. 
 Dorsomorphin Concentration Optimisation 3.6.3
Shef-1 cells were seeded to a 6 well plate as shown in Section 3.2.7 and cultured using 
CM+ (Conditioned embryonic stem cell media) supplemented with a range of 
Dorsomorphin concentrations (ranging from 1μM to 500μM) and cultured at 2% O2 for 5 
days and media change every 24 hours. 
After 5 days had elapsed cells were fixed and stained with Giemsa’s stain for analysis 
(Section 3.5.1) 
The concentration to be used for investigation of Dorsomorphin inhibition of SHEF-1 FGF 
driven differentiation was 1μM per ml (Figure 3.9). The concentration of 1μM per ml as 
this concentration impaired cellular proliferation whilst all higher concentrations were 
shown to have a toxic effect. 
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Figure 0.9 SHEF 1 cultured in Dorsomorphin supplemented media at a range of concentrations. 
Shows a range of concentrations of Dorsomorphin with concentrations in excess of 1μm having a high 
level of cellular toxicity.  
 FGF driven differentiation of hESC cultured with Vitamin C and 3.6.4
Dorsomorphin at 2% O2 
hESC when cultured at 2% O2 in differentiation media containing FGF-4 & 8 and Vitamin C 
showed a continued expression of both TNMD, THBS-4 genes and COL1A2 genes. COL3A1 
expression was present at Day 0, 2 and weakly present at Day 5, by day 10 expression had 
returned to pre-day 5 levels and COL1A2 was expressed through to day 40. TENC was 
expressed from day 10 through to day 40. DCN gene expression was only detected at day 
40 (Figure 3.10). 
Conversely, the addition of Dorsomorphin to the culture media inhibited the gene 
transcription of THBS-4 and DCN. Furthermore, TENC and TNMD were not detected post 
day 20. Conversely, both COL1A2 and COL3A1 were detected throughout the 
investigation (Figure 3.10). 
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Figure 0.10 Tendon gene expression for hESC FGF-4 & 8 driven differentiation when supplemented 
with Dorsomorphin at 2% O2 
Tendon gene expression panel for FGF-4 & 8 supplemented differentiation media with Vitamin with and 
without Dorsomorphin cultured at 2% O2. 
hESC when cultured at 2% O2 and supplemented differentiation media containing FGF-4, 
6 & 8 and Vitamin C showed continued gene expression of TNMD, THBS-4, TENC, COL1A2, 
COL3A1 with DCN being detected from day 2 through to day 40 (Figure 3.11). 
Conversely, the addition of Dorsomorphin to the culture media inhibited the gene 
transcription of DCN. However, TNMD, THBS-4, TENC, COL1A2, COL3A1 were detected up 
to day 40, with TNMD being less expressed. 
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Figure 0.11 Tendon gene expression for hESC FGF-4, 6 & 8 driven differentiation when 
supplemented with Dorsomorphin at 2% O2 
Tendon gene expression panel for FGF-4, 6 & 8 supplemented differentiation media with Vitamin with 
and without Dorsomorphin cultured at 2% O2. 
hESC cultured in the presence of BMP-12 & 13 and differentiation media further 
supplemented with Vitamin C showed TNMD, TENC expression for the duration of the 
investigation (Figure 4.9). However, THBS-4 was detected until day 2 although the signal 
was weak. COL1A2 was detected throughout the 40 day investigation again this was a 
weak signal. COL3A1 was detected from day 5 through to day 40 with increasing levels 
with DCN only being detected on day 10 and day 20 (Figure 3.12). 
Conversely, the addition of Dorsomorphin to the differentiation media containing BMP-12 
& 13 and Vitamin C inhibited the gene transcription of TNMD and COL3A1. Furthermore, 
THBS-4 and COLA2 were detected up until day 20 and TENC until Day 10, whilst DCN was 
only detected on day 2 and day 5 (Figure 3.12). 
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Figure 0.12 Tendon gene expression for BMP-12 & 13 driven differentiation when supplemented 
with Dorsomorphin at 2% O2 
Tendon gene expression panel for BMP12 & 13 supplemented differentiation media with Vitamin with 
and without Dorsomorphin cultured at 2% O2. 
Having now established the gene expression for both Dorsomorphin supplemented 
growth factor differentiation media. We then used immunocytochemistry to identify the 
expression of TNMD protein this phase of the investigation utilised TNMD 
Immunocytochemistry.  
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  Immunocytochemistry  3.6.5
Immunocytochemistry was undertaken to detect the presence of tenomodulin protein 
expression after growth factor driven differentiation of hESC. Also, to evaluate the effect 
of further supplementation of differentiation media with Dorsomorphin and its 
subsequent affect upon TNMD expression. 
Prior to undertaking the immunocytochemistry staining for TNMD we looked at utilising 
rat tenocytes as a positive control.  
 Tenomodulin Antibody Staining of Rat Tenocytes 3.6.5.1
Rat tenocytes (rt-tenocytes) were harvested and expanded following the protocol shown 
in Section 3.4.3. After expansion the rt-tenocytes were seeded into a six well plate and 
subsequently immunocytochemistry stained for tenomodulin utilising the protocol in 
Section 3.4.3. 
The immunofluorescence showed positive expression for TNMD (confirming the cells 
were tenocytes), with a DAPI (blue) nuclear stain (Figure 3.13). The Cells appeared to 
show the presence of synapse-like morphology and fibroblast like appearance. 
 
Figure 0.13 Tenomodulin positive stained rat tenocyte 
Rat Tenocytes at passage 1 showing positive TNMD (green) and DAPI nuclear staining (Blue). 
W. R. Webb PhD Thesis Chapter 3 
146 
 
 Tenomodulin Staining of FGF Driven Differentiation of hESCs. 3.6.5.2
FGF driven differentiation of hESC cells were cultured for 40 days in FGF or BMP (n=3), 
Vitamin C supplemented differentiation media (Section 3.2.3 & 3.2.4) in the presence and 
absence of Dorsomorphin. Cells were fixed for staining (Section 3.4.3) at time-points 0, 2, 
5, 10, 20 and 40 days exposure to the respective media. 
hESCs supplemented with the combination of FGF-4 & 6 with Vitamin C showed the 
presence of TNMD stain which was localised to the nucleus which indicates a presence of 
TNMD throughout the investigation (Figure 4.11). However, there appeared to be little to 
no TNMD staining on the cellular membrane and the cells lacked the fibroblast like 
morphology observed in the rat tenocytes and appeared more cobble stone “like” (Figure 
3.14)  
hESCs supplemented with the combination of FGF-4 & 8 with Vitamin C and 
Dorsomorphin appeared to have reduced TNMD signalling (Figure 3.15) compared to the 
absence of Dorsomorphin (Figure 3.14). The addition of Dorsomorphin appeared to 
inhibit morphological change towards a fibroblast like appearance which the cells 
appearing to remain “embryonic-like”. 
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Figure 0.14 hESC FGF-4 & 8 with Vitamin C cultured at 2% O2 
TNMD (green) staining with DAPI (blue) nuclear stain of hESC cultured in differentiation media supplemented with FGF-4 & 8 with Vitamin C over 40 days (Time points 
0, 2, 5, 10, 20 and 40 days). 
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Figure 0.15 hESC FGF-4 & 8 with Vitamin C cultured at 2% O2 supplemented with Dorsomorphin 
TNMD (green) staining with DAPI (blue) nuclear stain of hESC cultured in differentiation media supplemented with FGF-4 & 8 with Vitamin C and Dorsomorphin over 40 
days (Time points 0, 2, 5, 10, 20 and 40 days). 
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hESCs supplemented with the combination of FGF-4, 6 & 8 with Vitamin C showed TNMD 
staining within the cytoplasm of the cells (Figure 3.16). However, the cells lacked the 
fibroblast-like morphology observed in rat tenocytes (Figure 3.13). As the investigation 
progressed in time the TNMD staining appeared as back ground staining which may 
indicate the TNMD protein being expressed within the cellular matrix, but lacking the 
morphological appearance of tenocytes and more spherical (cobble stone like). 
hESCs supplemented with the combination of FGF-4, 6 & 8 with Vitamin C and 
Dorsomorphin showed reduced TNMD staining within the cytoplasm of the cells (Figure 
3.17) when compared to the absence of Dorsomorphin (Figure 3.16). The addition of 
Dorsomorphin appeared to inhibit morphological change towards a fibroblast like 
appearance which the cells appearing to remain “embryonic-like”. 
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Figure 0.16 hESC supplemented with FGF-4, 6 & 8, Vitamin C and cultured at 2% O2 
TNMD (green) staining with DAPI (blue) nuclear stain of hESC cultured in differentiation media supplemented with FGF-4, 6 & 8 with Vitamin C and Dorsomorphin over 
40 days (Time points 0, 2, 5, 10, 20 and 40 days).  
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Figure 0.17 hESC Supplemented with FGF-4, 6 & 8, Vitamin C and Dorsomorphin Cultured at 2% O2 
TNMD (green) staining with DAPI (blue) nuclear stain of hESC cultured in differentiation media supplemented with FGF-4, 6 & 8 with Vitamin C and Dorsomorphin over 
40 days (Time points 0, 2, 5, 10, 20 and 40 days). 
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hESCs supplemented with the combination of BMP-12 & 13 with Vitamin C showed TNMD 
staining within the cytoplasm of the cells at day 5 (Figure 3.18). The BMP differentiated 
cells appeared to be fibroblast-like morphology similar to that observed in rat tenocytes 
(Figure 3.13) with distinct synapsing with other cells. Prior to day 5 and between the time 
points 10 -20 the cells appeared to lack TNMD staining. 
hESCs supplemented with the combination of BMP-12 & 13 with Vitamin C and 
Dorsomorphin showed no positive TNMD staining over the 40 day investigation (Figure 
3.19). This indicates that Dorsomorphin inhibited the effects of BMP12 & 13 observed in 
Figure 3.18.  
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Figure 0.18 hESC Supplemented with BMP-12 & 13 and Vitamin C and cultured at 2% O2 
TNMD (green) staining with DAPI (blue) nuclear stain of hESC cultured in differentiation media supplemented with BMP-12 & 13 with Vitamin C and Dorsomorphin over 
40 days (Time points 0, 2, 5, 10, 20 and 40 days). 
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Figure 0.19 hESC BMP-12 & 13 cultured at 2% O2 and Supplemented with Dorsomorphin 
TNMD (green) staining with DAPI (blue) nuclear stain of hESC cultured in differentiation media supplemented with BMP-12 & 13 with Vitamin C and Dorsomorphin over 
40 days (Time points 0, 2, 5, 10, 20 and 40 days). 
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 Histological Analysis 3.6.6
Histological staining of growth factor (and Vitamin C supplemented differentiation media) 
driven differentiation of hESC towards a tenocyte lineage was undertaken in parallel to 
immunocytochemistry and rt-PCR. Growth factor driven differentiation of hESC was 
undertaken utilising the procedure shown in Section 3.2.3– 3.2.6. 
Glycosaminoglycans were stained utilising Alcian Blue stain procedure shown in Section 
3.5.2 and analysed utilising Image J analysis shown in Section 3.5.4– 3.5.5. 
Collagen was stained using Masson’s Trichrome staining procedure shown in Section 3.5.3 
and image J analysis was undertaken utilising the procedure outlined in Section 3.5.4– 
3.5.5. 
A selection of growth factor driven hESC stained with Masson’s Trichrome is shown in 
Figure 3.20. Each time point had a n=3 and each well imaged 3 times to produce the data 
shown in Table 3.8. 
From the Data shown in Table 3.8 comparisons were made between growth factor in the 
absence of Dorsomorphin and the presence of Dorsomorphin in the differentiation 
media. 
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 Masson’s Trichrome Staining 3.6.6.1
 
Figure 0.20 Masson’s Trichrome staining for each group of Shef-1 over 40 Days. 
All groups showed Masson’s Trichrome staining. All time points (n=9) were analysed and data extracted from the images. From the data extracted each time point for 
each condition was compared and statistically tested and the data is shown in Table 3.8. 
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Time 
(Days) 
hESC 
Control –
d 
hESC 
Control 
+d 
hESC 
BMP-12 
&13 -d 
hESC 
BMP-12 
&13 +d 
hESC FGF-
4 & 8 -d 
hESC FGF-
4 & 8 +d 
hESC FGF-
4, 6 & 8 -
d 
hESC FGF-
4,6 & 8 
+d 
0 52.77 
±3.39 
52.63 
±3.22 
52.77 
±3.39 
52.57 
±3.66 
52.67 
±3.13 
52.57 
±3.66 
52.77 
±3.31 
52.57 
±3.66 
2 49.41 
±1.36 
49.85 
±1.26 
61.70 
±2.65 
53.41 
±1.42 
61.23 
±1.99 
52.79 
±1.49 
56.58 
±6.85 
54.59 
±2.22 
5 49.52 
±1.48 
50.60 
±2.22 
65.35 
±3.05 
53.96 
±2.53 
64.79 
±2.52 
52.97 
±1.62 
66.56 
±3.18 
64.55 
±5.23 
10 50.23 
±2.81 
49.24 
±1.19 
68.55 
±3.55 
54.29 
±2.93 
69.30 
±4.21 
53.50 
±4.21 
69.62 
±3.70 
68.72 
±5.44 
20 60.82 
±2.91 
49.86 
±2.28 
74.48 
±6.71 
54.29 
±2.38 
75.17 
±4.96 
54.24 
±2.44 
79.24 
±5.00 
73.54 
±6.56 
40 64.87 
±4.13 
49.62 
±1.16 
79.72 
±3.66 
57.86 
±3.06 
77.89 
±1.92 
56.75 
±1.87 
86.62 
±2.27 
74.98 
±6.22 
Table 0.8 Masson’s Trichrome data extraction from Image J for human Embryonic Stem cells 
The data shown is obtained from Image J and is a total colour extraction of images taken from growth 
factor driven differentiation. 
From the data shown in Table 3.8 the following observations were made: 
hESC cultured in control differentiation media (DMEM supplemented with: 10% FBS, 1% 
NEAA, 1% L-Glut) displayed a Masson’s Trichrome colour extraction value of 52.77±3.39 
on day 0, which decreased by day 2 (49.41±1.36). A slight increase in value was observed 
by day 5 (49.52±1.48), with further increases on day 10 (50.23±2.81), day 20 (60.82±2.91) 
and Day 40 (64.87±4.13).  
Conversely, hESC cultured in control differentiation media supplemented with 
Dorsomorphin had a Masson’s Trichrome colour extraction value of 52.63±3.22 on day 0, 
which decreased by day 2 (49.85±1.26). A slight increase in value was observed by day 5 
(50.60±2.22), with further decreased at day 10 (49.24±1.19), an increase on day 20 
(49.86±2.28) and a subsequent decrease on Day 40 (49.62±1.16).  
Statistical testing between Control differentiation media against control differentiation 
media plus Dorsomorphin showed significant difference between Control-d and Control 
+d day 20 (p<0.0001) and day 40 (p<0.0001) time points (Figure 3.21). 
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Figure 0.21 Masson’s Trichrome analysis of hESC supplemented with control differentiation media 
in the presence and absence of Dorsomorphin 
hESC cultured using differentiation media and differentiation media supplemented with Dorsomorphin 
over 40 days (*p<0.0001). 
Further, supplementation of differentiation media with BMP-12 & 13 produced a 
Masson’s Trichrome colour extraction value of 52.77±3.39 at day 0. Which increased 
continuously on: day 2 (61.70±2.65), day 5 (65.35±3.05), day 10 (68.55±3.55), day 20 
(74.48±6.71) and day 40 (79.72±3.66). 
Conversely, supplementation of differentiation media with BMP-12 & 13 and 
Dorsomorphin produced a Masson’s Trichrome colour extraction value of 52.57±3.66 at 
day 0. Which decreased on day 2 (53.41±1.42) and increase on day 5 (53.96±2.53).a 
further increase was observed on day 10 (54.29±2.93) and day 20 reporting similar values 
to day 10 (54.29±2.38) and day 40 showing a slight increase 57.86±3.06). 
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Further testing of BMP-12 & 13 –d and BMP-12 & 13 +d showed significant difference at 
day 2 (p<0.0005), day 5 (p<0.00001), day 10 (p<0.00001), day 20 (p<0.00001) and day 40 
(p<0.000001). FGF-4 & 8-d and FGF-4 & 8+d showed significant difference at day 2 
(p<0.0005), day 5 (p<0.00001), day 10 (p<0.0005), day 20 (p<0.00001) and day 40 
(p<0.00001). FGF-4, 6 & 8 –d and FGF-4, 6 & 8+d significant difference was observed at 
day 20 (p<0.05) and day 40 (p<0.001) (Figure 3.22) 
 
Figure 0.22 Masson’s Trichrome analysis of hESC supplemented with BMP-12 & 13 differentiation 
media in the presence and absence of Dorsomorphin 
hESC cultured using differentiation media supplemented with BMP-12 and 13 (Vitamin C) and 
differentiation media supplemented with BMP-12 and 13 (Vitamin C) and Dorsomorphin cultured for 40 
days (*p<0.0005, **p<0.00001 and +p<0.001). 
When hESC differentiation media was supplemented with FGF-4 & 8, an initial day 0 value 
for Masson’s Trichrome colour extraction of 52.67±3.13 was observed. By day 2 this value 
had increased to 61.23±1.99 with further increases observed on day 5 (64.79±2.52), day 
10 (69.30±4.21), day 20 (75.17±4.96) and day 40 (77.89±1.92). 
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Conversely, hESC differentiation media was supplemented with FGF-4 & 8 and 
Dorsomorphin, an initial day 0 value for Masson’s Trichrome colour extraction of 
52.57±3.66 was observed. By day 2 this value had increased to 52.49±1.49 with further 
increases observed on day 5 (52.97±1.62), day 10 (53.50±4.21), day 20 (54.24±2.44) and 
day 40 (56.75±1.87). 
On statistically testing hESC cultured in differentiation media supplemented with FGF-4 & 
8 and Vitamin C against hESC cultured in differentiation media supplemented with FGF-4 
& 8, Vitamin C and Dorsomorphin. Revealed a significant difference at all time points from 
Day 2 days through to 40 days where the absence of Dorsomorphin had significantly 
higher level of Masson’s Trichrome staining which implies increased collagen formation 
(Figure 3.23). 
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Figure 0.23 Masson’s Trichrome analysis of hESC supplemented with FGF-4 & 8 differentiation 
media in the presence and absence of Dorsomorphin 
hESC cultured using differentiation media supplemented with FGF-4 & 8 (Vitamin C) and differentiation 
media supplemented with FGF-4 & 8 (Vitamin C) and Dorsomorphin cultured for 40 days (*p<0.0005, 
**p<0.00001). 
hESC cultured in differentiation media supplemented with FGF-4, 6 & 8 had an initial day 
0 Masson’s Trichrome value of 52.77±3.31. Which increased further on: day 2 
(56.58±6.85), with further increases on Day 5 (66.56±3.18), day 10 (69.62±3.70), day 20 
(79.24±5.00) and day 40 (86.62±2.27) (Figure 4.21). 
Conversely, hESC cultured in differentiation media supplemented with FGF-4, 6 & 8 and 
Dorsomorphin had an initial day 0 Masson’s Trichrome value of 52.57±3.66. Which 
increased further on: day 2 (54.59±2.22), with further increases on Day 5 (64.55±5.23), 
day 10 (68.72±5.44), day 20 (73.54±6.56) and day 40 (74.98±6.22) (Figure 3.24). 
W. R. Webb PhD Thesis Chapter 3 
161 
 
On statistically testing hESC cultured in differentiation media supplemented with FGF-4, 6 
& 8 and Vitamin C against hESC cultured in differentiation media supplemented with FGF-
4, 6 & 8, Vitamin C and Dorsomorphin. Revealed a significant difference at time points 20 
days and 40 days where the absence of Dorsomorphin had significantly higher level of 
Masson’s Trichrome staining which implies a increased collagen formation (Figure 3.24). 
 
Figure 0.24 Masson’s Trichrome analysis of hESC supplemented with FGF-4, 6 & 8 differentiation 
media in the presence and absence of Dorsomorphin 
hESC cultured using differentiation media supplemented with FGF-4, 6 & 8 (Vitamin C) and differentiation 
media supplemented with FGF-4, 6 & 8 (Vitamin C) and Dorsomorphin cultured for 40 days (*p<0.005, 
**p<0.00005). 
Further statistical testing was undertaken by comparing BMP-12 & 13-d against both FGF-
4 & 8-d and FGF-4, 6 & 8-d, and also testing FGF-4 & 8-d against FGF-4, 6 & 8-d. On testing 
BMP-12 & 13 –d against FGF-4 & 8-d, no significant difference was observed. Conversely 
on testing BMP-12 & 13-d with FGF-4, 6 & 8-d significant difference was observed at day 
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40 (p<0.05). FGF-4 & 8-d testing against FGF-4, 6 & 8-d produced significant difference at 
Day 40 (p<0.05) (Figure 3.25). 
 
Figure 0.25 Masson’s Trichrome analysis of hESC supplemented with FGF-4, 6 & 8 and BMP12 & 13 
differentiation media in the and absence of Dorsomorphin 
hESC cultured using differentiation media supplemented with BMP-12 & 13 (Vitamin C) and 
differentiation media supplemented with FGF-4, 6 & 8 (Vitamin C) cultured for 40 days (*p<0.05). 
Further statistical testing was undertaken by comparing BMP-12 & 13+d against both 
FGF-4 & 8+d and FGF-4, 6 & 8+d, and also testing FGF-4 & 8+d against FGF-4, 6 & 8+d. On 
testing BMP-12 & 13+d against FGF-4 & 8+d, no significant difference was observed. 
Conversely on testing BMP-12 & 13+d with FGF-4, 6 & 8+d significant difference was 
observed at: day 5 (p<0.005), day 10 (p<0.0005), day 20 (p<0.0005) and day 40 
(p<0.0005). FGF-4 & 8+d testing against FGF-4, 6 & 8+d produced significant difference on 
day 5 (p<0.005), day 10 (p<0.0005), day 20 (p<0.0005) and day 40 (p<0.0005) (Figure 
3.26).  
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Figure 0.26 Masson’s Trichrome analysis of hESC supplemented with FGF-4, 6 & and BMP12 & 13 
differentiation media in the and presence of Dorsomorphin 
hESC cultured using differentiation media supplemented with BMP-12 & 13 (Vitamin C) and 
Dorsomorphin differentiation media supplemented with FGF-4, 6 & 8 (Vitamin C) and Dorsomorphin 
cultured for 40 days (*p<0.005 and **p<0.0005). 
On statistically testing FGF-4 & 8 and FGF-4,6 & 8 in the absence of Dorsomorphin 
revealed Masson’s Trichrome stain to be higher at day 2 for FGF-4 & 8 (Figure 
4.24)(p<0.05). Conversely on day 40, FGF-4,6 & 8 in the absence of Dorsomorphin had a 
higher Masson’s Trichrome staining (p<0.05) (Figure 3.27). 
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Figure 0.27 Masson’s Trichrome analysis of hESC supplemented with FGF-4 & 8 and FGF-4,6 & 8 
differentiation media in the absence of Dorsomorphin. 
hESC cultured using differentiation media supplemented with FGF-4 & 8 (Vitamin C) and  differentiation 
media supplemented with FGF-4, 6 & 8 (Vitamin C) cultured for 40 days (*p<0.005). 
Further statistical analysis revealed that from Day 5 through to day 40 that a higher level 
of collagen staining was observed in FGF-4, 6 & 8 samples than in FGF-4 and 8 when both 
differentiation media contained Dorsomorphin (p<0.005 and p<0.0005) (Figure 3.28) 
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Figure 0.28 Masson’s Trichrome analysis of hESC supplemented with FGF-4 & 8 and FGF-4,6 & 8 
differentiation media in the presence of Dorsomorphin. 
hESC cultured using differentiation media supplemented with FGF-4 & 8 (Vitamin C and Dorsomorphin) 
and differentiation media supplemented with FGF-4, 6 & 8 (Vitamin C and Dorsomorphin) cultured for 40 
days (*p<0.005 and **p<0.0005). 
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 Alcian Blue Staining 3.6.6.2
 
Figure 0.29 Alcian Blue staining for each group of Shef-1 over 40 Days. 
All groups showed Alcian Blue staining. All time points (n=9) were analysed and data extracted from the images. From the data extracted each time point for each 
condition was compared and statistically tested and the data is shown in Table 3.9. 
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Time 
(Days) 
hESC 
Control -d 
hESC 
Control 
+d 
hESC 
BMP-
12&13 -d 
hESC 
BMP-
12&13 +d 
hESC FGF-
4 & 8 -d 
hESC FGF-
4 & 8 +d 
hESC FGF-
4,6 & 8 -d 
hESC FGF-
4,6 & 8 
+d 
0 39.94 
±0.63 
40.42 
±0.79 
41.70 
±1.20 
40.00 
±0.64 
39.67 
±0.75 
39.98 
±0.36 
39.98 
±0.63 
40.01 
±0.72 
2 43.41 
±0.36 
40.42 
±0.91 
47.45 
±1.28 
42.93 
±0.44 
46.32 
±0.43 
44.37 
±0.60 
47.13 
±0.72 
44.70 
±0.58 
5 44.56 
±0.48 
40.30 
±0.47 
50.53 
±0.67 
45.08 
±0.58 
47.89 
±0.50 
46.01 
±0.23 
48.77 
±1.04 
47.31 
±1.03 
10 45.90 
±0.32 
40.44 
±0.78 
52.01 
±0.37 
46.52 
±0.67 
49.40 
±0.76 
47.14 
±1.36 
51.27 
±0.64 
49.63 
±0.27 
20 47.02 
±0.53 
40.60 
±0.84 
52.97 
±0.27 
47.89 
±1.45 
50.36 
±0.50 
49.15 
±0.30 
54.59 
±0.69 
51.04 
±0.62 
40 48.48 
±1.13 
40.58 
±1.11 
56.36 
±2.04 
50.44 
±0.64 
52.48 
±0.72 
51.30 
±0.62 
58.79 
±1.78 
54.90 
±1.82 
Table 0.9 Alcian Blue data extraction from Image J for human Embryonic Stem cells (SHEF-1) 
The data shown is obtained from Image J and is Alcian blue colour extraction of images taken from 
growth factor driven differentiation. 
From the data shown in Table 3.9 the following observations were made: 
hESC cultured in differentiation media had an Alcian blue colour extraction value of 
39.94±0.63 on day 0, which decreased by day 2 (43.41±0.36). A slight increase in value 
was observed by day 5 (44.56±0.48), with further decreased at day 10 (45.90±0.32), an 
increase on day 20 (47.02±0.53) and a subsequent decrease on Day 40 (48.48±1.13) 
(Figure 3.30). 
hESC cultured in differentiation media supplemented with Dorsomorphin had a Alcian 
Blue colour extraction value of 40.42±0.79 on day 0, which decreased slightly by day 2 
(40.42±0.91). A slight in value was observed by day 5 (40.30±0.47), with an increase at 
day 10 (40.44±0.78), with continued increase on day 20 (40.60±0.84) and a subsequent 
decrease on Day 40 (40.58±1.11) (Figure 3.30 
Statistical testing between Control differentiation media against control differentiation 
media plus Dorsomorphin showed significant difference between Control-d and Control 
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+d: Day 2 (p<0.0001), day 5 (p<0.0001), day 5 (p<0.0001), day 20 (p<0.0005) and day 40 
(p<0.0005) time points (Figure 3.30). 
 
Figure 0.30 Alcian Blue analysis of hESC supplemented with control differentiation media in the 
presence and absence of Dorsomorphin 
hESC cultured using differentiation media and differentiation media supplemented with Dorsomorphin 
over 40 days (*p<0.0001 and **p<0.0005). 
Further supplementation of differentiation media with BMP-12 & 13 produced Alcian 
Blue colour extraction value of 41.70±1.20 at day 0. Which on day 2 had a value of 
(47.45±01.28) and on day 5 (50.53±0.67).a further increase was observed on day 10 
(52.01±0.37) and day 20 reporting a further increase (52.97±0.27) and day 40 showing a 
slight decrease (56.36±2.04). 
Further supplementation of differentiation media with BMP-12 & 13 and Dorsomorphin 
produced Alcian Blue colour extraction value of 40.00±0.64 at day 0. Which an increase 
on day 2 (42.93±0.44) and increase on day 5 (45.08±0.58).a further increase was observed 
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on day 10 (46.52±0.67) and day 20 increased values to day 10 (47.89±1.45) and day 40 
showing a slight increase 50.44±0.64). 
Further testing of BMP-12 & 13 –d and BMP-12 & 13 +d showed significant difference at 
day 2 (p<0.00001), day 5 (p<0.00001), day 10 (p<0.00001), day 20 (p<0.00005) and day 40 
(p<0.00005 
 
Figure 0.31 Alcian Blue analysis of hESC supplemented with control ifferentiation media 
Supplemented with BMP-12 & 13 in the presence and absence of Dorsomorphin. 
hESC cultured using differentiation media and differentiation media supplemented with BMP-12 & 13 
and Dorsomorphin over 40 days (*p<0.00001 and **p<0.00005). 
When hESC differentiation media was supplemented with FGF-4 & 8, an initial day 0 value 
for Alcian Blue colour extraction of 39.67±0.75 was observed. By day 2 this value had 
increased to 46.32±0.43 with further increases observed on day 5 (47.59±0.50), day 10 
(49.40±0.76), day 20 (50.36±0.50) and day 40 (52.48±0.72). 
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When hESC differentiation media was supplemented with FGF-4 & 8 and Dorsomorphin, 
an initial day 0, value for Alcian Blue colour extraction of 39.98±0.36 was observed. By 
day 2 this value had increased to 44.37±0.60 with further increases observed on day 5 
(46.01±0.23), day 10 (47.14±1.36), day 20 (49.15±0.30) and day 40 (51.30±0.62). 
On statistically testing FGF-4 & 8-d and FGF-4 & 8+d showed significant difference with a 
decrease in Alcian Blue staining in Dorsomorphin supplemented media at day 2 
(p<0.00005), day 5 (p<0.01), day 10 (p<0.00005), day 20 (p<0.00005) and day 40 
(p<0.005). 
 
Figure 0.32 Alcian Blue analysis of hESC supplemented with control differentiation media 
Supplemented with FGF-4 & 8 in the presence and absence of Dorsomorphin. 
hESC cultured using differentiation media and differentiation media supplemented with FGF-4 & 8 and 
Dorsomorphin over 40 days (*p<0.00005, **p<0.01 and ***p<0.05). 
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hESC cultured in differentiation media supplemented with FGF-4, 6 & 8 had an initial day 
0 Alcian Blue value of 39.98±0.63. Which increased further on: day 2 (47.13±0.72), with 
further increases on Day 5 (48.77±1.04), day 10 (51.27±0.64), day 20 (54.59±0.69) and 
day 40 (58.79±1.78). 
hESC cultured in differentiation media supplemented with FGF-4, 6 & 8 and 
Dorsomorphin had an initial day 0 Alcian Blue value of 40.01±0.72. Which increased 
further on: day 2 (44.70±0.58), with further increases on Day 5 (47.31±1.03), day 10 
(49.63±0.27), day 20 (51.04±0.62) and day 40 (54.90±61.82). 
On statistically testing FGF-4, 6 & 8 –d and FGF-4, 6 & 8+d significant difference with a 
decrease in Alcian Blue staining in Dorsomorphin supplemented media was observed at 
day 2 (p<0.0005), day 5 (p<0.01), day 10 (p<0.0005), day 20 (p<0.00001) and day 40 
(p<0.00005) 
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Figure 0.33 Alcian Blue analysis of hESC supplemented with control differentiation media 
Supplemented with FGF-4 & 8 in the presence and absence of Dorsomorphin. 
hESC cultured using differentiation media and differentiation media supplemented with FGF-4 & 8 and 
Dorsomorphin over 40 days (*p<0.01, **p<0.0005,***p<0.0001 & +p<0.0005). 
Further statistical testing was undertaken by comparing BMP-12 & 13-d against both FGF-
4 & 8-d (Figure 3.34) and FGF-4, 6 & 8-d (Figure 3.35), and also testing FGF-4 & 8-d against 
FGF-4, 6 & 8-d (Figure 3.36). On testing between groups produced significant difference 
(p<0.05) 
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Figure 0.34 Alcian Blue analysis of hESC supplemented with FGF-4& 8 and BMP12 & 13 
differentiation media in the and absence of Dorsomorphin 
hESC cultured using differentiation media supplemented with BMP-12 & 13 (Vitamin C) and 
differentiation media supplemented with FGF-4 & 8 (Vitamin C) cultured for 40 days (*p<0.05). 
 
Figure 0.35 Alcian Blue analysis of hESC supplemented with FGF-4, 6 & 8 and BMP12 & 13 
differentiation media in the and absence of Dorsomorphin 
hESC cultured using differentiation media supplemented with BMP-12 & 13 (Vitamin C) and 
differentiation media supplemented with FGF-4, 6 & 8 (Vitamin C) cultured for 40 days (*p<0.05). 
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Figure 0.36 Alcian Blue analysis of hESC supplemented with FGF-4 & 8 and FGF-4, 6 & 8 
differentiation media in the and absence of Dorsomorphin 
hESC cultured using differentiation media supplemented with FGF-4 & 8 (Vitamin C) and differentiation 
media supplemented with FGF-4, 6 & 8 (Vitamin C) cultured for 40 days (*p<0.05). 
Further statistical testing was undertaken by comparing BMP-12 & 13+d against, both 
FGF-4 & 8+d (Figure 3.37) and FGF-4, 6 & 8+d (Figure 3.38), and also testing FGF-4 & 8+d 
against FGF-4, 6 & 8+d (Figure 3.39). On statistically testing BMP-12 & 13 –d against FGF-4 
& 8-d, significant difference was observed on Day 2 (p<0.0005), Day 5 (p<0.005), day 20 
(p<0.05) and day 40 (p<0.01). On testing BMP-12 & 13-d with FGF-4, 6 & 8-d significant 
difference was observed at day 2, Day 5, Day10, Day 20 and day 40 (p<0.001). FGF-4 & 8-d 
testing against FGF-4, 6 & 8-d produced significant difference on day 5, day 10, day 20 
and day 40 (p<0.05). 
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Figure 0.37 Alcian Blue analysis of hESC supplemented with BMP-12 & 13 and FGF-4 & 8 
differentiation media in the presence of Dorsomorphin 
hESC cultured using differentiation media supplemented with BMP-12 & 13 (Vitamin C) and 
differentiation media supplemented with FGF-4 & 8 (Vitamin C) cultured for 40 days (*p<0.05). 
 
Figure 0.38 Alcian Blue analysis of hESC supplemented with BMP-12 & 13 and FGF-4, 6 & 8 
differentiation media in the presence of Dorsomorphin 
hESC cultured using differentiation media supplemented with BMP-12 & 13 (Vitamin C) and 
differentiation media supplemented with FGF-4, 6 & 8 (Vitamin C) cultured for 40 days (*p<0.05). 
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Figure 0.39 Alcian Blue analysis of hESC supplemented with FGF-4 & 8 and FGF-4, 6 & 8 
differentiation media in the presence of Dorsomorphin 
hESC cultured using differentiation media supplemented with FGF-4 & 8 (Vitamin C) and differentiation 
media supplemented with FGF-4, 6 & 8 (Vitamin C) cultured for 40 days (*p<0.05). 
Statistical testing was undertaken by comparing growth factor supplemented groups 
against the control groups (Figure 3.40). Statistical difference was observed with all 
growth factor supplemented groups from day 2 (p<0.00005), day 5 (p<0.00005), day 10 
(p<0.00005), day 20 (p<0.00005) and day 40 (p<0.00005) with FGF-4, 6 & 8 combination 
having the greatest significant difference on day 40 (p<0.00001). 
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Figure 0.40 Alcian Blue colour extraction Comparison between all hESC cultured with growth 
factors and Vitamin C without Dorsomorphin 
Comparisons were made against the control group (*p<0.00005 & **p<0.00001). 
Statistical testing was undertaken by comparing growth factor supplemented groups 
against the control groups. Statistical difference was observed with all growth factor 
supplemented groups from day 2 (p<0.00005), day 5 (p<0.00005), day 10 (p<0.00005), 
day 20 (p<0.00005) and day 40 (p<0.00005), with FGF-4, 6 & 8 combination having the 
greatest significant difference on day 40 (p<0.00001). 
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Figure 0.41 Alcian Blue colour extraction Comparison between all hESC cultured with growth 
factors and Vitamin C with Dorsomorphin 
Comparisons were made against the control group (*p<0.00005 & **p<0.00001). 
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3.7 hMSC Characterisation 
 Immunocytochemistry Profiling of hMSC Markers (BMA-12) 3.7.1
hMSC were isolated from bone marrow aspirate following the previously described 
methodology [332, 333] (Section 3.2.5). Prior to experimentation, the phenotypic surface 
markers of hMSC were confirmed by immunocytochemistry (Section- 3.4.1). The hMSC 
surface markers were detected on passage-1 cells. Isolated hMSC were positive for 
surface antigens CD44, CD90, CD146, STRO-1 and negative for haematopoietic markers 
CD14 and CD19 (Figure 3.42). 
 
Figure 0.42 Immunophenotyping of hMSC 
hMSC showed positive expression of the surface antigens CD44, STRO-1, CD90 and CD146 and negative 
for the haemopoietic markers CD14 and CD19. DAPI was utilised as a nuclear counter stain. Scale bar 
100μm. 
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3.8 Tenomodulin Expression 
After identifying the BMA-12 (hMSCs) expressed hMSC markers the next phase of the 
investigation was to investigate the effects of FGF-4, FGF-6 and FGF-8 supplementation of 
differentiation media (DMEM supplemented with 10% FBS, 1% L-GLUT and 1% NEAA) in 
the presence and absence of Vitamin C (10μM) at two different oxygen environments (2% 
and 21%). SHEF-1 cells were seeded as shown in Section 3.2.6.  
This phase of the investigation utilised the time points 0, 2, 5, 10 and 20 days for RT-PCR 
to detect the presence of Tenomodulin (a known tendon marker). 
Preliminary hMSC RT-PCR showed. FGF-4 when cultured in the presence of Vitamin C and 
cultured at 2% O2 was capable of maintaining TNMD expression from day 2 to day 20 
(Figure 3.43). However, the expression post day 5, did appear to reduce. FGF-4, 6 & 8 
when cultured at 2% O2 and supplemented with Vitamin C were capable of sustaining 
TNMD gene expression in hMSCs (Figure 3.43) with no apparent reduction in expression. 
Conversely, FGF-4, FGF-6, FGF-8 FGF-4 & 6, FGF-4 & 8 and FGF-4, 6 & 8 when cultured for 
20 days at 21% O2 were incapable of sustaining TNMD gene expression in hESC when 
cultured in the presence or absence of Vitamin C (Figure 3.43 – Figure 3.44). 
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Figure 0.43 Tenomodulin expression of FGF driven differentiation of hMSC cultured at 2% O2 
supplemented with or without Vitamin C 
RT-PCR analysis for Tenomodulin (TNMD) showed that combinations of FGF-4 and the combination of 
FGF-4, 6 & 8 induced and maintained the expression of TNMD for 20 days when supplemented with 
Vitamin C at 10µM per mL. FGF supplemented media which was not supplemented with Vitamin C was 
unable to initiate and subsequently maintain the expression of TNMD. 
 
Figure 0.44 Tenomodulin expression of FGF driven differentiation of hMSC cultured at 21% O2 
supplemented with or without Vitamin C 
FGF supplemented media with/without Vitamin C was unable to initiate transcription of TNMD when 
hESC’s are cultured at 21% O2. 
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Having now identified the FGF growth factor combination capable of initiating and 
maintaining TNMD expression the next phase was to be initiated. The next investigation 
was to identify the concentration of Dorsomorphin that allowed cell survival. Then 
supplement the FGF/Vitamin C differentiation media with Dorsomorphin. 
 Dorsomorphin Optimisation 3.8.1.1
BMA-12 cells were seeded to a 6 well plate as shown in Section 3.2.7 and cultured using 
CM+ (Conditioned embryonic stem cell media) supplemented with a range of 
Dorsomorphin concentrations (ranging from 1μM to 500μM) and cultured at 2% O2 for 5 
days and media change every 24 hours. 
After 5 days had elapsed cells were fixed and stained with Giemsa’s stain for analysis 
(Section 3.5.1). 
The concentration to be used for investigation of Dorsomorphin inhibition of BMA-12 FGF 
driven differentiation was 1μM per ml (Figure 3.45). The concentration of 1μM per ml as 
this concentration impaired cellular proliferation whilst all higher concentrations were 
shown to have a toxic effect 
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Figure 0.45 hMSC cultured in Dorsomorphin supplemented media at a range of concentrations. 
Shows a range of concentrations of Dorsomorphin with concentrations in excess of 1um having a high 
level of cellular toxicity. Where a concentration of 1um showed reduced cellular proliferation, therefore, 
the concentration of 1uM was utilised in further investigations into the effects of FGF and BMP signal 
transduction using MSC human embryonic stem cells. 
 RT-PCR of Tendon markers for FGF driven differentiation of 3.8.1.2
hMSC cultured with Vitamin C and Dorsomorphin at 2% O2 
hMSC (BMA-12) cultured in differentiation media supplemented with: FGF-4 and Vitamin 
C showed the presence of: THBS-4, TENC, COL1A2, COL3A1 and DCN throughout the 40 
day investigation. Conversely, TNMD was detected up until day 20 and extremely weak 
detection at day 40. hMSC (BMA-12) cultured in differentiation media supplemented 
with: FGF-4, Vitamin C and Dorsomorphin showed the presence of: THBS-4, TENC, 
COL1A2, COL3A1 and DCN throughout the 40 day investigation. Conversely, TNMD was 
detected up until day 10, day 20 and 40 showed no transcription of TNMD (Figure 3.46). 
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Figure 0.46 Tendon gene expression for hMSC FGF-4 driven differentiation when supplemented 
with and without Dorsomorphin at 2% O2 
Tendon gene expression panel for FGF-4 supplemented differentiation media with Vitamin with and 
without Dorsomorphin cultured at 2% O2 
hMSC (BMA-12) cultured in differentiation media supplemented with: FGF-4, 6 & 8 and 
Vitamin C showed the presence of: THBS-4, TENC,TNMD, COL1A2 and COL3A1 throughout 
the 40 day investigation. DCN was expressed from day 2 through to day 40 (Figure 3.47). 
hMSC (BMA-12) cultured in differentiation media supplemented with: FGF-4, 6 & 8, 
Vitamin C  and Dorsomorphin showed the presence of: THBS-4, TENC,DCN, COL1A2 and 
COL3A1 throughout the 40 day investigation. TNMD was expressed from day 2 through to 
day 20, with day 10 and day 20 showing reduced expression and lack of expression on day 
40 (Figure 3.47).  
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Figure 0.47 Tendon gene expression for hMSC FGF-4, 6 & 8 driven differentiation when 
supplemented with and without Dorsomorphin at 2% O2 
Tendon gene expression panel for FGF-4, 6 & 8 supplemented differentiation media with Vitamin with 
and without Dorsomorphin cultured at 2% O2 
Having now established the gene expression for both Dorsomorphin supplemented 
growth factor differentiation media. We then used immunocytochemistry to identify the 
expression of TNMD protein this phase of the investigation utilised TNMD 
Immunocytochemistry. 
 Immunocytochemistry 3.8.2
Immunocytochemistry was undertaken to detect the presence of tenomodulin protein 
expression after growth factor driven differentiation of hMSC. Also, to evaluate the effect 
of further supplementation of differentiation media with Dorsomorphin and its 
subsequent affect upon TNMD expression. 
Prior to undertaking the immunocytochemistry staining for TNMD we looked at utilising 
rat tenocytes as a positive control. 
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 Tenomodulin staining of hMSC  3.8.2.1
FGF driven differentiation of hMSC cells were cultured for 40 days in FGF, Vitamin C 
supplemented differentiation media (Section 3.2.6) in the presence and absence of 
Dorsomorphin. Cells were fixed for staining (Section 3.4.3) at time-points 0, 2, 5, 10, 20 
and 40 days exposure to the respective media (n=3). 
hMSCs cultured in differentiation media in the absence of Dorsomorphin (Figure 3.48) 
and in the presence of Dorsomorphin (Figure 3.49) showed no apparent TNMD protein 
expression. 
hMSCs supplemented with the combination of FGF-4 with Vitamin C  and FGF-4, 6 & 8 and 
Vitamin C, showed the presence of TNMD stain which was shown to be cytoplasmic in  
presence of TNMD throughout the investigation (Figure 3.50 & Figure 3.51). FGF-4 and 
FGF-4, 6 & 8 further supplemented with Dorsomorphin and Vitamin C showed continued 
TNMD staining (Figure 3.52 & Figure 3.53) Furthermore, there appeared to be TNMD 
staining on the cellular membrane and the cells appeared to have fibroblast like 
morphology at day 20 which was similar to that observed in the rat tenocytes (Figure 
4.10).
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Figure 0.48 hMSC Cultured in differentiation media. 
hMSC (BMA-12) when cultured in differentiation media supplemented with Vitamin C lacked the presence of TNMD staining as observed in Figure 3.47. 
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Figure 0.49 MSC Cultured with differentiation media supplemented with Dorsomorphin 
hMSC (BMA-12) when cultured in differentiation media supplemented with Vitamin C and Dorsomorphin lacked the presence of TNMD staining as observed in Figure 
3.47. 
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Figure 0.50 hMSC FGF-4 with Vitamin C cultured at 2% O2 
hMSC (BMA-12) when cultured in differentiation media supplemented with FGF-4 and Vitamin C showed the presence of TNMD protein staining. 
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Figure 0.51 MSC FGF-4 with Vitamin C cultured at 2% O2 supplemented with Dorsomorphin. 
hMSC (BMA-12) when cultured in differentiation media supplemented with FGF-4, Vitamin C and Dorsomorphin showed the presence of TNMD protein staining. 
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Figure 0.52 hMSC FGF-4, 6 & 8 with Vitamin C cultured at 2% O2 
hMSC (BMA-12) when cultured in differentiation media supplemented with FGF-4, 6 & 8 and Vitamin C showed the presence of TNMD protein staining. 
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Figure 0.53 MSC FGF-4, 6 & 8 with Vitamin C cultured at 2% O2 and supplemented with Dorsomorphin. 
hMSC (BMA-12) when cultured in differentiation media supplemented with FGF-4, 6 & 8, Vitamin C and Dorsomorphin showed the presence of TNMD protein staining. 
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 Histological Analysis 3.8.3
Histological staining of growth factor (and Vitamin C supplemented differentiation media) 
driven differentiation of hMSC towards a tenocyte lineage was undertaken in parallel to 
immunocytochemistry and rt-PCR. Growth factor driven differentiation of hMSC was 
undertaken utilising the procedure shown in Section 3.5. 
Glycosaminoglycans were stained utilising Alcian Blue stain procedure shown in Section 
3.5.2 and analysed utilising Image J analysis shown in Section 3.5.4 – 3.5.6. 
Collagen was stained using Masson’s Trichrome staining procedure shown in Section 3.5.3 
and image J analysis was undertaken utilising the procedure outlined in Section 3.5.4 – 
3.5.6 
A selection of growth factor driven hESC stained with Masson’s Trichrome is shown in 
Figure 3.54. Each time point had a n=3 and each well imaged 3 times to produce the data 
shown in Table 3.10. 
From the Data shown in Table 3.10 comparisons were made between growth factor in the 
absence of Dorsomorphin and the presence of Dorsomorphin in the differentiation 
media.
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 Masson’s Trichrome 3.8.3.1
 
Figure 0.54 Masson’s Trichrome staining for each group of MSC over 40 Days. 
All groups showed Masson’s Trichrome staining. All time points (n=9) were analysed and data extracted from the images. From the data extracted each time point for 
each condition was compared and statistically tested and the data is shown in Table 3.10. 
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Time 
(Days) 
MSC  
Control -d 
MSC  
Control +d 
MSC  
FGF-4 –d 
MSC  
FGF-4 +d 
MSC FGF-4, 
 6 & 8 -d 
MSC FGF-4, 
6 & 8 +d 
0 56.82 
±1.86 
57.08 
±2.05 
56.82 
±1.96 
56.88 
±2.13 
56.13 
±1.78 
57.16 
±2.05 
2 59.44 
±1.53 
57.41 
±2.66 
59.40 
±2.89 
58.89 
±2.88 
58.51 
±2.64 
58.77 
±4.26 
5 59.47 
±3.15 
58.19 
±1.71 
60.17 
±4.80 
59.55 
±1.89 
60.03 
±3.93 
59.75 
±3.73 
10 59.87 
±4.86 
58.69 
±2.08 
60.25 
±1.14 
60.67 
±2.79 
61.11 
±2.38 
61.42 
±3.56 
20 61.59 
±2.77 
58.96 
±1.94 
61.05 
±1.67 
61.28 
±2.52 
62.97 
±3.14 
61.71 
±1.89 
40 61.78 
±4.00 
60.38 
±3.51 
62.77 
±3.14 
61.84 
±2.26 
65.25 
±3.21 
63.03 
±3.04 
Table 0.10 Masson’s Trichrome data extraction from Image J for human Mesenchymal Stem cells  
The data shown is obtained from Image J and is a total colour extraction of images taken from growth 
factor driven differentiation. 
From the data shown in table 3.10 the following observations were made: 
hMSCs cultured in the absence of Dorsomorphin in differentiation culture media had a 
colour extraction value for Masson’s Trichrome of 56.82 ± 1.86 at day 0 which increased 
to 61.78 ± 4.00 by day 40. Further supplementation of differentiation culture media with 
Dorsomorphin had an initial value of 57.08 ± 2.05 which increased to a value of 60.38 ± 
3.51 by day 40. Supplementation of differentiation media with FGF-4 had an initial value 
of 56.82 ± 1.96 at day 0, which increased to 62.77 ± 3.14. Further supplementation of 
FGF-4 differentiation media with Dorsomorphin had an initial value of 56.88 ± 2.13 which 
increased continuously over the investigation to a value of 61.84 ± 2.26 by da 40. 
Supplementation of differentiation media with FGF4, 6 & 8 had an initial day 0 value of 
56.13 ± 1.78 which produced the greatest increase over the 40 day investigation 
producing a value of 65.25 ± 3.21 at day 40. Further supplementation of FGF-4, 6 & 8 
differentiation media had an initial day 0 reading of 57.16 ± 2.05 which increased over the 
40 day investigation to a value of 63.03 ± 3.04. 
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Statistical analysis was undertaken between groups (Figure 3.55 and Figure 43.56) and 
individual groups against the controls with no significant difference being observed. 
 
Figure 0.55 Masson’s Trichrome growth factor driven differentiation of hMSC in the absence of 
Dorsomorphin. 
Masson’s Trichrome data extraction for all growth factor driven differentiation of hMSC with no 
significant difference observed. 
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Figure 0.56 Masson’s Trichrome growth factor driven differentiation of hMSC in the presence of 
Dorsomorphin. 
Masson’s Trichrome data extraction for all growth factor and Dorsomorphin driven differentiation of 
hMSC with no significant difference observed. 
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 Alcian Blue Analysis 3.8.3.2
 
Figure 0.57 Alcian Blue staining for each group of MSC over 40 Days. 
All groups showed Alcian Blue staining. All time points (n=9) were analysed and data extracted from the images. From the data extracted each time point for each 
condition was compared and statistically tested and the data is shown in Table 3.11. 
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Time 
(Days) 
MSC Control 
-d 
MSC Control 
+d 
MSC FGF-4 -
d 
MSC FGF-4 
+d 
MSC FGF-4, 
6 & 8 –d 
MSC FGF-4,6 
& 8 +d 
0 40.84 
±0.56 
41.12 
±0.22 
40.12 
±0.34 
41.10 
±0.38 
40.93 
±0.38 
40.74 
±0.28 
2 43.99 
±0.44 
42.30 
±0.37 
41.20 
±0.43 
42.11 
±0.31 
43.10 
±0.23 
41.11 
±0.13 
5 44.96 
±0.34 
44.18 
±0.39 
42.34 
±0.61 
43.33 
±0.42 
43.77 
±0.17 
41.43 
±0.07 
10 46.05 
±0.52 
45.23 
±0.22 
43.37 
±1.02 
44.35 
±0.26 
44.30 
±0.13 
43.67 
±0.06 
20 48.27 
±0.78 
45.59 
±0.08 
47.53 
±1.23 
44.87 
±0.29 
50.71 
±0.14 
49.80 
±0.69 
40 51.74 
±2.08 
45.82 
±0.10 
54.66 
±0.97 
50.49 
±1.44 
55.31 
±0.26 
50.89 
±0.61 
Table 0.11 Alcian Blue data extraction from Image J for human Mesenchymal Stem cells (hMSC) 
The data shown is obtained from Image J and is Alcian blue colour extraction of images taken from 
growth factor driven differentiation. 
From the data shown in table 3.11 the following observations were made: 
hMSC cultured in differentiation in the absence of Dorsomorphin (Control-d) media had a 
Alcian blue colour extraction value of 40.84±0.56 on day 0, which decreased by day 2 
(43.99±0.44). A slight increase in value was observed by day 5 (44.96±0.34), with further 
increase at day 10 (46.05±0.52), day 20 (48.27±0.78) and a subsequent decrease on Day 
40 (51.74±2.08).  
hMSC cultured in differentiation media supplemented with Dorsomorphin (Control +d) 
had a Alcian blue colour extraction value of 41.12±0.22 on day 0, which decreased by day 
2 (42.30±0.37). A slight increase in value was observed by day 5 (44.18±0.39), with further 
increase at day 10 (45.23±0.22), day 20 (45.59±0.08) and on Day 40 (45.82±0.10).  
Statistical testing between Control differentiation media against control differentiation 
media plus Dorsomorphin showed significant difference between Control-d and Control 
+d: Day 2 (p<0.0005), day 5 (p<0.005), day 5 (p<0.005), day 20 (p<0.005) and day 40 
(p<0.0005) time points. 
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Figure 0.58 Alcian Blue analysis of hMSC supplemented with control differentiation media in the 
presence and absence of Dorsomorphin 
hMSC cultured using differentiation media and differentiation media supplemented with Dorsomorphin 
over 40 days (*p<0.0001 ). 
When hMSC differentiation media was supplemented with FGF-4-d, an initial day 0 value 
for Alcian Blue colour extraction of 40.12±0.34 was observed. By day 2 this value had 
increased to 41.20±0.43 with further increases observed on day 5 (42.34±0.61), day 10 
(43.37±1.02), day 20 (47.53±1.23) and day 40 (54.66±0.97). 
When hMSC differentiation media was supplemented with FGF-4 and Dorsomorphin 
(FGF-4+d), an initial day 0 value for Alcian Blue colour extraction of 41.10±0.38 was 
observed. By day 2 this value had increased to 42.11±0.31 with further increases 
observed on day 5 (43.33±0.42), day 10 (44.35±0.26), day 20 (44.87±0.29) and day 40 
(50.49±1.44). 
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Further testing of FGF-4 –d and FGF-4 +d showed significant difference at day 2 
(p<0.0005), day 5 (p<0.05), day 10 (p<0.0005), day 20 (p<0.0005) and day 40 (p<0.0005) 
(Figure 3.59).  
 
Figure 0.59 Alcian Blue analysis of hMSC supplemented with FGF-4 and Control Differentiation 
media in the presence and absence of Dorsomorphin 
hMSC cultured using differentiation media with FGF-4 and differentiation media supplemented with FGF-
4 & Dorsomorphin over 40 days (*p<0.0005 and **p<0.05 ). 
hMSC cultured in differentiation media supplemented with FGF-4, 6 & 8-d had an initial 
day 0 Alcian Blue value of 40.93±0.38. Which increased further on: day 2 (43.10±0.23), 
with further increases on Day 5 (43.77±0.17), day 10 (44.30±0.13), day 20 (50.71±0.14) 
and day 40 (55.31±10.26). 
hMSC cultured in differentiation media supplemented with FGF-4, 6 & 8 and 
Dorsomorphin (FGF-4, 6 & 8+d) had an initial day 0 Alcian Blue value of 40.74±0.28. 
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Which increased further on: day 2 (41.11±0.13), with further increases on Day 5 
(41.43±0.07), day 10 (43.67±0.06), day 20 (49.80±0.69) and day 40 (50.89±0.61). 
FGF-4, 6 & 8-d and FGF-4, 6 & 8+d showed significant difference at day 2 (p<0.01), day 5 
(p<0.01), day 10 (p<0.01), day 20 (p<0.01) and day 40 (p<0.01). 
 
Figure 0.60 Alcian Blue analysis of hMSC supplemented with FGF-4, 6 & 8 and control 
differentiation media in the presence and absence of Dorsomorphin 
hMSC cultured using differentiation media and FGF-4,6 & 8 differentiation media supplemented with 
FGF-4, 6 & 8 and Dorsomorphin over 40 days (*p<0.001). 
Further statistical testing was undertaken comparing FGF-4-d against FGF-4, 6 & 8-d, 
significant difference was observed on day 2, day 5, day 10 and day 20 (p<0.05). On 
testing FGF-4+d against FGF-4, 6 & 8+d significant difference was observed on Day 2, day 
5, day 10 and day 20 (p<0.05) (Figure 3.61 and Figure 3.62). 
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Figure 0.61 Alcian Blue analysis of hMSC supplemented with FGF-4 differentiation media 
compared with FGF-4, 6 & 8 differentiation media in the absence of Dorsomorphin 
hMSC cultured using differentiation media and FGF-4 differentiation media against differentiation media 
supplemented with FGF-4, 6 & 8 over 40 days (*p<0.05). 
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Figure 0.62 Alcian Blue analysis of hMSC supplemented with FGF-4 and differentiation media 
compared with FGF-4, 6 & 8 differentiation media in the presence of Dorsomorphin 
hMSC cultured using differentiation media and FGF-4 differentiation media against differentiation media 
supplemented with FGF-4, 6 & 8  in the presence of Dorsomorphin over 40 days (*p<0.05). 
Statistical testing was undertaken by comparing growth factor supplemented groups 
against the control-d. When testing control-d against FGF-4-d statistical difference was 
observed on Day 2, day 5 and day 10 (p<0.0005) as the control group values were higher. 
By day 40 the FGF-4-d group value was significantly higher than the control group 
(p<0.005). On statistically testing the control group against FGF-4, 6 & 8-d the control 
group reported higher values with a significant difference being observed for day 2, day 5 
and day 10 (p<0.001). By day 20 and day 40 FGF-4, 6 & 8-d was reporting higher than 
control values which were significantly different (p<0.005) (Figure 3.63) 
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Figure 0.63 Alcian blue comparison of all groups supplemented in the absence of Dorsomorphin. 
 
Statistical testing was undertaken by comparing growth factor supplemented groups 
against the control groups. When testing control +d against FGF-4+d statistical difference 
was observed on Day 2, day 5 and day 10 and day 30 (p<0.0005) as the control group 
values were higher. By day 40 the FGF-4+d group value was significantly higher than the 
control group (p<0.0001). On statistically testing the control group against FGF-4, 6 & 8+d 
the control +d group reported higher values with a significant difference being observed 
for day 2, day 5 and day 10 (p<0.0005). By day 20 and day 40 FGF-4, 6 & 8-d was reporting 
higher than control values which were significantly different (p<0.0005) (Figure 3.64) 
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Figure 0.64 Alcian blue comparison of all groups supplemented in the absence of Dorsomorphin. 
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3.9 Discussion 
Tissue engineering and stem cell technologies aims to provide treatment regime for 
disease and damaged tissue were current therapeutical options are limited or 
inadequate. Tissue engineering specifically aims to deliver a regime whereby full function 
is restored to damaged and diseased tissue. The use of stem cells as a means to deliver a 
functional tendon is highly desired. This study investigated the use of a combination of 
growth factors, stem cells, Vitamin C along with normoxic and hypoxic cell culture to 
differentiate human embryonic stem cells and adult mesenchymal stem cells towards a 
tenocyte like cell lineage. This study employed the gene combination of TNMD and THBS-
4 expression as a marker of tendon differentiation first identified by Jelinsky et al [68]. 
Both hESC’s and hMSC’s were cultured supplemented with individual FGF’s and in the 
presence and absence of Vitamin C under both normoxic and hyperoxic conditions. RT-
PCR was undertaken on all samples over 20 days (time intervals 0, 2, 5, 10 and 20 Days). 
The results obtained showed FGF-4 and the combination of FGF-4, FGF-6 & FGF-8 were 
capable of maintaining TNMD expression in hMSC when cultured in the presence of 
Vitamin c under hypoxic conditions. The combinations of FGF-4 & FGF-8 and FGF-4, FGF-6 
& FGF-8 were both capable of maintaining TNMD expression over 20 days when cultured 
in the presence of Vitamin C under normoxic conditions. 
Vitamin C is well documented to play an active role in collagen synthesis [337] which is 
required or muscular skeletal tissue development and also more specifically tendon [338]. 
Previous unpublished studies conducted by our laboratory have highlighted the 
requirement for Vitamin C in tendon differentiation when using BMP-12 & 13. This study 
has shown that the supplementation of media with Vitamin C and the specific growth 
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factors of FGF-4 or FGF-4, 6 & 8 in mesenchymal stem cells, FGF-4 + 8 or FGF-4, 6 + 8 in 
embryonic stem cells can induce and maintain the expression of the tendon linked genes 
TNMD and THBS-4. The use of Vitamin C in this study agrees with previous studies using 
Vitamin C as a component of differentiation media which enhances differentiation 
towards cardiomyocytes [339], chondrogenic lineage [340] and osteogenic lineage [341]. 
On comparing 21% O2 and 2% O2 culture of both hESC and hMSC cells supplemented with 
growth factors and Vitamin C. 2% O2 showed continued expression of TNMD and THBS-4 
tendon markers when hESC and hMSC cells were cultured with the growth factor 
combination of FGF-4, FGF-6 and FGF-8 with Vitamin C. ESC cultured at 2% O2 with 
differentiation media supplemented with BMP-12, BMP-13 & Vitamin C (previous 
unpublished data) and FGF-4 + 8 and Vitamin C was also capable of maintaining TNMD 
and THBS-4 expression. Furthermore, FGF-4 and Vitamin C was capable of maintaining 
TNMD and THBS-4 gene expression with MSC cultured at 2% O2. Reduced oxygen levels 
have been previously been shown to play a role in differentiation control especially in 
embryogenesis. During embryogenesis with oxygen diffusion in the embryo is limited by 
size with the natural progression of tissue-genesis involves hypoxia. The cellular response 
to hypoxia involves HIF proteins. HIF proteins especially HIF-1 and HIF-2, which are 
activated during development and many genes involved in differentiation being effected 
by hypoxia such as; POU5F1 (HIF-2α) and NANOG (HIF-1α) [342, 343]. Recently studies 
have found evidence of classical hypoxia response pathways in tendon injury where rota 
cuff injuries express high levels of HIF-1α [344]. This study has shown oxygen level plays a 
critical role in the differentiation of both embryonic and mesenchymal stem cells towards 
a tenocyte-like cell lineage. HIF-1α has previously been shown to up regulate the 
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transcription of COL1A2 [345]. Furthermore, HIF-1α has also been shown to up regulate 
TENC in human small cell lung carcinoma [346]. This study has shown that hypoxic stem 
cell culture is vital for the differentiation of stem cells towards tenocyte lineage and the 
possible role of HIF proteins in differentiation of both embryonic and mesenchymal stem 
cells towards a tenocyte-like lineage. 
The results of a previous unpublished study showed that BMP-12 & 13 could induce for 
hESCs in vitro tenogenic differentiation under normoxic conditions (2% O2). Distinct up-
regulation of tendon-linked genes (i.e. COL1A2, COL3A1, TENC, TNMD, THBS-4 and DCN) 
being observed in BMP-12 & 13 treated samples cultured under normoxic conditions (2% 
O2).  
Previous studies suggested that the transcriptional control of tendon-specific genes relied 
on BMP signalling pathway and Smad1, 5 & 8 activation [179, 183, 347-349]. As ligands, 
BMP-12 & 13 bind to Type II BMP serine/threonine kinase receptor followed by the 
activation of Type I receptor and subsequently activate the SMAD1, 5 & 8 which leads to 
tenocyte-like gene expression [350, 351]. This might be the explanation for the signal 
transduction pathway for the genes up-regulation observed in BMP-12 and 13 
supplemented differentiation media.  
FGF-4 has previously been shown to play an active and pivotal role in embryonic 
development. FGF-4 is expressed in pre-implantation murine blastocysts and is also 
present in the ICM [197, 198]. Previous studies focusing of the effect of FGF-4 on chick 
wing bud tendon development has shown overexpression FGF-4 was capable of up-
regulation of scleraxis a known tendon transcription factor. FGF-6 Studies conducted 
using the murine model has shown FGF-6 presence at E9.5 and to be exclusively present 
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in the myotomal compartment of the somite [201, 202]. FGF-6 has been shown to play a 
significant role in myogenesis employing knockdown murine model [201, 202]. Due to the 
highlighted importance of interactions between muscle and tendon during limb 
development FGF-6 was investigated as a possible signalling molecule in tendon 
development. Early investigation into the role of FGF-8 in limb development was 
conducted by Moon and Capecchi in 2000 were they undertook experimental work to 
assess the role of FGF-8 during mouse limb development [203]. Further, investigations 
utilising chick embryos highlighted the presence of FGF-8 transcripts in tendon of the 
developing limb in a chick [352]. Our findings agree in that both FGF-6 and FGF-8 are 
required for tenocyte differentiation, in that tendon is a constituent part of a limb. 
The individual FGF signal pathways are under researched along with FGF combinational 
studies in tendon differentiation. FGF’s are known to bind to one of the FGF receptors of 
which there are 4 (namely FGFR1-4) with subclass receptors. Post receptor ligation results 
in the activation of either PKC (Protein Kinase C) by means of activation of FGFR1/FGFR2 
signal cascade via FGF-4 ligation, ERK1/2 via activation of FGFR2 by FGF-4. JNK activation 
via FGFR1 by FGF-4 Ligation,FGFR2-FGF-4 ligation activation of p38 or Akt all of which can 
induce gene transcription by means of regulation of transcriptional promoters and 
enhancers [353]. However, the biochemical cues required for in vitro tenogenesis are 
poorly defined since the signalling pathways during the differentiation are complex and 
under-investigated. 
THBS-4 is an adhesive glycol protein that mediates cell-cell and cell-matrix interactions 
which has been identified that together with TNMD can be considered as tendon markers 
[68]. TNMD, as one of the type II transmembrane glycoproteins, was found to be 
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predominantly in dense connective tissue such as tendon and ligament [68], and thus was 
considered as a marker for tendon maturation when used in conjunction with COL1A2, 
COL3A1, TENC and DCN [354]. In our study, we observed distinct TNMD, THBS-4 
transcription over 2 days in the untreated SHEF-1 cells. This may due to the spontaneous 
differentiation progress of hESCs. Conversely, the SHEF-1 samples supplemented with 
BMP-12 & 13 or FGF-4 & 8 or FGF-4, 6 & 8 and hMSC supplemented with either: FGF-4 or 
FGF-4, 6 & 8, TNMD and THBS-4 transcription was observed to be transcribed throughout 
the 40-day differentiation. FGF-4 & 8 (hESC) and FGF-4 (hMSC) showed TNMD and THBS-4 
transcription up to day 20. Also, the clear synapsing of the cells observed at day 40 with 
the supplementation of BMP-12 & 13 with hESC indicated by the positive green TNMD 
staining which was not observed with FGF-4, 6 & 8 supplemented hESC or MSC although 
the expression of TNMD was observed. Taken together, these results suggested that 
BMP1-12 & 13 and FGF-4, 6 & 8 are capable of maintaining TNMD expression in hESC and 
FGF-4, 6 & 8 is also capable of maintaining expression of TNMD expression in hMSC. Both 
BMP-12 & 13 and FGF-4, 6 & 8 are capable of inducing tenocyte-like morphology when 
cultured at 2% O2, with FGF-4,6 & 8 is also capable of inducing a tenocyte-like gene 
expression in hMSC when cultured at 2% O2. 
This study agreed with previous studies as FGF-4 alone was capable to induce or maintain 
the tendon marker TNMD and THBS-4 up to 20 days in hMSC. This study showed FGF-6 
alone was incapable of inducing or maintain TNMD and THBS-4 expression in hESC and 
hMSC (post day 10). In this study FGF-8 alone was incapable of initiating and maintaining 
TNMD and THBS-4 expression past day 10 in hESC and was not detected in hMSC. FGF-4 
and FGF-6 have both been detected in AER and provide the signals to maintain 
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mesenchymal cells in the proliferative state in the PZ during limb development. As 
mentioned previously, FGF-4 has been shown to initiated scleraxis and FGF-6 having a 
role in myogenesis. However, the combination of FGF4 & FGF-6, were unable to maintain 
TNMD and THBS-4 expression past day 10 in hESC and again was not detectable in hMSC. 
On investigating the combination of FGF-4 and FGF-8, both THBS-4 and TNMD 
transcription was detected at day 40 in hESC supplemented media. 
The combination of FGF-4, 6 & 8 in this study provides the strongest expression of TNMD 
and THBS-4 in both hESC and hMSC over 40 day cultured at 2% O2. Understanding the 
close relationship between bone, cartilage, muscle and tendon development would 
underpin a stem cell based tissue engineered approach to tendon injuries. 
Further investigation employed the known SMAD inhibitor Dorsomorphin which was 
supplemented into growth factor supplemented media. FGF-4 & 8+d (hESC) and BMP-12 
& 13+d (hESC) showed inhibition of THBS-4 and therefore impaired tenogenesis. FGF-4+d 
(hMSC) showed inhibition of TNMD expression post 10 days. Conversely, FGF-4, 6 & 8 +d 
(hESC and hMSC) showed change to Tenogenic gene expression in that both TNMD and 
THBS-4 were both expressed. BMP signalling is known to utilise the SMAD signalling 
pathway and due to the inhibition of FGF-4 and FGF-4 + 8 by Dorsomorphin would infer 
that FGF-4 and FGF-4 +8 stimulate BMP production and subsequent signalling which 
would agree with previous studies linking FGF and BMP signalling and the requirement of 
both growth factors for cardiomyocyte differentiation [355, 356]. 
Histological comparisons made between growth factor supplementation and growth 
factor and Dorsomorphin supplementation of differentiation media highlighted subtle 
differences. hESC cultured in the presence of both BMP12 & 13 and Dorsomorphin 
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showed a distinct reduction in Collagen staining (Masson’s Trichrome) which highlights a 
inhibition of the SMAD signalling pathway results in a decrease in collagen synthesis. hESC 
cultured with BMP-12 & 13 and Dorsomorphin also a distinctive reduction in GAG staining 
(Alcian Blue) further highlighting that media supplemented with Dorsomorphin and 
inhibition of the SMAD signalling cascade also resulted in impaired GAG synthesis and 
secretion, which is confirmed by rt-PCR showing distinctive reduction in the gene 
transcripts for DCN, TENC, THBS-4, TNMD, COL3a1 and COL1a2. Similar down regulation 
was observed in the FGF-4 & 8 hESC cultured with the further supplementation of 
Dorsomorphin showed a distinct reduction in GAG staining and with THBS-4, DCN and 
TENC down regulation. Masson’s Trichrome staining for collagen also showed a distinctive 
reduction. However, both collagen 1a2 and Collagen 3a1 RNA were detected at all-time 
points using rt-pcr. hESC supplemented with both FGF-4, 6 & 8 and Dorsomorphin 
showed a distinct reduction at day 40 when compared with FGF-4, 6 & 8 only 
supplementation. Although, the alican blue measurements were reduced in the 
Dorsomorphin supplemented media from day 5 to day 40. Rt-pcr showed inhibition of the 
GAG decorin (DCN) with both THBS-4 and TNMD being detected throughout all time 
points. Masson’s Trichrome measurements showed a reduction in collagen staining at all 
time-points. However both COL1a2 and COL3a1 transcription were detected at all-time 
points. The effects of Dorsomorphin on BMP-12 & 13 supplementation agree with 
previous SMAD inhibition. However, the effects of Dorsomorphin on FGF induced hESC 
response indicates, the distinct possibility of FGF-BMP signalling cross talk. 
hMSC cultured with both FGF-4 or FGF-4, 6 & 8 and Dorsomorphin no significant 
difference in Masson’s Trichrome staining when compared to hMSC cultured with FGF-4 
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or FGF-4, 6 & 8 only. However, Alcian blue measurement revealed significant difference 
between FGF-4 and FGF-4 & Dorsomorphin and FGF-4, 6 & 8 and FGF-4, 6 & 8 with 
Dorsomorphin at day 40. Rt-PCR analysis showed Dorsomorphin to inhibit TNMD when 
supplemented into FGF-4 and FGF-4, 6 & 8 media at day 40. This further adds to the 
hypothesis that there is a distinct possibility of FGF-BMP cross talk. 
Morphological comparisons between FGF-4, 6 & 8 supplemented hESC and hMSC 
revealed the differentiated hESC cells to have a “cobble stone” like appearance. 
Conversely, the hMSC had a distinct fibroblastic morphology, similar to that of native 
tenocytes. The natural differentiation pathway for tenocytes would be embryonic stem 
cells to mesodermal to tenocyte stem cell to mature tenocyte. We hypothesis that the 
hESC have partially differentiated to a tenocyte derived “like” stem cell as the cobble 
stone like morphology [357] is not dissimilar to that observed in FGF-4, 6 and 8 
supplemented hESC differentiation. These distinct finding may be due to mesenchymal 
stem cells specialisation and differentiation having already occurred when compared to 
embryonic stem cells? 
This study has shown Vitamin C in conjunction with FGF-4, 6 & 8 cultured at 2% O2 was 
capable of inducing and maintaining tendon like gene markers such as tenomodulin 
(TNMD) and Thrombospondin-4 (THBS-4) over a 40 day culture period.  
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3.10 Conclusion 
In this study we have shown for the first time that FGF-4, 6 & 8 being capable of 
maintaining tendon specific genes TNMD and THBS-4 in both embryonic stem cells and 
mesenchymal stem cell when cultured at 2% O2. Furthermore, this study has for the first 
time shown FGF-4 as being capable of maintaining TNMD and THBS-4 gene expression in 
human mesenchymal stem cells and FGF 4 & 8 being capable of maintaining TNMD and 
THBS-4 gene expression in embryonic stem cell when cultured at 2% O2 for a limited time 
periods.
  
 
 
 
 
 
 
Chapter 4: PHBHHx Nanoparticle 
Production
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4.1 Introduction 
This study aims to control nanoparticle size to deliver a growth factor concentration 
previously identified in chapter 4. The multidisciplinary field of nanomedicine aims to 
produce materials in the nanometre range to restore or maintain tissues, deliver drugs 
and proteins as well as combination products for the purpose of improving human health. 
Nanotechnology has quickly evolved within medical engineering due to its ability to 
produce structures mimicking the dynamic biological micro environment, combining cells, 
scaffolds and drug releasing nanoparticles to efficiently produce functional tissue [358-
360] as well as effective destruction of diseased tissue [361-364] for medical applications.  
Nanoparticles have been shown to have an array of applications ranging from 
nanosensing, drug delivery, and gene transfection to growth factor delivery [365-370]. 
The ability to manipulate nanoparticle size to fit the needs of a desired application would 
provide increased utility to treat a range of diseases, including cardiovascular disease 
[371], osteoarthritis [372], diabetes [373], cancer [371, 374-377] and neurodegenerative 
disease [378] to mention but a few. Recently, nanoparticles have been shown to pass 
across the blood-brain barrier which is a major obstacle when delivering 
chemotherapeutical drugs for the treatment of nervous system tumours [379] as well as 
neurodegenerative diseases. For controlled drug release, linking nanoparticle size to a 
drug release rate would create a system whereby a specified drug release rate and 
duration could be achieved via a controlled manufacturing process. This would lead to 
improved treatment methods by removing drug metabolism and loss via administration 
route (i.e. the digestive tract) as the nanoparticle would serve to protect the 
encapsulated drug allowing for reduced drug loading. An immediate benefit of improved 
delivery would be in cost reduction of drug due to reduced concentration requirements 
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to meet efficacious dosage compared to oral administration. More importantly, limiting 
the administered dose would potentially reduce the risk of toxicity and non-specific side 
effects in the patient and could be combined with a targeted drug release systems [380-
384] for advanced drug delivery. 
The ability to control the size of nanoparticles during production would allow for the 
reliable and reproducible creation of smaller nanoparticles for applications such as 
nanoparticle-mediated gene transfection and direct low does growth factor delivery. This 
holds much promise in regenerative medicine as non-viral gene vectors present a 
significantly reduced safety hazard compared to viral based gene vectors [374]. The 
nanoparticle-mediated cellular response is critical for successful therapies with particles 
below 100nm actively mediating biological effects such as the binding and activation of 
membrane receptors and subsequent protein expression [385], a critical aspect within a 
variety of nanoparticle applications. The advantage of the use of smaller particles in 
clinical practise include easier intravenous injection, sterilisation by filtration [386, 387] 
and the avoidance of spleen filtration [388-390] which are critical for treating and 
managing the disease state. Isolating the key production variables affecting the size of 
nanoparticles would allow for more effective fabrication of smaller nanoparticles and 
promote efficient utilisation of their biological and practical benefits. 
Here, the controlled production of PHBHHx nanoparticles was investigated via the DOE 
method to determine the sensitivity of process variables and the repeatability of 
producing PHBHHx nanoparticles of a desired size. The DOE approach uses parallel 
multivariate designed experiments to investigate the action and interaction of variables in 
order to improve understanding, and therefore control of complex processes [391]. A key 
aspect of this is identifying controlled and uncontrolled variables, which affect the 
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response from the process, with preliminary studies aimed at highlighting which input 
variables affect the desired process output. Heperzine-A, Paclitaxel and ALB-PLC 
encapsulated nanoparticles showed conformity to this trend with high process 
repeatability. This study shows that controlled manufacture of PHBHHx nanoparticles via 
the solvent evaporation method is achievable and has been utilised to produce 
nanoparticles of below 100 nm. Demonstrating this level of controlled manufacture is 
essential for developing products in the tightly regulated medical industry where 
precision manufacture is essential for successful commercialisation and also increasing 
the control of desired drug delivery and drug concentration.  
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4.2 Materials and Methods 
 Nanoparticle Formulation 4.2.1
A range of PHBHHx w/v Chloroform solutions were prepared at a volume of 2mL (Organic 
Phase), 0.5% w/v of F68 (150mg)(Nanjing Well Chemical Co., Ltd. Nanjing, China) and 
0.5% w/v of Sodium deoxycholate (150mg) (Amresco, Solon, USA) were prepared in a 
volume of 28ml of 0.22µm filtered Water (Aqueous Phase). Once both the organic and 
aqueous phases were dissolved, the aqueous phase was filtered and added drop-wise to 
the organic phase. The aqueous/organic phase were then sonicated (Scientz JY92 – II) for 
various cycles whilst on ice (sonication cycle was 1 second sonication at a range of power 
settings and 1 second rest).The nanoparticle emulsion was then placed on a rotary 
evaporator(Buchi Rotavapor R-3) set at 30oC until all the organic phase was evaporated 
(emulsion becomes transparent). 
 Phospholipid Entrapment of Bovine Serum Albumin/FITC 4.2.2
Albumin 
Phospholipid, namely, soybean lecithin containing 70-97% phosphatidylcholine (PC), was 
purchased from Shanghai Tai-wei Pharmaceutical Co. Ltd. (Shanghai, China). Bovine 
serum albumin Fraction V was purchased from Xuzhou Wanbang Bio- Chemical Co. Ltd. 
(Jiangsu, China). Poloxamer188 (F68) was provided by Nanjing Well Chemical Co., Ltd. 
(Nanjing, China). Sodium deoxycholate (DOC-Na) was supplied by Amresco (Solon, USA). 
PHBHHx (MW 174,000) containing 14 mol% of R-3-hydroxyhexanoate (HHx) was kindly 
donated by Professor G. Chen (Tsinghua University, China). All other chemical reagents 
were of analytical grade or better. 
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 Preparation of PHBHHx Encapsulated Nanoparticles 4.2.3
PHBHHx nanoparticles were prepared with adjustments from a previous study [373] 0.5% 
(1mg) of ALB-PLC/FITC-Albumin or drug and 3% (7.5mg) PHBHHx w/v Chloroform solution 
were prepared at a volume of 2mL (Organic Phase), 0.5% w/v of F68 (150mg) (Nanjing 
Well Chemical Co., Ltd. Nanjing, China)  and 0.5% w/v of Sodium Deoxycholate (150mg) 
(Amresco, Solon, USA) were prepared at a volume of 28ml of 0.22µm filtered Water 
(Aqueous Phase). Once both the organic and aqueous phases were dissolved, the 
aqueous phase was filtered and added drop-wise to the organic phase. The 
aqueous/organic phase were then sonicated (Scientz JY92 – II) for various cycles whilst on 
ice (sonication cycle was 1 second sonication at a range of power settings and 1 second 
rest).The nanoparticle emulsion was then placed on a rotary evaporator(Buchi Rotavapor 
R-3) set at 30OC until all the organic phase was evaporated (emulsion becomes 
transparent). 
 Nanoparticle Characterization: Size, Zeta Potential and Poly-4.2.4
dispersity Index 
The mean particle size, size distribution and zeta potential of the resulting PHBHHX 
nanoparticles were characterized using dynamic light scattering (DLS) and electrophoretic 
light scattering (ELS) technology, respectively, with a Zetasizer Nano ZS90 instrument 
(Malvern Instruments Ltd., U.K.), using water as a dispersant at 25 C with each cycle of 
the measurement automatically determined by the instrument system. The particle size 
was displayed by intensity distribution, and the size distribution was evaluated by 
polydispersity index (PDI). 
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 Nanoparticle Stability Study 4.2.5
NP and ALB-PLC-NPs were produced as shown previously and zeta sized immediately 
(time point zero) further measurements were taken at time points 12hrs, 24hrs, 48hrs, 96 
hrs and 168 hrs from samples stored at 4 C and room temperature. 
 Multifactoral Experiment Design 4.2.6
Minitab® (16.2.2) was used to design and evaluate the multifactorial experiment and 
produce graphical outputs of the data. Three factors were assessed, namely, PHBHHx 
concentration, sonication power and number of sonication cycles at high and low 
conditions to bind the key experimental conditions (Table 4.1). This gave a total of eight 
experimental conditions (cube plot) with a centerpoint to complete the experimental 
design (Figure 4.1). An N=3 was taken for each run to account for variability in the 
measurement system and a total of three experimental runs were completed to account 
for batch-to-batch variability, an assessment of common-cause variation within the 
nanoparticle production process and an indication of the repeatability of the 
methodology. 
 
 
W. R. Webb PhD Thesis Chapter 4 
223 
 
 
Figure 0.1 Multifactoral Cube illustration of experimental design. 
 
Multifactorial 
Value 
PHBHHx Concentration 
(mg/ml) 
Sonication Power 
(W) 
Number of 
Sonication Cycles 
HIGH 2.000 500 40 
MIDDLE 1.125 300 25 
LOW 0.250 100 10 
Table 0.1 Multifactoral experimental parameters 
 
 Encapsulation Efficiency 4.2.7
Briefly, 5 ml of the drug/albumin NPs suspension was mixed with 5 ml NaOH (0.05M). The 
mixture was stirred for 24 h at room temperature so that the PHBHHx nanoparticles could 
be degraded by alkaline hydrolysis. The sample was then underwent centrifugation using 
(100,000 Da molecular weight cut off). The resultant flow-through sample was analysed 
by GCMS (Drug) or HPLC (Albumin) after a 1:20 dilution. As a result the total added 
amount of drug/albumin was obtained. Meanwhile, another 0.5 ml drug/albumin NPs 
suspension was taken, and mixed with 0.5 ml dH2O. The sample was also analysed by 
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GCMS after proper dilution. As such the amount of non-encapsulated drug/albumin was 
obtained. Therefore, the encapsulation efficiency could be calculated according to the 
following equation 
 
Equation 1 Encapsulation Efficiency Formulae 
Where Wt= Original concentration at start of encapsulation process, Wf= free drug or protein. 
 LC-MS/MS Detection of Paclitaxel and Haperzine A 4.2.7.1
The LC-MS/MS system consisted of an Agilent 1200 series RRLC, which includes an SL 
auto-sampler, degasser, SL binary pump and an Agilent triple-quadrupole MS (Agilent, 
USA). The system was controlled with B01.03 software for qualitative analysis and B01.04 
software for quantification. Separation was performed in a Diamonsil ODS column (50 × 
3.5 mm, 3.4 µm) with a corresponding guard column (ODS, 5 µm). The column was 
maintained at 30 °C and the injection volume was 1 µl.  The mass spectrometer was 
operated using an electrospray source configured to positive ion mode and the 
quantification analysis was performed using multiple reaction monitoring (MRM). (M+H) 
of each analyte was selected as the precursor ion. Instrumental parameters were as 
follow: gas temperature: 350oC; with a gas flow:  8 ml/min; nebulizer: 30 psi; capillary: 4 
000 v. 
Gas chromatography separation of Haperzine A was performed using a mobile phase 83% 
: 17% H2O and MeOH with 0.1% v/v Formic Acid with a flow rate of 0.4ml/min. Mass 
spectrometry detection using (M+H)+ m/z 243 - 226, Dwell: 300, fragmentor : 185, 
collision energy: 4, Polarity: positive. 
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Gas chromatography separation of Paclitaxel was performed using a mobile phase 30% : 
70% H2O and MeOH with 0.1% v/v Formic Acid with a flow rate of 0.4ml/min. Mass 
spectrometry detection using (276)+ m/z 876.3 – 308.1, Dwell: 550, Fragmentor : 185, 
collision energy: 28, Polarity: positive. 
 High Pressure liquid Chromatography detection of Bovine 4.2.7.2
Serum Albumin 
Bovine serum albumin fraction V was dissolved in sterile filtered dH2O to make a stock 
concentration of 1mg/ml. Serial dilutions of the stock solution was undertaken to produce 
a range of concentration  0.125mg/ml, 0.0625mg/ml, 0.03125mg/ml, 0.015625mg/ml, 
0.007825mg/ml, 0.0039025mg/ml and 0mg/ml for production of a standard curve. The 
samples were then analysed using two phase separation using: mobile phase (A) (double 
filtered water 99.9% with 0.1% TFA) and mobile phase (B) dH2O (double filtered 
acetonitrile 79.95%, 19.95% water and 0.1% TFA). A gradient analysis was set up starting 
with: 100:0 with a gradient increase to 0:100, over a 20 minute separation using Sepax 
Bio-C4 protein separation HPLC column. Protein analysis was undertaken using UV 
analysis at a wavelength of 215nm post separation. 
 Design of Experiments 4.2.8
Minitab® 16.2.2 was utilised to set-up a 2 level, 3 factor design of experiment (Full 
Factorial 23). Whereby, the upper, median and lower limits of each variable were entered 
and a randomised run output was created by Minitab®. All samples were then run 
according to the Minitab® output. Analysis of all factorial data was undertaken utilising 
the DOE commands in Minitab® 16.2.2 which produced Pareto and interaction plot 
graphical outputs. 
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Pareto charts and standardised plots demonstrate the magnitude and importance of an 
effect in relation to the individual and combinations of variables. The x-axis is dependent 
upon whether an error term is present. If no error term exists Minitab® uses Lenth’s 
pseudo-standard error which is based upon sparse effect (assumption that the variation 
in the smallest effect is because of random error, with α=0.05 is set as default). 
Interaction plots are a plot of the fitted means (post analysis) for each variable utilising 
the levels (high, low and median) for each mean and shows the interaction of the 
variables on the investigated factor. 
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 Experimental Plan 4.2.9
Stability Tesing
Verify Prediction of NP size
END
Identify Factors affecting nanoparticle size
PHBHHx Concentration Sonication Power Sonication Cycles
Multifactoral Experiment Design
Particle Size Particle Zeta Potential Particle Polydispersity Index
Are Results Reproducable
Yes No END
Repeat Multifactoral with encapsulated 
Drugs and Proteins
Particle Size Particle Zeta Potential Particle Polydispersity Index
STAGE 1
STAGE 2
Repeat Stage 2 with Different Users
 
Figure 0.2 Experimental Plan 
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4.3 Results 
 Multifactoral Design Blank Nanoparticles 4.3.1
Minitab® (16.2.2) was used to design and evaluate the DOE and produce graphical 
outputs of the data. Three key factors were assessed, namely, PHBHHX concentration, 
sonication power and number of sonication cycles at high and low conditions to enclose 
the experimental. 
This gave a total of eight experimental conditions (cube plot) with a centerpoint to 
complete the experimental design. An N=3 taken for each run to account for variability in 
the measurement system and a total of three experimental runs were completed to 
account for batch-to-batch variability, an assessment of common-cause variation within 
the nanoparticle production process and an indication of the repeatability of the 
methodology. 
From the data obtained from the cube plot shown in Figure 4.3 a range of nanoparticle 
properties are produced with a size range of 89.5nm – 229.3nm, PDI ranging from 0.1293 
– 0.1923 and a zeta potential ranging from -9.8mV - -13.7mV.  
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Figure 0.3 Cube plot of the multifactorial designed experiment showing the process variables 
Shows high/low values and the centre point for first run. A) Size, B) PDI and C) Zeta potential 
From the cube plot in Figure 4.4 nanoparticle properties with a size range of 89.4nm – 
234.05nm, PDI ranging from 0.127 – 0.202 and a zeta potential ranging from -10.3mV - -
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12.9mV. From both cube plots the major effectors of nanoparticle size can be identified 
by magnitude of effect. 
 
 
 
Figure 0.4 Cube plot of the multifactorial designed experiment showing the process variables 
Shows high/low values and the centre point for second run. A) Size, B) PDI and C) Zeta potential 
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From Figure 4.5 the magnitude of effect of each variable can be shown for each 
nanoparticle property. Sonication rate had the greatest effect on nanoparticle size (Figure 
4.5A), followed by PHBHHx concentration then sonication power. However all variables 
were shown to have an effect on nanoparticle size. The major effector of PDI (Figure 4.5B) 
was shown to be sonication rate followed by combination of PHBHHx concentration with 
sonication rate and finally sonication power with PHBHHx concentration and the 
combinations of PHBHHx and sonication power, sonication power and sonication rate & 
the combination of sonication power, PHBHHx concentration and sonication rate having 
no effect. Zeta potential (Figure 4.5C) showed all combinations and individual variables 
with the exception of the combination of sonication power and sonication rate having no 
magnitude effects. 
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Figure 0.5 Pareto chart of standardised effects for the size production of nanoparticles. 
Graph shows single and multi-variable effects with statistical significance shown at p=0.05 for first run. A) 
Size, B) PDI and C) Zeta potential 
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From Figure 4.6 the magnitude of effect of each variable can be shown for each 
nanoparticle property. Sonication rate had the greatest effect on nanoparticle size (Figure 
4.6A), followed by PHBHHx concentration then sonication power. However all variables 
were shown to have an effect on nanoparticle size. The major effector of PDI (Figure 4.6B) 
was shown to be sonication rate followed by combination of PHBHHx concentration with 
sonication rate and finally sonication power with PHBHHx concentration and the 
combinations of PHBHHx and sonication power, sonication power and sonication rate & 
the combination of sonication power, PHBHHx concentration and sonication rate having 
no effect. Zeta potential (Figure 4.6C) showed all combinations and individual variables 
with the exception of the combination of sonication power & sonication rate and the 
combination of PHBHHx concentration, sonication power and sonication rate having no 
magnitude effects. 
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Figure 0.6 Pareto chart of standardised effects for the size production of nanoparticles. 
Graph shows single and multi-variable effects with statistical significance shown at p=0.05 for Second 
run. A) Size, B) PDI and C) Zeta potential 
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The Standardised plots shown in Figure 4.7A-C, show the variable factors which are 
significant to the nanoparticle properties of Size (Figure 4.7A), PDI (Figure 4.7B) and Zeta 
Potential (Figure 4.7 C) for Run 1. 
 
 
 
Figure 0.7 Main effects plot showing the effect of the three variables from the first run. 
A) Size of nanoparticles during production, B) PDI of nanoparticles during production and C) Zeta 
Potential. 
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The Standardised plots shown in Figure 4.8A-C, show the variable factors which are 
significant to the nanoparticle properties of Size (Figure 4.8A), PDI (Figure 4.8B) and Zeta 
Potential (Figure 4.8C) for Run 2. 
 
 
 
Figure 0.8 Main effects plot showing the effect of the three variables from the second run. 
A) Size of nanoparticles during production, B) PDI of nanoparticles during production and C) Zeta 
Potential 
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The Interaction plots shown in Figure 4.9A-C, show the interaction of factors (the further 
the lines are from parallel the greater the interaction) to the nanoparticle properties of 
Size (Figure 4.9A), PDI (Figure 4.9B) and Zeta Potential (Figure 4.9C) for Run 1. 
 
 
 
Figure 0.9 Interaction plot showing the effect of the three variables from the first run. 
A) Size of nanoparticles during production and B) PDI of nanoparticles during production and C) Zeta 
Potential. 
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The Interaction plots shown in Figure 4.10A-C, show the interaction of factors (the further 
the lines are from parallel the greater the interaction) to the nanoparticle properties of 
Size (Figure 4.10A), PDI (Figure 4.10B) and Zeta Potential (Figure 4.10C) for Run 2 
 
 
 
Figure 0.10 Interaction plot showing the effect of the three variables from the second run. 
A) Size of nanoparticles during production and B) PDI of nanoparticles during production and C) Zeta 
Potential. 
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From the DOE investigation we deduced that by fixing concentration PHBHHx molecular 
weight and sonication power and introducing variations in sonication cycles we may be 
able to produce a prediction curve for the production of PHBHHx nanoparticles.  
 Production of a controlled Blank Nanoparticle Size by fixing 4.3.1.1
PHBHHx concentration and Power and varying the number of 
sonication cycles. 
From the preliminary data observed in the multifactorial design the inclusion of 3 extra 
sonication points were included in production of a standard curve to predict nanoparticle 
size namely 15, 25 and 35 sonication cycles. The PHBHHx concentration was fixed at 
0.25mg/ml and sonication power was fixed at either 100W or 500W (Table 4.2). 
Power 10 
Sonication 
Cycles 
15 
Sonication 
Cycles 
20 
Sonication 
Cycles 
25 
Sonication  
Cycles 
30 
Sonication  
Cycles 
35 
Sonication 
Cycles 
40 
Sonication  
Cycles 
 
100W 
204.32nm 
±  
3.74nm 
185.00nm 
± 
2.87nm 
167.65nm 
±  
4.50nm 
154.33nm  
± 
2.75nm 
140.07nm 
 ±  
1.85nm 
132.87nm 
± 
1.16nm 
122.43nm 
± 
2.79nm 
 
500W 
165.78nm 
 ±  
1.55nm 
134.80nm 
± 
4.56nm 
117.03nm 
±  
3.37nm 
107.07nm 
± 
0.69nm 
98.45nm 
 ± 
2.45nm 
94.88nm 
± 
0.67nm 
94.26nm  
± 
0.88nm 
Table 0.2 Nanoparticle prediction curve full data set 
From the data obtained in the addition of sonication points a standard curve graph for 
two power settings with fixed PHBHHx concentration was created (Figure 4.11). 
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Figure 0.11 Blank Nanoparticle prediction Standard Curve 
Blank nanoparticle size prediction curve at high and low sonication power and PHBHHX concentration of 
0.25 mg/mL. 100W: Sonication power of 100 W. 500W: Sonication power of 500 W. Graph shows mean 
values  1 standard deviation (N=6) over two batches of N=3. 100W R2= 0.99549, 500W R2= 0.99475. 
From the graph in Figure 4.11 an equation was extracted to predict nanoparticle size by 
fixing PHBHHx concentration, Sonication Power and using sonication cycles as a variable 
to produce a range of blank nanoparticles to test the logistic dose response curve Table 
4.4 and Equation 2). 
From the data in Table 4.3 and subsequent graph the following equations were created to 
predict nanoparticle size for sonication power of both 100W and 500w. 
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Equation 
Component 
100W 500W 
A1 (Initial Value)  241.622 197.357 
A2 (Final Value) 67.8974 87.0395 
x0 (centre) 25.4944 15.1511 
p (Curve constant) 1.54875 2.84045 
Table 0.3 Values to be attributed to the equation for nanoparticle prediction 
 
 
Where n=number of Sonication cycles. 
Equation 2 Logistic dose response curve 
 Investigating whether encapsulation of a drug/protein has an 4.3.1.2
effect on Nanoparticle size 
To validate the standard curve nanoparticles which encapsulated either paclitaxel (Table 
4.4  and Figure 4.12), Albumin (Table 4.5 and Figure 4.13) or Haperzine A (Table 4.6  and 
Figure 4.14) were produced using two power settings of 500W and 100W with fixed 
PHBHHx concentration of 0.25mg/ml and utilising sonication cycle settings of 10, 20, 30 
and 40. 
Power 10 
Sonication 
Cycles 
20 
Sonication 
Cycles 
30 
Sonication  
Cycles 
40 
Sonication  
Cycles 
 
100W 
199.0nm 
±  
1.65nm 
163.5nm 
±  
2.87nm 
139.8nm 
 ±  
4.24nm 
124.1nm 
± 
2.2nm 
 
500W 
161.7nm 
 ±  
1.85nm 
116.8nm 
±  
2.13nm 
99.5nm 
 ± 
1.93nm 
92.3nm 
± 
2.77nm 
Table 0.4 Paclitaxel Loaded nanoparticle Size validation 
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Figure 0.12 Paclitaxel loaded Nanoparticle validation Curve 
Size validation compared to original blank PHBHHX nanoparticle curve of Paclitaxel. 100W: Sonication 
power of 100 W. 500W: Sonication power of 500 W. Graph shows mean values  1 standard deviation 
(N=6) over two batches of N=3. 
Power 10 
Sonication 
Cycles 
20 
Sonication 
Cycles 
30 
Sonication  
Cycles 
40 
Sonication  
Cycles 
 
100W 
204.0nm 
±  
5.28nm 
164.0nm 
±  
4.25nm 
135.2nm 
 ±  
5.13nm 
116.4nm 
± 
2.69nm 
 
500W 
161.4nm 
 ±  
2.57nm 
115.6nm 
±  
5.33nm 
98.6nm 
 ± 
3.67nm 
93.4nm 
± 
5.97nm 
Table 0.5 Albumin-PLC Loaded nanoparticle Size validation 
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Figure 0.13 Albumin-PLC loaded Nanoparticle validation Curve 
Size validation compared to original blank PHBHHX nanoparticle curve of Albumin encapsulated 
nanoparticles. 100W: Sonication power of 100 W. 500W: Sonication power of 500 W. Graph shows mean 
values  1 standard deviation (N=6) over two batches of N=3. 
 
Power 10 
Sonication 
Cycles 
20 
Sonication 
Cycles 
30 
Sonication  
Cycles 
40 
Sonication  
Cycles 
 
100W 
210.1nm 
±  
1.65nm 
167.5nm 
±  
4.60nm 
145.5nm 
 ±  
2.01nm 
132.1nm 
± 
5.2nm 
 
500W 
165.2nm 
 ±  
7.08nm 
117.8nm 
±  
1.38nm 
98.2nm 
 ± 
0.63nm 
94.2nm 
± 
1.46nm 
Table 0.6 Haperzine A Loaded nanoparticle Size validation 
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Figure 0.14 Haperzine A loaded Nanoparticle validation Curve 
Size validation compared to original blank PHBHHX nanoparticle curve of HaperzineA encapsulated 
nanoparticles. 100W: Sonication power of 100 W. 500W: Sonication power of 500 W. Graph shows mean 
values  1 standard deviation (N=6) over two batches of N=3. 
From the data obtained in tables 4.4 – 4.6 a prediction error (nm) and percentage (%) can 
be calculated to establish the validity of the nanoparticle prediction curve. 
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Sonication 
Power (W) 
Curve 
Prediction 
(nm) 
Paclitaxel HaperzineA ALB-PLC-NP 
Prediction 
Error (nm) 
Prediction 
Error (%) 
Prediction 
Error (nm) 
Prediction 
Error (%) 
Prediction 
Error (nm) 
Prediction 
Error (%) 
100 
204.5 5.47 2.67 5.65 2.76 0.44 0.21 
167.7 4.26 2.54 0.26 0.15 3.69 2.20 
141.7 1.96 1.38 4.08 2.86 6.52 4.60 
124.2 0.07 0.06 7.88 6.35 7.75 6.24 
500 
165.7 3.98 2.40 0.48 0.29 4.28 2.58 
118.3 1.54 1.31 0.54 0.46 2.68 2.26 
99.8 0.30 0.30 1.65 1.66 1.21 1.21 
93.2 0.85 0.91 1.03 1.10 0.16 0.17 
Overall Average 
Prediction Error 
2.30 ± 2.02 1.45 ± 1.01 
2.70 ± 
2.84 
1.96 ± 
2.06 
3.34 ± 
2.78 
2.44 
± 2.10 
Table 0.7 Loaded Nanoparticle Size prediction Evaluation and Error. 
Following the evaluation of blank nanoparticles, the process was repeated with 
Heperzine-A, Paclitaxel and ALB-PL-NPs to see if the same rule applied to these complexes 
since then the size evaluation can be conducted using blank polymer only nanoparticles 
and the results extrapolated for drug encapsulated nanoparticles. From Figures 4.15 – 
4.17 it can be seen that these encapsulated drugs conformed to the same production size 
curve as the blank nanoparticles, meaning that the original curve can be used to select a 
desired nanoparticle size, for a specified application. 
The accuracy of this relationship has also been evaluated in Table 4.7, which shows that 
the maximum overall (mean) prediction error from blank to drug encapsulated 
nanoparticles as 3.34  2.78 nm which equates to 2.44  2.10 %, with a prediction error 
range of 0.07 – 7.88 nm or 0.06 – 6.35% for the three drugs. 
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 Encapsulation Efficiency 4.3.2
Encapsulation Efficiency was calculated using the following formulae: 
Drug Loaded NPs Size 
(nm) 
PDI Zeta Potential 
(mV) 
EE 
(%) 
Haperzine A (1:60) 95.2 ± 0.73 0.128 ± 
0.007 
-12.2 ± 0.35 49.98 ± 1.50 
Haperzine A (1:90) 94.2 ± 1.46 0.146 ± 
0.012 
-13.8 ± 1.85 48.81 ± 1.69 
Haperzine A (1:120) 93.3 ± 1.46 0.137 ± 
0.013 
-15.33 ± 1.10 63.50 ± 1.57 
Table 0.8 Haperzine-A loaded nanoparticles optimisation.  
Values are mean  s.d. (n=3). 
 
Drug Loaded NPs Size 
(nm) 
PDI Zeta Potential 
(mV) 
EE 
(%) 
Albumin (1:60) 93.4 ± 0.42 0.246± 
0.002 
-35.9 ± 2.4 59.11 ± 1.50 
Albumin (1:90) 95.5 ± 0.25 0.211 ± 
0.006 
-35.3 ± 0.9 76.63 ± 2.14 
Albumin (1:120) 94.2 ± 0.36 0.250 ± 
0.010 
-37.8 ± 1.7 66.89 ± 2.30 
Table 0.9 Albumin loaded nanoparticles optimisation.   
Values are mean  s.d. (n=3). 
The encapsulation efficiency of Heperzine-A (Table 4.8) was found to highest at a drug to 
polymer ratio of 1:120 with 63.50  1.57 % with lower entrapment of around 50% for 
ratios of 1:60 and 1:90. Transmission electron microscopy (Figure 4.15) showed that the 
Heperzine-A loaded nanoparticles were spherical in shape and that the size distribution of 
the nanoparticles was low.  
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Figure 0.15 Transmission Electron Microscopy (TEM) of PHBHHx nanoparticles 
A) Haperzine A loaded PHBHHx nanoparticles (low magnification), B) Haperzine A loaded PHBHHx 
nanoparticles (high magnification), C) Blank PHBHHx nanoparticles (low magnification) and D) Blank 
PHBHHx nanoparticles (high magnification). (A & B imaged at West China School of Pharmacy, C & D 
imaged at School of Medicine, Tsinghua University.) 
 Effects of controlled manufacture on drug release profiles 4.3.3
Having previously identified that Haperzine A showed a high encapsulation. The next step 
in the investigation was to evaluate the effects of DOE manufacture of drug containing 
nanoparticles. This investigation would produce a new batch of 4 haperzine A 
nanoparticles with varying PHBHHx concentrations and production settings (Table 4.10). 
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Sample PHBHHx 
Concentration 
(mg/ml) 
Sonication 
Power 
Sonication 
Cycles 
Haperzine A 
Concentration 
(mg/ml) 
1 0.25 500 25 0.000521 
2 0.25 100 20 0.000521 
3 2 500 35 0.004167 
4 2 100 15 0.004167 
Table 0.10 Haperzine A loaded nanoparticles for release profile production settings 
From the above experimental settings the following Haperzine A loaded nanoparticle 
profile were obtained and showed a decrease in encapsulation efficiency when PHBHHx 
concentration was increased (Table 4.11).  
Sample Size (nm) PDI 
Zeta Potential 
(mV) 
Prediction 
Curve 
Percentage 
Error (%) 
Encapsulation 
Efficiency (%) 
1 108.33±3.69 0.11±0.03 -17.83±1.39 0.95 60.93±4.85 
2 119.93±3.02 0.17±0.04 -21.18±3.08 0.3 75.54±4.5 
3 134.77±7.56 0.07±0.02 -23.37±1.14 1.4 22.81±5.44 
4 183.27±5.5 0.14±0.06 -32.10±2.38 1.05 21.39±7.27 
Table 0.11 Haperzine A nanoparticle properties and Encapsulation Efficiency. 
4.4 Multifactoral investigation into the effects of surfactant 
From the data obtained from the cube plot shown in Figure 4.16 range of nanoparticle 
properties are produced with a size range of 77.7nm – 102.8nm, PDI ranging from 0.092 – 
0.169 and a zeta potential ranging from -8.37mV - -33.95mV. 
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Figure 0.16 Cube plot of the multifactorial DOE for surfactant. 
A) Size, B) PDI and C) Zeta potential. 
Figure 4.17A and Figure 4.17B shows the magnitude effects of DO and F68. F68 has the 
greatest magnitude effect on nanoparticle size and PDI. Figure 4.17C shows DO having the 
greatest effect on zeta potential followed by F68 and the combination of F68 and DO. 
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Figure 0.17 Combined and individual effects of surfactants  
A) Size, B) PDI and C) Zeta Potential 
Figure 4.18A, B & C shows the variables that have a significant effect on nanoparticle 
properties. 
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Figure 0.18 Standardised Effects 
Shows Standardised effects on A) Size, B) PDI and C) Zeta potential 
The Interaction plots shown in Figure 4.19A-C, show the interaction of factors (the further 
the lines are from parallel the greater the interaction) to the nanoparticle properties of 
Size (Figure 4.19A), PDI (Figure 4.19B) and Zeta Potential (Figure 4.19C). 
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Figure 0.19 Interaction Plot for F68 and Deoxycholate  
Shows the interaction of the Surfactants on PDI, Zeta Potential and Size 
Figure 4.20 shows the 3D combinational effects of DO and F68 on nanoparticle size 
(Figure 4.20A), PDI (Figure 4.20B) and nanoparticle zeta potential (Figure 4.20C). 
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Figure 0.20 Surfactant Surface Plot  
showing interactions between surfactant concentration and nanoparticle properties. 
By fixing sonication power at 500w, sonication rate at 40 and PHBHHx concentration at 
025mg/ml and producing a further two factorial DOE for the surfactants we have 
W. R. Webb PhD Thesis Chapter 4 
254 
 
identified a further mechanism of decreasing nanoparticle size to 77.31 ± 0.35 nm and the 
possibility of control nanoparticle charge (Table 4.12). 
Sample Size (nm) PDI 
Zeta Potential 
(mV) 
0.25mg/ml + 7.5mg of F68 
and 7.5mg/ml DO 
77.31±0.35 0.123±0.010 -12.57±0.58 
0.5mg/ml + 5mg of F68 
and 5mg/ml DO 
85.61±0.63 0.125±0.005 -15.75±0.80 
0.25mg/ml + 7.5mg of F68 
and2.5 mg/ml DO 
95.68±0.60 0.092±0.022 -33.95±4.96 
0.75mg/ml + 7.5mg of F68 
and 7.5mg/ml DO 
96.40±0.73 0.169±0.017 -8.37±0.50 
0.75mg/ml + 7.5mg of F68 
and 2.5 mg/ml DO 
102.80±0.74 0.127±0.016 -15.03±3.29 
Table 0.12 Surfactant multifactorial results for Size, PDI and zeta potential 
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4.5 Nanoparticle Stability 
The blank nanoparticle stability study was conducted over 168 hours (7 days) to assess 
the change in size, PDI and zeta potential of the nanoparticles (Table 4.13 – Table 4.16 
and Figure 4.21A, B and C). The nanoparticle size was stable for the full 168 hours at both 
high and low sonication settings over the range of nanoparticle sizes. There was also no 
significant difference seen in the nanoparticle size stability when stored at room 
temperature compared to 4 C.  
 
The PDI of the blank nanoparticles showed a slight fluctuation over the 168 hour period, 
resulting in a slightly elevated after 168 hours (Figure 4.21B). The PDI recorded at the end 
of the 168 hour period was still below the 0.3 benchmark figure for in vivo drug delivery 
applications and there was no significant difference between the nanoparticles PDI after 
168 hours stored at room temperature compared to 4 C.  
The zeta potential of the blank nanoparticles remained stable over the 168 hour period 
albeit with minor fluctuations at the measurement intervals (Figure 4.21C). This 
considered, the zeta potential for the nanoparticles remained in the accepted range of -
10 to -40 mv for the duration of the study and there was no observed difference between 
those stored at 4 C and those stored at room temperature. 
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Sample number Sample description 
1 
0.25mg/ml refrigerated (4oC)100W 40 
cycles 
2 
0.25mg/ml room temperature 
(4oC)100W 40 cycles 
3 
0.25mg/ml refrigerated (4oC)500W 40 
cycles 
4 
0.25mg/ml room temperature 
(4oC)500W 40 cycles 
Table 0.13 Sample guide for stability study 
Sample 0 hrs 24 hrs 48 hrs 96 hrs 168 hrs 
1 189.2±1.1 186.9±5.0 184.0±6.4 181.1±4.2 178.2±1.0 
2 189.2±1.1 190.5±0.9 186.3±1.8 185.2±3.1 182.7±4.0 
3 97.6±1.0 94.6±0.8 95.3±1.9 96.4±1.4 98.7±2.4 
4 97.6±1.0 94.4±0.8 93.9±1.5 97.4±1.7 98.5±2.5 
Table 0.14 Stability Study Nanoparticle Size 
Shows size of nanoparticles size in nm over 168 hours 
Sample 0 hrs 24 hrs 48 hrs 96 hrs 168 hrs 
1 0.125±0.033 0.142±0.029 0.108±0.033 0.144±0.020 0.137±0.012 
2 0.125±0.033 0.139±0.035 0.170±0.021 0.170±0.017 0.154±0.007 
3 0.172±0.009 0.184±0.010 0.242±0.008 0.234±0.006 0.225±0.004 
4 0.172±0.009 0.174±0.024 0.183±0.012 0.207±0.007 0.208±0.026 
Table 0.15 Stability Study PDI 
Sample 0 hrs 24 hrs 48 hrs 96 hrs 168 hrs 
1 -13.5±0.2 -18.0±1.2 -18.6±0.7 -23.1±2.3 -37.6±0.9 
2 -13.5±0.2 -16.6±1.0 -15.8±1.5 -13.6±0.9 -24.5±1.6 
3 -26.3±6.3 -36.9±5.1 -37.5±3.8 -21.6±3.0 -34.3±6.2 
4 -26.3±6.3 -31.6±4.0 -36.4±2.1 -34.3±6.0 -37.0±2.1 
Table 0.16 Stability Study Zeta Potential 
Shows zeta potential over 168 hours values in mV 
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Figure 0.21 Nanoparticle Stability testing. 
A) Size stability study of blank PHBHHX nanoparticles at 0.25mg/mL. B) PDI stability study of blank 
PHBHHX nanoparticles at 0.25mg/mL. C) Zeta potential stability study of blank PHBHHX nanoparticles at 
0.25mg/mL. High/low sonication settings at room temperature (rt) and 4 C. Graph shows mean values  
1 standard deviation(N=3).  
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4.6 Discussion 
To our knowledge there are, no published protocol for controlling nanoparticle size. 
Controlled drug delivery, more so growth factor delivery over 40 days with an aim to 
deliver a precise dose being able to control nanoparticle size may well help to deliver a 
nanoparticle with such properties. To date there has been little focus on controlling 
nanoparticle properties such as size during the manufacturing process. Experimental 
design is a vital aspect of any research that is often overlooked but when well executed, 
has the potential to deliver high impact results with precise planning and reduced cost. A 
factorial experiment consists of two or more factors, taking into account the effect of 
each variable on the process as well as the interaction of multiple variables in order to 
optimise production. Within a manufacturing process such as nanoparticle production, 
the control of these variables is critical and the knowledge of how they interact as well as 
which variables have the largest effect on controlling the desired process output will lead 
to more tightly controlled production. This interaction of variables is often ignored but is 
critical for a full understanding of the process [392].  
Lamprecht et al [393, 394] achieved variation in Poly (lactic-co-glycolic acid) (PLGA) and 
bovine serum albumin (BSA) nanoparticle size by altering production variables 
(homogenisation time, polymer concentration and surfactant concentration) using a ‘one 
factor at a time’ (OFAT) approach. The absence of consideration of the interaction of 
competing variables within their process resulted in the production of nanoparticles with 
a minimum size of 230 nm with no indication of repeatability. A separate study by 
Gutierro et al [395] also varied PLGA-BSA nanoparticle size by altering the production 
process and managed to reduce the nanoparticles from 1000 nm to 200 nm which led to 
a reduced immune response, also using an OFAT approach. Gryparis et al [396] employed 
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a pseudo-multivariate batch method to vary the size of PLGA nanoparticles and were able 
to create drug encapsulated nanoparticles with a minimum size of 150 nm and a PDI of 
close to 0.3, the accepted limit for clinical applications [397].  
Perhaps the most rigorous study to date on size control of nanoparticles employed a 5-
factor 3-level experimental design for the production of PLGA-BSA nanoparticles [398]. 
Detailed computer analysis of this factorial design revealed a theoretic minimum 
nanoparticle diameter for their double emulsion production method of 122.4 nm. As 
described previously, nanoparticles with a mean diameter of less than 100 nm would be 
highly desirable to mediate cellular response, for sterilisation via filtration, for use in gene 
transfection and to actively cross the blood-brain barrier and. By producing a nanoparticle 
size range of 90 – 205 nm, this study has demonstrated the advantage of using PHBHHx 
for nanoparticle production to fit a variety of applications. In this study, blank 
nanoparticles showed the same size trend as encapsulated nanoparticles meaning that 
various biocompatible polymers can be characterised by this method in the knowledge 
that the introduction of drugs/growth factors to the nanoparticles will not affect the 
production size.  
From the data in table 5.8 it is evident that the process described is highly repeatable and 
can accurately produce nanoparticles of a desired size. This is a critical component of any 
production system, since if a process is not reproducible or repeatable it cannot be used 
for reliable or commercial production. If batch to batch production is not considered 
within an experimental process, then common cause variability is not accounted for and 
the process cannot be reliably evaluated. A large number of experimental methods only 
account for inter-batch variability which is an assessment of the accuracy of the 
measurement system in use i.e. an N of three on one occasion, but gives no indication of 
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the repeatability of the experimental methodology. Bridging the gap between industry 
and research by implementing a DOE approach in research laboratories is an invaluable 
way to attract industry and produce high quality research. This is a highly critical 
consideration for the successful commercialisation of medical products which should be 
the aspiration of all research groups not only in the field of drug delivery and 
pharmaceutical research but also regenerative medicine.  
One consideration that must be noted in this process is the effect of sonication on the 
encapsulated protein or drug, since high sonication power may have a destructive effect 
on the encapsulated protein. Observations from the encapsulation of Albumin and 
HaperzineA showed a low entrapment efficiency which can be explained by the 
sonication power being high enough to destroy the drug. This has been highlighted due to 
the total drug concentration being calculated from the amount of drug input at the start 
of the process, taking into account the overall efficiency. In contrast, traditional 
encapsulation efficiency calculations use the total drug concentration after breakdown of 
the nanoparticles via sonication and therefore do not account for the destruction of drug 
due to sonication.  It can be noted from a previous study that a sonication power of 400 
W also had no apparent effect on the encapsulation of insulin [373], however repeat and 
high power sonication on the formed nanoparticle to release the entrapped drug or 
protein can cause destruction of the analyte of interest resulting in underestimated 
encapsulated drug dose, which may have a significant effect on the target whether it is 
cellular differentiation or diabetic control. At higher sonication power and duration, there 
was a tighter distribution of particle sizes and a reduction in PDI  compared to the lower 
settings which is consistent with previous studies [399]. This is due to the increased 
exposure to ultrasonic force, which acts to push the size distribution curve down towards 
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the lower size limit, reducing the overall range and creating a tighter size distribution. This 
is advantageous from a process perceptive since creating a tighter size distribution means 
that the process is inherently more reproducible when creating smaller nanoparticles.   
The nanoparticles in this study were assessed over seven days and showed no size 
deviation for this period as well as small and acceptable changes to PDI and zeta potential 
which is critical for the viability of the nanoparticles for clinical applications [287]. This 
was found to be the case for both 4 C and room temperature, showing the viability of this 
method in terms of stability. Clearly, storage will need to be considered in relation to the 
encapsulated drug as well, since most proteins will need to be stored at 4 C to retain 
their integrity.  
In this study we created nanoparticles as small as 90 nm with a PDI of well below 0.3, 
which is far smaller than the theoretical minimum of 122.4 nm using PLGA-BSA as 
described by Feczkó et al [398]. This shows that the use of PHBHHx as a drug 
encapsulating polymer has greater potential compared to PLGA, producing smaller 
nanoparticles as required for precise growth factor concentration delivery. 
The bio distribution of nanoparticles on entry into the circulatory system should be 
considered when embarking on the use of nanoparticles as a delivery vehicle for bioactive 
molecules. This study investigated the possibility of PHBHHx nanoparticles as a delivery 
vehicle for growth factors. The growth factors to be delivered were either a combination 
of BMP-12 & BMP-12 or FGF-4, FGF-6 and FGF-8. Growth factors are well documented to 
induce and enhance tumour growth. This study aimed to control the production of 
PHBHHx nanoparticles to produce a desired property namely “nanoparticle Size”, which 
will then be contained within a PHBHHx hybrid scaffold that would contain a collagen and 
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stem cell core. As with all implants there is always a risk of implant failure and thus a 
further risk of growth factor containing nanoparticles entering the circulatory system. 
This study showed PHBHHx nanoparticles accumulated in the liver, spleen and brain. Data 
from this study indicated a higher brain tissue uptake with particles smaller than 100nm. 
Conversely, the data also suggested that as nanoparticle size increased there was a 
greater uptake of nanoparticles into liver and spleen tissue which agrees with previous 
studies [400]. 
Combining this key attribute with the highly favourable biodegradability of PHBHHx and 
the potential for cost effective large scale production means that this system has 
remarkable and unique commercial potential as a drug delivery device and not only 
growth factor delivery to suit a multitude of applications within the field of nano-
medicine. 
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4.7 Conclusion 
It has been shown that the DOE approach can be employed to control the production of 
nanoparticles to fit a variety of applications within nano-medicine, whereby a size 
prediction curve can be produced for each polymer which can then be applied to any 
encapsulated drug to achieve a desired nanoparticle size. The knowledge gained from this 
preliminary optimisation is important to pave the way for more in depth analysis to 
obtain a full understanding of the process. This study highlights the most sensitive aspects 
of nanoparticle production via the solvent evaporation method, which can be used to 
reduce variability in the production process leading to increased precision within the 
manufacture of nanoparticles. Reliable production of drug encapsulated nanoparticles 
provides key evidence that PHBHHx can be used to investigate new applications in the 
field that require the production of nanoparticles less than 100 nm. Preliminary 
Investigation into the effect of different surfactant concentration during production using 
the solvent evaporation method highlighted the potentially lead to the creation of smaller 
nanoparticles and is a key area for further detailed investigation. This chapter has shown 
reasonable PHBHHX nanoparticle entrapment efficiency of the hydrophobic drug 
Heperzine-A and bovine serum albumin which can be combined with this controlled 
manufacture process for delivery of growth factors. Aligning research practices with those 
of current commercial research institutions has been highlighted as an invaluable way to 
attract commercial interest and to allow research to evolve alongside industry which is 
critical for the success of nano-medicine, controlled drug delivery and regenerative 
medicine in general.  
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Tendon injury is an increasing problem in medicine, with between 3 – 5 million tendon 
related injuries worldwide annually, with over 300,000 tendon procedures performed 
annually in the United States alone [156, 295]. Tendon is characterised by poor repair 
following injury or disease, is relatively acellular and has poor blood supply [6]. Treatment 
can involve many different types of surgical intervention, such as xenograft or allograft to 
treat large tendon defects, however potential problems with this method (such as foreign 
body reaction) can occur [296]. A lack of adequate strategies for tendon repair has led to 
the development of engineered replacement tendon tissue for use in surgical 
implantation [297]. Tissue engineering could be used to develop a regenerative medicine 
solution to tendon tissue repair [156]. 
The aim of this thesis was to investigate three possible components which may lead to 
the development of a tissue engineered tendon implant: 
1. PHBHHx tendon scaffold design (Chapter 2) 
2. Growth factor induced differentiation of human stem cells (Chapter 3) 
3. Controlled production of nanoparticles to predict the size of nanoparticles to be 
used in the delivery of growth factors (Chapter 4) 
The aim of this investigation (Chapter 2) was to identify a PHBHHx scaffold design that 
could be used to facilitate repair of damaged tendon tissue while not initiating an 
immune response or prolonging inflammation. A composite scaffold was developed which 
featured a PHBHHx tube, a collagen core, and PHBHHx fibres which would facilitate 
cellular migration and tissue remodelling, while at the same time allowing for limited 
restoration of movement. The design was mechanically similar to the rat Achilles tendon 
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and to other commercially available human tendon repair materials [117, 297]. 
Furthermore, this study has shown that PHBHHx scaffold encourages cellular infiltration 
and proliferation which agrees with previous studies [119, 312, 313, 329]. Furthermore, 
cellular alignment was observed along the force baring tube and fibre which agrees with 
earlier studies indicating cellular alignment with direction of force [401-403]. 
The ability of any implant to not elucidate an immune response is one of the key 
components of evaluation of a potential implant [404] .The CRP results from this study 
clearly indicate that the PHBHHx implant did not induce an immune response and in- fact 
the immune response 48hrs post-surgery in a natural response to the induced trauma 
caused by surgery with no subsequent increase in CRP. These findings add to the body of 
evidence indicating PHBHHx does not elucidate an immune response in vivo [318-320, 
323]. 
The ability of a biological implant/scaffold being able to perform as “normal tissue” is 
highly desired. In this study we utilised AFI testing to measure return of function. AFI 
testing showed a continued improvement for all groups over the 40 day investigation, 
with complete return of function being as early as day +20 in the tenocyte-PHBHHx-
collagen group which was a full 20 days prior to the PHBHHx only and PHBHHx-collagen 
group, with the control group remaining below pre-surgical implantation levels. These 
results show the implanted scaffolds are capable of withstanding the forces which are 
exposed to native tendon and the implantation of a scaffold returns function to the limb 
faster than the absence of an implant which agrees with previous studies [314]. 
 
W. R. Webb PhD Thesis Chapter 5 
267 
 
Cellular infiltration into the scaffold was observed in both the PHBHHx only and Collagen-
PHBHHx scaffold designs with sinusoidal cellular alignment which is a key marker in the 
histological analysis of tendon tissue, signifying the presence of crimp angles between 
collagen fibrils [33, 43]. The PHBHHx scaffold which contained tenocytes and collagen the 
cells appeared to be more elongated and sinusoidal in morphology, when compared to 
the other implanted scaffold designs, as with the PHBHHx only and collagen-PHBHHx 
scaffold designs, when cells were in direct contact with the scaffold, especially the fibre 
component this feature was more apparent and the sinusoidal-elongated morphology 
could possibly indicating that force transmission resulting in mechanotransduction from 
the fibre to the cells promoted tendon cell proliferation and alignment [90, 301, 312]. This 
further highlights the importance of collagen not only in the tissue integration and 
remodelling of tendon but in a means of delivering cells to a point of repair and further 
adds to previous studies suggesting collagen is a beneficial inclusion in tendon graft 
material [114, 300, 326]. 
However, careful consideration should be given to whether a PHBHHx scaffold can be 
constructed to deliver the properties that are observed within the human Achilles 
tendon. The adult Achilles tendon has ultimate force to break in excess of 435N 
[405]compared with a ultimate force to break in rat Achilles tendon of this study of 
17.35N.  
This study has potentially identified PHBHHx can be utilised as a tendon scaffold capable 
of delivering a cellular component to a tendon defect area which was capable of: 1) the 
return of function to the implant site, 2) did not elucidate an immune response and 3) 
provided favourable conditions for cellular proliferation and force transmission.  
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The next stage of this study (Chapter 3) was to identify whether FGF-4, FGF-6 and FGF-8 
singularly or as a combination could induce and maintain tendon specific gene expression 
in human derived stem cells. Therefore, this study employed the gene combination of 
TNMD and THBS-4 expression as a marker of tendon differentiation first identified by 
Jelinsky et al [68] 
This study has shown Vitamin C in conjunction with FGF-4, 6 & 8 cultured at 2% O2 was 
capable of inducing and maintaining tendon like gene markers: tenomodulin (TNMD), 
Tenascin C (TENC), Collagen 3A1 (COL3A1), Collagen 1A2 (COL1A2) and Thrombospondin-
4 (THBS-4) over a 40 day culture period in both human embryonic stem cells and human 
mesenchymal stem cells. However, the mechanisms by which FGF signalling induced and 
maintained tendon gene expression remain un-identified. FGF’s are well documented to 
bind in an order of hierarchy with many FGF’s competitively binding to the same 
receptors with FGF specificity to a given receptor dictating the order of binding to the 
FGFR [222, 406].FGF-4, FGF-6 and FGF-8 all bind to FGFR-1, FGFR-2 and FGFR-4. However, 
competitive affinity to a specific receptor by one of the FGF’s will then have a knock on 
effect on the affinity of the next FGF to its next favourable ligand and so on and so forth 
with the third FGF. Furthermore, the preferential FGFR binding will have a combined 
effect on which post receptor signal cascade is active.  
FGF’s have been previously been shown to preferentially bind to specific FGFR’s [222, 
406].The hierarchical order/relationship between FGF-4, FGF-6 and FGF-8 with their 
common receptors is currently poorly defined. The potential of preferential binding to 
induce a priority of specific FGF-FGFR interactions and subsequent hierarchical shift of 
preference of other FGF’s to bind with a receptor further down its hierarchical order may 
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well dictate the transcriptional outcomes observed in this investigation. Only in the 
presence of FGF-4, FGF-6 and FGF-8 in the differential media is a “true” tenocyte-like 
gene expression observed. Furthermore, the presence of tenocyte-like gene expression 
may only indicate cellular priming towards a tenocyte-lineage. 
The use of Dorsomorphin in this study as a SMAD inhibitor has highlighted the possibility 
of cross – talk between the FGF-FGFR signal transduction and possible up-regulation of 
BMP juxtacrine signalling. This study has highlighted the inclusion of Dorsomorphin to 
FGF supplemented media induced a decrease in both GAG and collagen synthesis in all 
FGF-4, FGF-4 & 8 and to a lesser extent FGF-4, 6 & 8 supplemented media. These findings 
agree with previous studies highlighting FGF-BMP signalling cross talk [407, 408]. 
Previous publications have indicated to the requirement of mechanical force in late 
tenocyte differentiation and maturation [409]. The Adjunct relationship of mechanical 
force, cellular positioning and growth factor stimulation remains poorly defined and is a 
specific area in tendon research that requires further investigation. 
Mechanical force has previously been shown to induce tenocyte proliferation with an 
increased detection of the transcription factor Scleraxis [331, 410]. SCX has previously 
been shown to directly regulate the transcription of Type I collagen (COL1a1) in the 
presence of TGF-β (Transforming Growth Factor –β) [411, 412], which encodes for the 
most abundant protein found in tendon tissue. SCX has been shown to be up-regulated in 
numerous animal models utilising either TGF-β in the equine model which utilised 
embryonic derived stem cells [354] or the combination of BMP-12 and BMP-13 in both 
the rat [181] and canine which utilised adipose derived mesenchymal stem cells [413] 
model for stem cell differentiation towards a tenocyte lineage. 
W. R. Webb PhD Thesis Chapter 5 
270 
 
SCX has shown limited detection in human samples with the majority of finding showing 
the presence of SCX post mechanical loading [331]. This Study did not focus on SCX, but 
did focus on the tendon makers TNMD and THBS-4 with future studies aimed and focused 
on elucidating the function of SCX in human stem cell differentiated tenocyte-like cells. 
Heparin sulphate has previously been shown to be vital in FGF-FGFR interaction [236]. 
The concept of heparin/HS-FGF dimer being an essential component/step in the 
transduction of FGF/FGFR signalling complex still remains controversial [237]. Although, it 
is well established that heparin is essential for high affinity binding of FGF to FGFR when 
cells are unable to synthesis cell-surface HS, cells pre-treated with heparin degrading 
enzymes or cells exposed to sulphation inhibiting agents [238, 239]. In this study heparin 
was not added as a component of the differentiation media, although heparin sulphate is 
present in Matrigel which is used to coat culture plastic prior to seeding with hESC’s. This 
study at disagrees with previous studies utilising heparin sulphate inclusion as part of the 
FGF-FGFR binding due to hMSC did not have matrigel coating of plastic prior to seeding 
and this may indicate that heparin sulphate supplementation is not required. Secondly, 
when both hESC and hMSC’s showed the gene expression of TENC and the tenascin C 
protein may have influenced FGF-FGFR high affinity binding as tenascin C has previously 
been shown to be capable of binding FGF and influencing binding affinity with the FGFR 
[414] and this could negate the absence of heparin sulphate.  
However, this study has shown in the absence of all three FGF’s tendon specific gene 
expression is not detected post 20 days. This highlights the requirement of the 
combination of FGF-4, FGF-6, FGF-8, Vitamin C and a 2% O2 environment. 
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After identifying a growth factor combination capable of inducing and maintaining tendon 
like gene markers the next logical step was to investigate the use of nanoparticle delivery 
of the identified growth factors. 
This thesis has also highlighted the importance of controlling the parameters (Chapter 4) 
within the manufacturing process of PHBHHx nanoparticles with an aim to produce a 
controlled range of nanoparticle sizes. The control of nanoparticle size and properties will 
aid in the design of nanoparticle capable of delivering a precise bioactive molecule 
concentration over a specific time-course.  
Research undertaken by Peng et al. [373] showed low molecular weight proteins namely 
insulin could be encapsulated and produce high encapsulation efficiency with a prolonged 
release pattern. However, this study along with numerous other studies focuses upon a 
single nanoparticle size [393-395].  
This thesis has shown that being able to control the key process variables: Polymer 
concentration, sonication power and sonication cycles. A range of PHBHHx nanoparticles 
size can be produced (94nm – 220nm) which is significantly smaller than the particles 
produced in previous studies of polymer drug encapsulation [393-395].  
Furthermore, this thesis has shown that altering the ratio of surfactants that a smaller 
nanoparticle can be produced (<75nm). The results observed in surfactant ratio alteration 
highlights the requirement for further multifactorial design of experiment to be 
undertaken utilising surfactant ratio as the fourth variable. The author of this thesis 
believes this undertaking will further aid in the delivery of precise nanoparticle based 
drug delivery. Also, the alteration of polymer concentration may well affect release 
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properties of the nanoparticle system in that the thickness of polymer coating acts as a 
release barrier. Understanding the release kinetics in both aqueous and hydrogel 
environments is another key area for investigation.  
Further concerns in reducing nanoparticle size are: 1) physical barriers of the nanoparticle 
construct in that the thicker the nanoparticle polymer shell the reduced permeability for 
drug/bioactive molecule release. This study did not investigate the effects of reducing 
polymer concentration on nanoparticle coating thickness. However, future studies should 
employ techniques such as Atomic Force Microscopy (AFM) to quantify the polymer layer 
thickness with an aim of relating this physical barrier to release profile. 2) As nanoparticle 
size decreases a higher percentage of bioactive agent will be found on the surface of the 
nanoparticle which may lead to a higher level of burst release [389]. 
This thesis has identified that PHBHHx scaffold that contains both a stem cell and 
nanoparticle growth factor release system is distinctively possible with further research 
being focused on release kinetics of the growth factors encapsulated within a polymer 
nanoparticle. The identification of the growth factors capable of differentiating human 
stem cells towards a tenocyte-like lineage has highlighted the potential for a stem cell 
based alternative to current surgical techniques employed in tendon repair. Also, the use 
of PHBHHx-hybrid scaffold indicates a potential polymer design to be utilised in tendon 
repair whilst also providing a vehicle by which both a stem cell and nanoparticle loaded 
growth factors component can be delivered to the defect site. 
Possibly the finding of most interest contained within the body of this thesis is the 
capability of controlling nanoparticle size and being able to predict the size of 
nanoparticle with a high level of accuracy. This opens the door of possibilities to the 
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application of polymer based nanoparticles in delivering not only growth factors but 
chemotherapeutical agents with a precise concentration to a desired target which may 
reduce systemic toxicity that is observed when administering these agents via traditional 
administration.
  
 
 
 
 
 
Chapter 6: Conclusion 
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This thesis has demonstrated that a PHBHHx based scaffold can be utilised to repair 
tendon defects in the rat model. Implanted hybrid PHBHHx scaffold were capable of 
withstanding the forces exposed to native tendon coupled with a return of function 
(observed in the Achilles functional index). The collagen-PHBHHx scaffold containing 
tenocytes showed an accelerated return of function when compared to all other 
experimental groups. The implanted scaffolds did not elucidate an immune response and 
also showed cellular alignment along the force barring fibres. The rat model also showed 
the PHBHHx hybrid scaffold underwent degradation of the polymer bulk which has no 
adverse effects on function or immune response. 
This thesis has demonstrated that the growth factor combination of FGF-4, FGF-6 and 
FGF-8 in combination with Vitamin C and cultured at 2% O2 as being capable of initiating 
cellular priming towards a tenocyte “like” differentiation with transcription of THBS-4 and 
TNMD being detected up to 40 days of culture. Furthermore, this thesis has indicated an 
element of cross-talk between FGF and BMP signalling cascades during tenogenesis. The 
cross-talk was identified by inhibition of the BMP induced SMAD signalling cascade. This 
was elucidated by the use of Dorsomorphin in FGF supplemented differentiation media, 
which resulted in a reduction in RNA expression for DCN and TNMD in both FGF-4 & 8 and 
FGF-4, 6 & 8 supplemented differentiation of human embryonic stem cells. Similar 
observations were made with FGF-4 and FGF-4, 6 & 8 supplemented differentiation of 
human mesenchymal stem cells in that TNMD transcription was not observed post 20 
days stimulation.  
The final chapter of this thesis has demonstrated that DOE approach can be employed to 
control the production of nanoparticles to fit a variety of applications within nano-
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medicine. Whereby, a size prediction curve can be produced for each polymer which can 
then be applied to any encapsulated drug to achieve a desired nanoparticle size. These 
findings allow for a greater control of nanoparticle size and drug delivery in that we can 
manipulate the manufacturing variables to produce a nanoparticle of differing size and 
drug release profiles. Therefore, allowing for greater control of delivery of drug/growth 
factor dose to site of interest. 
This thesis has utilised the combination of an in vivo investigations that PHBHHx can be 
utilised as a suitable implant material for the potential for the treatment of damaged 
tendon. Whilst utilising in vitro investigation to show the combination FGF-4, FGF-6 and 
FGF-8 in the presence of Vitamin C and cultured in 2% O2 as having a potential role in the 
cellular priming of human mesenchymal stem cells and human embryonic stem cells to 
differentiate into a tenocyte “like” lineage. 
The contents of this thesis, has also highlighted the importance of a controlled production 
of nanoparticles. By mapping the production variables and subsequent control of the 
variables this thesis has shown that a range of nanoparticles can be produced that have 
specific size and release profiles. The impact of such control mechanisms can lead to a 
nanoparticle based delivery system capable of delivering a precise drug/growth factor 
dose over a prolonged period of time.  
 
  
 
 
 
 
 
 
Chapter 7: Future Perspective 
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The body of work of this thesis has shown that a PHBHHx scaffold was capable of 
withstanding the forces observed in native rat Achilles tendons, without initiating an 
immune response. Chapter 3 has shown that combination of FGF-4, FGF-6, FGF-8 and 
Vitamin C as being capable of initiating stem cell differentiation towards a tenocyte “like” 
lineage using both human embryonic and mesenchymal stem cells.  
The ability to deliver return of function along with the capability of cellular differentiation 
is a logical next step in that combining the scaffold with stem cells and a drug delivery 
vehicle capable of controlled and sustained release of growth factors. 
Therefore future investigations should employ: 
1. Bioreactor investigation of growth factor release kinetics 
2. Investigation of the role of HIF proteins in tenocyte differentiation 
3. Atomic force microscopy of Nanoparticle shell to relate to release kinetics. 
4. Investigation of FGF-4, FGF-6 and FGF-8 signalling cascade and combinational 
relationship. 
5. Addition of Heparin Sulphate to growth factor combination to evaluate 
amplification of FGF signalling. 
6. Design of NEW tendon bioreactor utilising hypoxic environments and the ramping 
of cyclic strain over time. 
7. Investigate the combinational effects of FGF’s and mechanical stimulation on stem 
cell differentiation towards a tenocyte lineage. 
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